CA 03142360 2021-11-30
BICYCLIC COMPOUND AS RIP-I KINASE INHIBITOR AND APPLICATION
THEREOF
[0001] This application claims the priority of:
CN201910471672.3, filed on May 31, 2019;
CN201911089490.6, filed on November 08, 2019; and
CN202010432710.7, filed on May 20, 2020.
FIELD OF THE INVENTION
[0002] The present disclosure relates to a compound represented by formula
(I), or an isomer
or pharmaceutically acceptable salt thereof, and use thereof in the
manufacture of a
medicament for treating diseases related to RIP-1 (receptor-interacting
protein) kinase.
BACKGROUND OF THE INVENTION
[0003] RIP1 is a critical upstream kinase that regulates cell necrosis and
apoptosis. RIP1 is
also involved in a variety of inflammatory signaling pathways, and can be
stimulated by TNF
and TLR family ligands to trigger an inflammatory response (Weinlich, R. Nat.
Rev. Mol. Cell.
Biol. 2017, 18, 127; Pasparakis M. et al. Nature 2015, 517, 311; Berger, S.B.
Cell Death
Discovery, 2016, 2, e16056). RIP1 drives a variety of inflammatory signaling
pathways [Fas
ligand, TNF-related apoptosis inducing ligand (TRAIL), TLR3 and TLR4] through
TNF
receptor 1 (Lukens J. R., et al. Nature, 2013, 498, 224). Inhibiting the
activity of RIP1 can be
used as a treatment for many inflammatory diseases.
SUMMARY OF THE INVENTION
[0004] The present disclosure provides a compound of formula (I), or an isomer
or
pharmaceutically acceptable salt thereof,
1
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
T T4
(R2)n
T2
Ri s
(I)
[0005] wherein:
[0006] Ti is selected from N and CRit;
[0007] T2 is selected from N and CR2t;
100081 T3 is selected from N and CR3i;
[0009] T4 is selected from N and CR4i;
100101 Ei is selected from C(R1e)2, 0, C(=0), S, and NR2e;
[0011] Ring A is selected from 1,2,4-triazolyl, 1,2,3-triazolyl, imidazolyl,
isoxazolyl,
1,3,4-oxadiazoly I, , tetrazolyl, pyridyl, and ,
wherein the
N
1,2,4-triazolyl, 1,2,3-triazolyl, imidazolyl, isoxazolyl, 1,3,4-oxadiazolyl,
N
Nc0
tetrazolyl, pyridyl, and are
optionally substituted with 1, 2 or 3 halogen or C1-3
alkyl;
[0012] Ring B is selected from phenyl and -;
[0013] L is selected from single bond, 0, C(=0), S, NH, and C1-3 alkyl,
wherein the C1-3 alkyl
is optionally substituted with 1, 2 or 3 Ra;
[0014] Ri is selected from H and C1_3 alkyl, wherein the Ci_3 alkyl is
optionally substituted
with 1, 2 or 3 Rb;
[0015] Rat, Kit, R3t, and Rat are each independently selected from H, F, Cl,
Br, I, OH, CN, NH2,
C1-3 alkyl, COOH, and -C(=0)NH2, wherein the C1-3 alkyl is optionally
substituted with 1, 2 or
3 Re;
[0016] Rie is each independently selected from H, F, Cl, Br, I, OH, CN, NH2,
and C1-3 alkyl,
2
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 Rd;
[0017] R2e is selected from H and Ci_3 alkyl, wherein the Ci_3 alkyl is
optionally substituted
with 1, 2 or 3 Re;
[0018] R2 is each independently selected from H, F, Cl, Br, I, OH, NH2, CN, C1-
3 alkyl, and
C1_3 alkoxy, wherein the C1_3 alkyl and C1-3 alkoxy are optionally substituted
with 1, 2 or 3 Re;
[0019] n is 1, 2, 3, 4, or 5;
[0020] R., Rb, Re, Rd, Re, and Re are each independently selected from F, Cl,
Br, I, OH, CN,
NH2, and D.
[0021] The present disclosure provides a compound of formula (I), or an isomer
or
pharmaceutically acceptable salt thereof,
T3-14
õ 0
(R2)n
T2 0 L
s
(I)
[0022] wherein
[0023] Ti is selected from N and CItit;
[0024] T2 is selected from N and CR2t;
[0025] T3 is selected from N and CR3t;
[0026] T4 is selected from N and CR4t;
[0027] El is selected from C(Rie)2, 0, C(=0), S, and NR2e;
[0028] Ring A is selected from 1,2,4-triazolyl, 1,2,3-triazolyl, imidazolyl,
isoxazolyl,
..<\N
N
1,3,4-oxadiazolyl, and , wherein the 1,2,4-triazolyl, 1,2,3-triazolyl,
imidazolyl,
N
isoxazolyl, 1,3,4-oxadiazolyl, and µ, are optionally substituted with 1, 2
or 3
halogen or C1-3 alkyl;
[0029] Ring B is phenyl;
[0030] L is selected from single bond, 0, C(=0), S, NH, and C1_3 alkyl,
wherein the C1-3 alkyl
is optionally substituted with 1, 2 or 3 R.;
3
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[0031] Ri is selected from H and C1-3 alkyl, wherein the C1-3 alkyl is
optionally substituted
with 1, 2 or 3 Rb;
[0032] RR, R2t, R3t, and Rat are each independently selected from H, F, Cl,
Br, I, OH, CN, NH2,
and C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or
3 Re;
[0033] Rie is each independently selected from H, F, Cl, Br, I, OH, CN, NH2,
and C1-3 alkyl,
wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 Rd;
[0034] R2e is selected from H and C1_3 alkyl, wherein the C1_3 alkyl is
optionally substituted
with 1, 2 or 3 Re;
[0035] R2 is each independently selected from H, F, Cl, Br, I, OH, NH2, CN,
and C1-3 alkyl,
wherein the C1_3 alkyl is optionally substituted with 1, 2 or 3 Re;
[0036] n is 1, 2, 3, 4, or 5;
[0037] Ra, Rb, Re, Rd, Re, and Re are each independently selected from F, Cl,
Br, I, OH, CN,
NH2, and D.
[0038] The present disclosure provides a compound of foimula (I), or an isomer
or
pharmaceutically acceptable salt thereof,
T3.A-4
0
(R2)n
T2
\Tr
A
s
(I)
[0039] wherein
[0040] Ti is N or CRit;
[0041] T2 is N or CR2t;
[0042] T3 is N or CR3t;
[0043] T4 is N or CR4t;
[0044] El is C(Rie)2, 0, C(=0), S, or NR2e;
[0045] Ring A is 5-membered heteroaryl optionally substituted with C1-3 alkyl;
[0046] Ring B is phenyl or 6-membered heteroaryl;
[0047] L is 0, C(=0), S, NH, or C1_3 alkyl, wherein the C1-3 alkyl is
optionally substituted
with 1, 2 or 3 Ra;
4
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[0048] Ri is selected from H and C1-3 alkyl, wherein the C1-3 alkyl is
optionally substituted
with 1, 2 or 3 Rb;
100491 RR, R2t, R3t, and Rat are each independently selected from H, F, Cl,
Br, I, OH, CN, NH2,
and C1_3 alkyl, wherein the C1-3 alkyl is optionally substituted with 1, 2 or
3 Re;
[0050] Rie is each independently selected from H, F, Cl, Br, I, OH, CN, NH2,
and C1-3 alkyl,
wherein the C1-3 alkyl is optionally substituted with 1, 2 or 3 Rd;
[0051] R2e is selected from H and C1_3 alkyl, wherein the C1_3 alkyl is
optionally substituted
with 1, 2 or 3 Re;
[0052] R2 is each independently selected from H, F, Cl, Br, I, OH, NH2, CN,
and C1-3 alkyl,
wherein the C1.3 alkyl is optionally substituted with 1, 2 or 3 Re;
[0053] n is 1, 2, 3, 4, or 5;
[0054] Ra, Rb, Re, Rd, Re, and Re are each independently selected from F, Cl,
Br, I, OH, CN,
and NH2.
[0055] In some embodiments disclosed herein, the above-mentioned Ri is
selected from H
and CH3, wherein the CH3 is optionally substituted with 1, 2 or 3 Rb, and
other variables are as
defined herein.
[0056] In some embodiments disclosed herein, the above-mentioned Ri is
selected from H,
CH3, and CD3, and other variables are as defined herein.
[0057] In some embodiments disclosed herein, the above-mentioned Ri is
selected from H
and CH3, and other variables are as defined herein.
[0058] In some embodiments disclosed herein, the above-mentioned Rit, R2t,
R3t, and R41 are
each independently selected from H, F, Cl, Br, I, OH, CN, NH2, CH3, COOH, and -
C(=0)NH2,
wherein the CH3 is optionally substituted with 1, 2 or 3 Re, and other
variables are as defined
herein.
[0059] In some embodiments disclosed herein, the above-mentioned Rit, R2t,
R3t, and R4t are
each independently selected from H, F, Cl, Br, I, OH, CN, NH2, and CH3,
wherein the CH3 is
optionally substituted with 1, 2 or 3 Re, and other variables are as defined
herein.
[0060] In some embodiments disclosed herein, the above-mentioned Rit, R2t,
R3t, and Rat are
each independently selected from H, F, Cl, Br, I, OH, CN, NH2, and CH3, and
other variables
are as defined herein.
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[0061] In some embodiments disclosed herein, the above-mentioned Rie is each
independently selected from H, F, Cl, Br, I, OH, CN, NH2, and CH3, and other
variables are as
defined herein.
[0062] In some embodiments disclosed herein, the above-mentioned R2e is
selected from H
and CH3, and other variables are as defined herein.
[0063] In some embodiments disclosed herein, the above-mentioned El is CH2, 0,
C(=0), S,
or NH, and other variables are as defined herein.
[0064] In some embodiments disclosed herein, the above-mentioned R2 is each
independently selected from H, F, Cl, Br, I, OH, NH2, CN, CH3, and OCH3,
wherein the CH3
and OCH3 are optionally substituted with 1, 2 or 3 Re, and other variables are
as defined herein.
[0065] In some embodiments disclosed herein, the above-mentioned R2 is each
independently selected from H, F, Cl, Br, I, OH, NI-12, CN, CH3, OCH3, CF3,
and OCF3, and
other variables are as defined herein.
[0066] In some embodiments disclosed herein, the above-mentioned R2 is each
independently selected from H, F, Cl, Br, I, OH, NH2, and CN, and other
variables are as
defined herein.
[0067] In some embodiments disclosed herein, the above-mentioned Ring A is
selected from
H - N-- ,
0--1,-' N' --<a
N
-
\ - -4, h.....r,
N-NN--
,
N N , 1
H
- - N-N-' __O - - -</N,c0 N......r-'
N- -- '
N'--"N 's , and : , wherein the ' N
N-
, ,
--<i'.
--
N
__ j"-N' f------z-i' Nz-_-., NzN 0
-\Ns--..-1
N-0
N-N
__ _N
N-N-' -,
,.
--"N I
-:.--N
, ", and : are
optionally substituted with 1, 2 or 3 halogen or
C1-3 alkyl, and other variables are as defined herein.
[0068] In some embodiments disclosed herein, the above-mentioned Ring A is
selected from
6
Date recue / Date received 2021-11-30
- -
\N-C) -N-
N111 , and
[0069] In some embodiments disclosed herein, the above-mentioned Ring A is
pyrrolyl,
imidazolyl, pyrazolyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-
triazolyl,
1,2,4-triazolyl, or 1,3,4-thiadiazolyl, wherein the pyrrolyl, imidazolyl,
pyrazolyl, furyl, thienyl,
oxazolyl, isoxazolyl, thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, or 1,3,4-
thiadiazoly1 is
optionally substituted with C1-3 alkyl, and other variables are as defined
herein.
[0070] In some embodiments disclosed herein, the above-mentioned L is selected
from single
bond, -CH2-, and -0-, and other variables are as defined herein.
[0071] In some embodiments disclosed herein, the above-mentioned L is selected
from single
bond and -CH2-, and other variables are as defined herein.
N,-'
[0072] In some embodiments disclosed herein, the above-mentioned Ring A is
N¨N
and other variables are as defined herein.
[0073] In some embodiments disclosed herein, the above-mentioned Ring B is
phenyl or
pyridyl, and other variables are as defined herein.
[0074] The present disclosure also includes some embodiments that are obtained
by
combining any of the above-mentioned variables.
[0075] In some embodiments disclosed herein, the above-mentioned compound is
selected
from
(rN2in T3 TI21.
\
(IN N " = -
0
Tii()/N R
6.2/n
N T1N
S S
Ri
(I - 1 ) (111-2)
7
Date Recite/Date Received 2023-04-14
CA 03142360 2021-11-30
O N._-.T.---\\
(RA
I ,
.¨NH N1\1 (R2)n
I S
R1 T1 N
r s
R1
( 1-3 ) and (Iii-i)
wherein
n, Ti, Tz, T3, RI, Rz, and R are as defined herein;
the carbon atom with "*" is a chiral carbon atom, which exists in the form of
a single (R) or (S)
enantiomer or a mixture enriched in one enantiomer;
or an isomer or pharmaceutically acceptable salt thereof.
[0076] In some embodiments disclosed herein, the above-mentioned compound is
selected
from
H
,
0
k 1
Tiii)...NEi N--N
(RAI...NH N---"--,R
(R2),,
T, N T, N
Ri S / S
R1
(1 - 5) (111-6)
O N,--).õ....,,,\
0 1 j (R2)n 0 N-N
-N 0 I 1 \(R2)n
I = 'NH N
-PN - N
T1 N I =.IINH N-
Rii S :-N,
T1 N
i S
Ri
( 1-7 ) and (111-9)
wherein
n, Ti, T2, T3, Ri, Rz, and R are as defined herein;
or an isomer or pharmaceutically acceptable salt thereof.
[0077] The present disclosure also provides compounds of the formulae below,
or isomers or
pharmaceutically acceptable salts thereof:
H H CN
0 N
1104 C1/4 N
0 0
¨NH \N¨IN
0 0
N N
/ S / S
8
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
110
0 CN H
/ _o
<HC)Ni NNI_IN
0
I ¨NH NI"
N N--",, N N
/ S / S
0 N
0 0
__________________________________________________ N
NH N -NH -rµl'hi ei \,'
NNreNN i s
D3C / S
CN
0 0 N-
O 0 Nil
_______________ rµIF1 1
NH N-JNci
NN leNr\J
0 t'Lk I 0,µ ji-ZN .
z())_ _____________ 0
-''µIl
I NH N I -NH
reNN N N
/ S / S
C
1C)=---(I p 0 0 0
0 \ I
7"----% N
Ir' ==---NH " - r0 )-N1-1 ?: µN-N
leNN TheNiN s / S
0 N
0
N F 0 N
NH N - I
N
NH N -
TheN/N s IIII H
N
F H S
0 1\1,-ki , 0 N-N
0 0 _____
________________ rNO-) NH .N.:"rill NH N
N-"" reNI\I
/ S / 5
,;:j
I NH N NH N'-'1\1
TheN reNN1
/ S / S
9
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
F F
0 N
_______________________ _j
'-/io)
I NH N I NH N-- F
NN'eNN
F
0 N-N
C1/0_ _________________ j CI0 j
I NH N I NH N
eNrµl F\I\ N
/ S / S
0 N-N 0 N-
Br0_ , _________________ ___J 0
N \ ________________________________________________ rµr_r\jj
NH N
HO
reNN N
S
0 N N
../0)_
ro-Ni.1-1 \Nj NH \
N.,---,- ,
0 .
N--- NN
/ S / S
/
0 0 N -N-Th
_
0 N-N
rl 0 ) N,H _____________ c r: ___ j NH N--
N N)
rµr N / S
/ S
F
0\\ N1 N 0 N-
O
Y ___________________ J 0
rX NN-NH N-- NH N 0
leNNI
/ S / S
CN
0 N-N 0 N-N
0 0
)_Ni.i N-----H
NH N
.!" N
N N reNN
/ S / S
F
0 NH- j 0 N._
NH N
_______________________ ,____N /1 _______ 0_
-[.. I NH N
leNN) 1\1=NN ) s F
/ S I
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
CI
z N N-
0 j 0
N I NH N
r`l-N I\INN
/ S / S
Br
0 N
0 0
------, ,,j-N
N OCF3
1\( IN s 'eNrjj s
0-- pki
0 0
j NH.1\lj
NH N
H2N
eNj s
0 / S
0
0 N-.. N-N
I NH N CF3 rV
NH N
Th\INN leNN
/ S / S
[0078] In some embodiments disclosed herein, the above-mentioned compound is
selected
from
H H CN
0 N 0 N
*I
0 ,__µ
..'NH N"N ..'NH N-"N
N I N
/ S / S
H CN H
0 N
0 , =0 ( IN 110
X--\
I ..'NH N-N a ..11\1H N--
N N N N
0 N
0 0
.,z )
c--N H 0
= 'NH N
r\INNI r\IN
I S
D3C / S
CN
0 _.,..._
\ n
N-- I .,'NH N-- CI
feNN leNN
/ S / S
11
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
0 N-N
/ 0 N--zN 0
0 ___
) j 0
,----S,N
-INN N--
NN r\l'.-.NNI
/ S / S
o I
..'NH N-- ..INH N-N
1\1#N TheNN
/ S / S
0 N1
NN--/0) 0 N
,"NH N
FyzTh
I
-INN N-N1
H
/ S N
F H S
0 NN' 0 N-N
,,, 0
VN = "NH N
N NNN
/ S / S
-NH N =.'NH N-:"N
reNN TheNN
/ S / S
F F
0
r/ 0
=.INH N ."NH N F
reNN eNN
/ S / S
F
0 N-,,,,
CIO 2 _________ CIO
I -INN N 1 "NH N
eNr\I TheNN
/ S / S
BrC) ,, __ (/ ,--_,l
NN 1 0
\
"NH N .., NH N:5--j
HO
N N
/ S
12
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
=..NI\H r\l---rj
=.INH
0
1µ1N =
N leµ"/N s / S
Or
0 N
0 ____
a _____________________
0 N =-=,./ )
0) ,..e.j.-N -INN N
'NH N - .. NN
/ S / S
N N
F
0 NN 0 N-N
j0
I
I == !NH N = . '/ ) 'NH N Or
1\l'NN TheN/N s / S
CN
0 NN 7' N
,CD) __ .11 0 3
1 .,'NH N F 1 == 'NH N
-,.
TheNN s N-4-NN
I / S
F
0 N- 0 N-N
0
,IJ\I <-/o)
== 'NH N I ',NH N
eNrµJ reNN F
/ S / S
CI
0 N--Ki 0 N_N
,C) N _IIN
1o)
I -NH I -INH N
reNN 1\1N
/ S / S
Br
0 N-N
0
-,
OCF3
NH N
N N reN N
S / s
/
0)0 N CH2N -i 0 N
=.INH N j === NH N-
N N N
/ S 0 / S
13
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
N N¨N
0
>.\ j 0
/.õ/
.1H N- CF3
0
I = 'NH N
s and s
or an isomer or pharmaceutically acceptable salt thereof.
[0079] The present disclosure also provides the use of the above-mentioned
compound, or
the isomer or pharmaceutically acceptable salt thereof, in the manufacture of
a medicament
for treating diseases related to RIP-1 kinase.
Technical effects
[0080] As a novel RIP-1 kinase inhibitor, the compound of the present
disclosure has a good
inhibitory effect on the programmed cell necrosis (Necroptosis) of U937 cells
induced by
TNFa/QVD-OPh, and has achieved a good effect of inhibiting the decrease of
body
temperature of mice in a model of TNF-driven systemic inflammatory response
syndrome.
Definitions and Terms
[0081] Unless otherwise specified, the following terms and phrases used herein
are intended
to have the following meanings. A specific term or phrase should not be
considered indefinite
or unclear in the absence of a particular definition, but should be understood
in the
conventional sense. When a trade name appears herein, it is intended to refer
to its
corresponding commodity or active ingredient thereof.
[0082] The temi "pharmaceutically acceptable" is used herein in terms of those
compounds,
materials, compositions, and/or dosage forms, which are suitable for use in
contact with human
and animal tissues within the scope of reliable medical judgment, with no
excessive toxicity,
irritation, allergic reaction or other problems or complications, commensurate
with a
reasonable benefit/risk ratio.
[0083] The wan "pharmaceutically acceptable salt" means a salt of compounds
disclosed
herein that is prepared by reacting the compound having a specific substituent
disclosed herein
with a relatively non-toxic acid or base. When compounds disclosed herein
contain a relatively
acidic functional group, a base addition salt can be obtained by bringing the
neutral form of the
14
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
compound into contact with a sufficient amount of base in a pure solution or a
suitable inert
solvent. The pharmaceutically acceptable base addition salt includes a salt of
sodium,
potassium, calcium, ammonium, organic amine or magnesium or similar salts.
When
compounds disclosed herein contain a relatively basic functional group, an
acid addition salt
can be obtained by bringing the neutral form of the compound into contact with
a sufficient
amount of acid in a pure solution or a suitable inert solvent. Examples of the
pharmaceutically
acceptable acid addition salt include an inorganic acid salt, wherein the
inorganic acid includes,
for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid,
bicarbonate,
phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid,
hydrogen
sulfate, hydroiodic acid, phosphorous acid, and the like; and an organic acid
salt, wherein the
organic acid includes, for example, acetic acid, propionic acid, isobutyric
acid, maleic acid,
malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic
acid, mandelic acid,
phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid,
tartaric acid, and
methanesulfonic acid, and the like; and an salt of amino acid (such as
arginine and the like), and
a salt of an organic acid such as glucuronic acid and the like. Certain
specific compounds
disclosed herein contain both basic and acidic functional groups and can be
converted to any
base or acid addition salt.
[0084] The pharmaceutically acceptable salt disclosed herein can be prepared
from the parent
compound that contains an acidic or basic moiety by conventional chemical
methods.
Generally, such salt can be prepared by reacting the free acid or base form of
the compound
with a stoichiometric amount of an appropriate base or acid in water or an
organic solvent or a
mixture thereof.
[0085] Unless otherwise specified, the term "isomer" is intended to include
geometric
isomers, cis- or trans- isomers, stereoisomers, enantiomers, optical isomers,
diastereomers, and
tautomers.
[0086] Compounds disclosed herein may be present in a specific geometric or
stereoisomeric
form. The present disclosure contemplates all such compounds, including cis
and trans isomers,
(-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereoisomer, (D)-
isomer, (L)-isomer,
and a racemic mixture and other mixtures, for example, a mixture enriched in
enantiomer or
diastereoisomer, all of which are encompassed within the scope disclosed
herein. The
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
substituent such as alkyl may have an additional asymmetric carbon atom. All
these isomers
and mixtures thereof are encompassed within the scope disclosed herein.
[0087] Unless otherwise specified, the term "enantiomer" or "optical isomer"
means
stereoisomers that are in a mirrored relationship with each other.
[0088] Unless otherwise specified, the tenn "cis-trans isomer" or "geometric
isomer" is
produced by the inability of a double bond or a single bond between ring-
forming carbon atoms
to rotate freely.
[0089] Unless otherwise specified, the term "diastereomer" means a
stereoisomer in which
two or more chiral centers of are contained in a molecule and is in a non-
mirrored relationship
between molecules.
[0090] Unless otherwise specified, "(D)" or "(+)" means dextroisomer, "(L)" or
"(-)" means
levoisomer, and "(DL)" or "( )" means racemate.
[0091] Unless otherwise specified, a wedged solid bond (". ) and a wedged
dashed bond
) indicate the absolute configuration of a stereocenter; a straight solid bond
(F) and a
straight dashed bond ( 0"1..) indicate the relative configuration of a
stereocenter; a wavy line
(pr) indicates a wedged solid bond (..# ) or a wedged dashed bond ("); or a
wavy line ( )
indicates a straight solid bond (i' ) and a straight dashed bond (").
[0092] Unless otherwise specified, when a double bond structure such as a
carbon-carbon
double bond, a carbon-nitrogen double bond, and a nitrogen-nitrogen double
bond is present in
a compound, and each atom on the double bond is attached to two different
substituents (in the
double bond containing a nitrogen atom, a pair of lone pair electrons on the
nitrogen atom is
considered as one of the substituents to which it is attached), the compound
represents (Z)
isomer, (E) isomer, or a mixture of two isomers of the compound, if the atoms
on the double
bond in the compound are attached to their substituents by a wavy line (jj's
). For example, the
compound having following formula (A) means that the compound is present as a
single
isomer of formula (A-1) or formula (A-2) or as a mixture of two isomers of
formula (A-1) and
formula (A-2); and the compound having following formula (B) means that the
compound is
present as a single isomer of formula (B-1) or formula (B-2) or as a mixture
of two isomers of
16
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
formula (B-1) and formula (B-2). The compound having following formula (C)
means that the
compound is present as a single isomer of formula (C-1) or foimula (C-2) or as
a mixture of
two isomers of formula (C-1) and formula (C-2).
OH OH OH
HO 0 (z) HO (E)
0 OH 0
(A) (A-1) (A-2)
OH OH OH
HO 0 HO, 0 (E) 0
N(z) N
(B) (B-1) OH (B-2)
Me
ss' HO, Me (E) ,Me
N=N N=N N=N
HO (C)
(C) (Z) (C-1) HO (C-2)
[0093] Compounds disclosed herein may be present in a particular form. Unless
otherwise
specified, the terms "tautomer" or "tautomeric form" means that different
functional groups are
in dynamic equilibrium at room temperature and can be rapidly converted into
each other. If
tautomers are possible (as in solution), a chemical equilibrium of tautomers
can be achieved.
For example, proton tautomers (also known as prototropic tautomers) include
interconversions
by proton transfer, such as keto-enol isomerization and imine-enamine
isomerization. Valence
tautomers include interconversions by recombination of some bonding electrons.
A specific
example of keto-enol tautomerization is interconversion between two tautomers
pentane-2,
4-dione and 4-hydroxypent-3-en-2-one.
[0094] Unless otherwise specified, the term "enriched in one isomer", "isomer
enriched",
"enriched in one enantiomer" or "enantiomeric enriched" means that the content
of one isomer
or enantiomer is less than 100%, and the content of the isomer or enantiomer
is 60% or more, or
70% or more, or 80% or more, or 90% or more, or 95% or more, or 96% or more,
or 97% or
more, 98% or more, 99% or more, 99.5% or more, 99.6% or more, 99.7% or more,
99.8% or
more, or 99.9% or more.
[0095] Unless otherwise specified, the term "isomer excess" or "enantiomeric
excess" means
the difference between the relative percentages of two isomers or two
enantiomers. For
example, if one isomer or enantiomer is present in an amount of 90% and the
other isomer or
enantiomer is present in an amount of 10%, the isomer or enantiomeric excess
(ee value) is
17
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
80%.
[0096] Optically active (R)- and (S)-isomer, or D and L isomer can be prepared
using chiral
synthesis or chiral reagents or other conventional techniques. If one kind of
enantiomer of
certain compound disclosed herein is to be obtained, the pure desired
enantiomer can be
obtained by asymmetric synthesis or derivative action of chiral auxiliary
followed by
separating the resulting diastereomeric mixture and cleaving the auxiliary
group. Alternatively,
when the molecule contains a basic functional group (such as amino) or an
acidic functional
group (such as carboxyl), the compound reacts with an appropriate optically
active acid or base
to form a salt of the diastereomeric isomer which is then subjected to
diastereomeric resolution
through the conventional method in the art to afford the pure enantiomer. In
addition, the
enantiomer and the diastereoisomer are generally isolated through
chromatography which uses
a chiral stationary phase and optionally combines with a chemical derivative
method (for
example, carbamate generated from amine).
[0097] Compounds disclosed herein may contain an unnatural proportion of
atomic isotopes
at one or more of the atoms that make up the compounds. For example, a
compound may be
labeled with a radioisotope such as tritium (3H), iodine-125 (125I) or C-
14(14C). For another
example, hydrogen can be replaced by heavy hydrogen to form a deuterated drug.
The bond
between deuterium and carbon is stronger than that between ordinary hydrogen
and carbon.
Compared with undeuterated drugs, deuterated drugs have advantages of reduced
toxic side
effects, increased drug stability, enhanced efficacy, and prolonged biological
half-life of drugs.
All changes in the isotopic composition of compounds disclosed herein,
regardless of
radioactivity, are included within the scope of the present disclosure.
[0098] The term "optional" or "optionally" means that the subsequent event or
condition may
occur but not requisite, that the term includes the instance in which the
event or condition
occurs and the instance in which the event or condition does not occur.
[0099] The Willi "substituted" means one or more than one hydrogen atom(s) on
a specific
atom are substituted by a substituent, including deuterium and hydrogen
variants, as long as the
valence of the specific atom is normal and the substituted compound is stable.
When the
substituent is oxo (i.e., =0), it means two hydrogen atoms are substituted.
Positions on an
aromatic ring cannot be substituted by oxo. The teini "optionally substituted"
means an atom
18
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
can be substituted by a substituent or not, unless otherwise specified, the
species and number of
the substituent may be arbitrary as long as being chemically achievable.
[00100] When any variable (such as R) occurs in the constitution or structure
of the compound
more than once, the definition of the variable at each occurrence is
independent. Thus, for
example, if a group is substituted by 0 to 2 R, the group can be optionally
substituted by up to
two R, wherein the definition of R at each occurrence is independent.
Moreover, a combination
of the substituent and/or the variant thereof is allowed only when the
combination results in a
stable compound.
[00101] When the number of a linking group is 0, such as -(CRR)o-, it means
that the linking
group is a single bond.
[00102] When one of the variables is a single bond, it means that the two
groups linked by the
single bond are connected directly. For example, when L in A-L-Z represents a
single bond, the
structure of A-L-Z is actually A-Z.
[00103] When a substituent is vacant, it means that the substituent does not
exist. For example,
when X is vacant in A-X, the structure of A-X is actually A.
[00104] When an enumerated substituent does not indicate the atom through
which the
enumerated substituent is linked to the substituted group, such substituent
can be bonded
through any of its atoms. For example, a pyridyl group as a substituent may be
linked to the
substituted group through any one of carbon atoms on the pyridine ring.
[00105] When an enumerated linking group does not indicate its linking
direction, its linking
A
direction is arbitrary. For example, when the linking group L in ¨ is -
M-W-,
the -M-W- can be linked to the ring A and the ring B in the same direction as
the reading order
A M - W
from left to right to constitute , or can
be linked to the ring A and the
ring B in the reverse direction as the reading order from left to right to
constitute
A W-M
. A combination of the linking groups, substituents and/or variants
thereof is allowed only when such combination can result in a stable compound.
[00106] Unless otherwise specified, the term "halo" or "halogen" by itself or
as part of another
19
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
substituent represents a fluorine, chlorine, bromine or iodine atom.
[00107] Unless otherwise specified, the term "Ci_3 alkoxy" refers to an alkyl
group containing
1 to 3 carbon atoms and attached to the remainder of a molecule by an oxygen
atom. The C1-3
alkoxy group includes C1-2, C2-3, C3, C2 alkoxy groups, and the like. Examples
of C1-3 alkoxy
groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-
propoxy and
isopropoxy), and the like.
[00108] Unless otherwise specified, the twit "C 1_3 alkyl" is used to indicate
a linear or
branched saturated hydrocarbon group consisting of 1 to 3 carbon atoms. The C1-
3 alkyl group
includes C1-2 and C2-3 alkyl groups and the like. It may be monovalent (e.g.,
methyl), divalent
(e.g., methylene) or multivalent (e.g., methenyl). Examples of C1-3 alkyl
groups include, but are
not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and
isopropyl), and the like.
[00109] Unless otherwise specified, the terms "5- to 6-membered heteroaromatic
ring" and "5-
to 6-membered heteroaryl" may be used interchangeably. The term "5- to 6-
membered
heteroaryl" means a monocyclic group having a conjugated pi electron system
and consisting
of 5 to 6 ring atoms, of which 1, 2, 3 or 4 ring atoms are heteroatoms
independently selected
from 0, S and N, and the remainder atoms are carbon atoms, wherein the
nitrogen atom is
optionally quatemized and the nitrogen and sulfur heteroatoms are optionally
oxidized (i.e.,
NO and S(0)p, p is 1 or 2). The 5- to 6-membered heteroaryl group may be
attached to the
remainder of a molecule by a heteroatom or a carbon atom. The 5- to 6-membered
heteroaryl
group includes 5-membered and 6-membered heteroaryl groups. Examples of the 5-
to
6-membered heteroaryl group include, but are not limited to, pyrrolyl
(including N-pyrrolyl,
2-pyrrolyl, 3-pyrrolyl, and the like), pyrazolyl (including 2-pyrazoly1 and 3-
pyrazolyl, and the
like), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl, and 5-
imidazolyl, and
the like), oxazolyl (including 2-oxazolyl, 4-oxazolyl, and 5-oxazolyl, and the
like), triazolyl
(1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazoly1 and 4H-1,2,4-
triazolyl, and the like),
tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazoly1 and 5-isoxazolyl, and the
like), thiazolyl
(including 2-thiazolyl, 4-thiazoly1 and 5-thiazolyl, and the like), furyl
(including 2-furyl and
3-furyl, and the like), thienyl (including 2-thienyl and 3-thienyl, and the
like), pyridyl
(including 2-pyridyl, 3-pyridyl and 4-pyridyl, and the like), pyrazinyl or
pyrimidinyl
(including 2-pyrimidinyl and 4-pyrimidinyl, and the like).
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00110] Unless otherwise specified, or Cri-
Cn+m includes any one of ri to n+m carbons.
For example, C1-12 includes Cl, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, and
C12. Cn-n+m or
Cn-Cn+m also includes any range of ri to n+m. For example, C1_12 includes
C1_3, C1-6, C1-9, C3-6,
C3-9, C3-12, C6-9, C6-12, C9-12, and the like. Similarly, the n-membered to
n+m-membered ring
means that the number of atoms on the ring is n to n+m. For example, 3- to 12-
membered ring
includes 3-membered ring, 4-membered ring, 5-membered ring, 6-membered ring,
7-membered ring, 8-membered ring, 9-membered ring, 10-membered ring, 11-
membered ring,
and 12-membered ring. The n-membered to n+m-membered ring also means that the
number
of atoms on the ring includes any range from n to n+m. For example, 3-to 12-
membered ring
includes 3- to 6-membered ring, 3- to 9-membered ring, 5- to 6-membered ring,
5- to
7-membered ring, 6- to 7-membered ring, 6- to 8-membered ring, and 6- to 10-
membered ring,
and the like.
[00111] The term "leaving group" refers to a functional group or atom which
can be replaced
by another functional group or atom through a substitution reaction (such as
affinity
substitution reaction). For example, representative leaving groups include
triflate; chlorine,
bromine and iodine; sulfonate group, such as mesylate, tosylate, p-
bromobenzenesulfonate,
p-toluenesulfonate and the like; acyloxy, such as acetoxy, trifluoroacetoxy
and the like.
[00112] The term "protecting group" includes, but is not limited to "amino
protecting group",
"hydroxy protecting group" or "thio protecting group". The term "amino
protecting group"
refers to a protecting group suitable for blocking the side reaction on the
nitrogen of an amino.
Representative amino protecting groups include, but are not limited to:
fonnyl; acyl, such as
alkanoyl (e.g., acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl,
such as
tert-butoxycarbonyl (Boc); arylmethoxycarbonyl such as benzyloxycarbonyl (Cbz)
and
9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl such as benzyl (Bn), trityl
(Tr), 1,
1-bis-(4'-methoxyphenyl)methyl; silyl such as
trimethylsilyl (TM S) and
tert-butyldimethylsilyl (TBS) and the like. The twin "hydroxy protecting
group" refers to a
protecting group suitable for blocking the side reaction on hydroxy.
Representative hydroxy
protecting groups include, but are not limited to: alkyl such as methyl, ethyl
and tert-butyl; acyl
such as alkanoyl (e.g., acetyl); arylmethyl such as benzyl (Bn), p-
methoxybenzyl (PMB),
9-fluorenylmethyl (Fm), and diphenylmethyl (benzhydryl, DPM); silyl such as
trimethylsilyl
21
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
(TMS) and tert-butyl dimethyl silyl (TBS) and the like.
[00113] The structures of compounds disclosed herein can be confiiined by
conventional
methods well known to those skilled in the art. If the present disclosure
relates to an absolute
configuration of a compound, the absolute configuration can be confirmed by
conventional
techniques in the art, such as single crystal X-Ray diffraction (SXRD). In the
single crystal
X-Ray diffraction (SXRD), the diffraction intensity data of the cultivated
single crystal is
collected using a Bruker D8 venture diffractometer with a light source of CuKa
radiation in a
scanning mode of (Pim scan; after collecting the relevant data, the crystal
structure is further
analyzed by the direct method (Shelxs97) to confirm the absolute
configuration.
[00114] Compounds disclosed herein can be prepared by a variety of synthetic
methods well
known to those skilled in the art, including the following enumerated
embodiment, the
embodiment follned by the following enumerated embodiment in combination with
other
chemical synthesis methods, and equivalent replacement well known to those
skilled in the art.
Alternative embodiments include, but are not limited to the embodiment
disclosed herein.
[00115] Solvents used in the present disclosure are commercially available.
[00116] The following abbreviations are used in the present disclosure: aq
represents aqueous;
NaNO2 represents sodium nitrate; H2504 represents sulfuric acid; CuC12
represents copper
chloride; LiOH=1420 represents lithium hydroxide monohydrate; NaBH3CN
represents sodium
cyanoborohydride; HO/Et0Ac represents a solution of hydrochloric acid in ethyl
acetate; HC1
represents hydrochloric acid; CO2 represents carbon dioxide; ACN represents
acetonitrile; FA
represents founic acid; H20 represents water; NH3H20 represents ammonia;
Na2SO4
represents sodium sulfate; MgSO4 represents magnesium sulfate; NCS represents
N-chlorosuccinimide; NH4HCO3 represents ammonium bicarbonate; Pd/C represents
palladium on carbon; psi represents pressure unit; MeCN represents
acetonitrile; Ts0H.1-120
represents p-toluenesulfonic acid mon ohy drate ;
Pd(dppf)C12 represents
[1,1'-bis(diphenylphosphino)ferrocene[palladium dichloride; Neu represents
neutral; HPLC
represents high performance liquid chromatography; HATU represents
0-(7-azabenzotriazol- I -y1)-N,N,N',NI-tetramethy luronium
hexafluorophosphate; K2 C 03
represents potassium carbonate; EDC represents
22
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
N-(3-dimethylaminopropy1)-N'-ethy lcarbodiimide hydrochloride; m-CPBA
represents
3-chloroperoxybenzoic acid; eq represents equivalent or equivalence; T3P
represents
propylphosphonic anhydride; CDI represents carbonyl diimidazole; DCM
represents
dichloromethane; PE represents petroleum ether; DIAD represents diisopropyl
azodicarboxylate; DMF represents N,N-dimethylformamide; DMS0 represents
dimethyl
sulfoxide; Et0Ac represents ethyl acetate; Et0H represents ethanol; Me0H
represents
methanol; CBz represents benzyloxycarbonyl, which is an amino protecting
group; BOC
represents tert-butoxycarbonyl, which is an amino protecting group; HOAc
represents acetic
acid; NaCNBH3 represents sodium cyanoborohydride; r.t. represents room
temperature; 0/N
represents overnight; THF represents tetrahydrofuran; Boc20 represents di-tert-
butyl
dicarbonate; TFA represents trifluoroacetic acid; SOC12 represents thionyl
chloride; CS2
represents carbon disulfide; Ts0H represents p-toluenesulfonic acid; NFSI
represents
N-fluoro-N-(phenylsulfonyl)benzenesulfonamide; n-BuaNF represents
tetrabutylammonium
fluoride; iPrOH represents 2-propanol; mp represents melting point; LDA
represents lithium
diisopropylamide; IPAm represents isopropy lamine; DIPEA
represents
/V,N-diisopropylethylamine; Xantphos
represents
4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; t-Bu Xphos
represents
2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl; DPPP
represents
1,3-bis(dipheny 1phosphino)propane; Et3SiH represents tri ethy lsilane; DMAP
represents
4-dimethylaminopyricline; Py represents pyridine; DPBS represents Dulbecco's
phosphate
buffer; TNF-a represents tumor necrosis factor; 1050 represents half maximal
inhibitory
concentration; mg represents milligrams, kg represents kilograms; and HEPES
represents
N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid buffer.
[00117] Compounds are named according to general naming principles in the art
or by
ChemDraw software, and commercially available compounds are named with their
vendor
directory names.
DETAILED DESCRIPTION OF THE INVENTION
[00118] The present disclosure is described in detail below by means of
examples. However, it
is not intended that these examples have any disadvantageous limitations to
the present
23
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
disclosure. The present disclosure has been described in detail herein, and
embodiments are
also disclosed herein. It will be apparent to those skilled in the art that
various changes and
modifications may be made to the embodiments disclosed herein without
departing from the
spirit and scope disclosed herein.
[00119] Reference example 1: Fragment BB-1
HO N
[00120] Route for synthesis:
0 NH
0 H NI-NH 0¨
) 0
0 lo BB-1-2 NH2 0 N
> ON,NH =
2 10
0 IV
BB-1-1 BB-1-3 BB-1-4
0 N
HON""IN 40
BB-1
[00121] Step 1: synthesis of compound BB-1-3
[00122] To a pre-dried 100 mL flask were added BB-1-1 (2.60 g, 17.31 mmol,
1.00 eq) and
solvent Et0H (11.25 mL) and isopropyl ether (37.50 mL). BB-1-2 (2.59 g, 17.83
mmol, 1.03
eq) was slowly added under stirring, and the reaction solution was stirred at
20 C for 12 hours.
The reaction solution was filtered, and the resulting filter cake was washed
with isopropyl ether
(30 mL * 3) to give compound BB-1-3. 1H NMR (400MHz, DMSO-d6) 6 = 9.95 (s,
1H), 9.90 (s,
1H), 7.39 - 7.08 (m, 6H), 4.21 - 4.19 (m, 2H), 3.82 (s, 2H), 1.27 - 1.23 (m,
3H); LCMS m/z --
250.1 [M+H]t
[00123] Step 2: synthesis of compound BB-1-4
[00124] To a pre-dried 250 mL flask were added compound BB-1-3 (7.00 g, 28.08
mmol, 1.00
eq) and xylene (100.00 mL). A Dean-Stark trap was installed. The reaction
system was reacted
at 180 C for 10 h. 100 mL of isopropyl ether was added to the reaction system
and the mixture
was stirred for 30 minutes in an ice-water bath. The reaction system was
filtered, and the
resulting filter cake was washed with 50 mL of n-hexane to give compound BB-1-
4. 1H NMR
24
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
(400MHz, DMSO-d6) 6 = 14.44 (br s, 1H), 7.42 - 7.14 (m, 4H), 4.29 (q, J= 6.5
Hz, 2H), 4.13
(br s, 2H), 1.28 (br t, J= 7.0 Hz, 3H); LCMS m/z = 232.2 [M+Hr.
[00125] Step 3: synthesis of compound BB-1
[00126] To a thumb bottle were added compound BB-1-4 (4.10 g, 17.73 mmol, 1.00
eq),
tetrahydrofuran (1.00 mL) and water (200.00 ML), and lithium hydroxide
monohydrate (1.74 g,
41.49 mmol, 2.34 eq) was then added. The solution was stirred at 20 C for 12
hours. The
solvent was removed under reduced pressure. 25 mL of 1N aqueous hydrochloric
acid solution
was added dropwise with stifling until the pH of the system reached 2.
Compound BB-1 was
obtained after suction filtration. LCMS m/z = 202.1 [M-Hr.
[00127] Reference example 2: Fragment BB-2
CN
0 N
HO,
[00128] Route for synthesis:
o NH
0 0
0 CN 0 CN 0 CN ) BB-1-2
OH 0
BB-2-1 BB-2-2 BB-2-3
0 CN
NH2 H CN
0 N CN
0 N
0 N-N -** * _____ NI
HO BB-2.4 BB-2-5 BB-2
[00129] Step 1: synthesis of compound BB-2-2
[00130] To a solution of BB-2-1 (2.5 g, 15.51 mmol, 2.94 mL, 1 eq) in
dichloromethane (40
mL) was added methanol (4.97 g, 155.13 mmol, 6.28 mL, 10 eq) at 23 C. TMSCHN2
(2 M,
9.31 mL, 1.2 eq) was then added and the mixture was stirred for another 2
hours. The raw
materials were completetly consumed by TLC (petroleum ether:ethyl acetate =
5:1) monitoring.
0.1 mL of glacial acetic acid was added to the reaction solution, and the
reaction solution was
concentrated under reduced pressure to give BB-2-2.
[00131] Step 2: synthesis of compound BB-2-3
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00132] To a solution of BB-2-2 (3 g, 17.12 mmol, 1 eq) in methanol (30 mL)
was added
hydrazine hydrate (3.21 g, 51.37 mmol, 3.12 mL, 80% purity, 3 eq), and the
mixture was then
stin-ed in an oil bath at 70 C for 2 hours. By LCMS monitoring, the raw
materials were
completely consumed, and a target signal appeared. The reaction solution was
concentrated
under reduced pressure to remove the solvent, and 50 mL of ethyl acetate was
added. The
mixture was washed with 30 mL of saturated brine. The organic phase was dried
over
anhydrous sodium sulfate, and filtered, and the filtrate was concentrated
under reduced
pressure to give BB-2-3. '11 NMR (400 MHz, DMSO-d6) ö = 9.25 (br s, 1 H), 7.66
- 7.74 (m, 2
H), 7.45 - 7.65 (m, 2 H), 4.24 (s, 2 H), 3.43 (s, 2 H); LCMS m/z = 176.1
[M+H]t
[00133] Step 3: synthesis of compound BB-2-4
[00134] To a pre-dried three-necked bottle were added BB-1-2 (2.07 g, 14.27
mmol, 1 eq),
ethanol (10 mL), and isopropyl ether (20 mL), and BB-2-3 (2.5 g, 14.27 mmol, 1
eq) was then
added. The mixture was reacted at 25 C for 5 hours. By LCMS monitoring, the
raw materials
were completely consumed, and a target signal appeared. The reaction solution
was filtered,
and the filter cake was washed with 50 mL petroleum ether to give BB-2-4. LCMS
m/z = 275.2
[M+Hr.
[00135] Step 4: synthesis of compound BB-2-5
[00136] To a microwave tube were added BB-2-4 (0.5 g, 1.82 mmol, 1 eq),
molecular sieves
(4A, 0.05 g) and xylene (15 mL). The microwave tube was sealed and the
reaction was stirred
in a microwave reactor at 150 C for 4 hours. A target signal appeared by LCMS
monitoring. 30
mL of acetonitrile was added to the reaction solution, and the mixture was
filtered. The filtrate
was concentrated under reduced pressure to give BB-2-5. LCMS m/z = 257.1
[M+H].
[00137] Step 5: synthesis of compound BB-2
[00138] To a solution of BB-2-5 (1 g, 3.90 mmol, 1 eq) in tetrahydrofuran (50
mL) was added
a solution of lithium hydroxide monohydrate (654.96 mg, 15.61 mmol, 4 eq) in
water (15 mL)
at 21 C, and the mixture was then stirred for another 12 hours. By LCMS
monitoring, the raw
materials were completely consumed, and a target signal appeared. 15 mL of
water was added
to the reaction solution, and the mixture was extracted with ethyl acetate (30
mL). The resulting
aqueous phase was adjusted to a pH of about 3 with 2 N aqueous hydrochloric
acid solution,
and lyophilized to give BB-2. LCMS m/z = 227.0 [M-H].
26
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00139] Reference example 3: Fragment BB-3
N ..NH2
S
[00140] Route for synthesis:
NHBoc
HO OH
0
BB-3-2 NHBoc NHBoc
v.
NO2 1.11 0
OOH ___________________________________________________________
N.2 NH2
BB-3-1 BB-3-3 BB-3-4
0 so 0 0
..,,NHBoc =
.NHBoc 1111 ,NHBoc
N)
BB-3-5 BB-3-6 BB-3-7
2
S
BB-3
[00141] Step 1: synthesis of compound BB-3-3
[00142] BB-3-2 (20.00 g, 97.46 mmol, 1.00 eq) was dissolved in DMF (50 mL) and
the
solution was added dropwise to a suspension of NaH (8.19 g, 204.67 mmol, 60%
purity, 2.10
eq) in DMF (150 mL). Compound BB-3-1 (13.75 g, 97.46 mmol, 10.26 mL, 1.00 eq)
was then
added dropwise. The reaction solution was stirred at 20 C for 16 hours. Ethyl
acetate (200 mL)
and water (200 mL) were then added to the reaction solution, and the aqueous
phase was
adjusted to a pH of about 1 with hydrochloric acid. The mixture was extracted
with ethyl
acetate (200 niT,). The organic phase was dried over anhydrous magnesium
sulfate, and filtered,
and the filtrate was concentrated under reduced pressure to give compound BB-3-
3. LCMS m/z
= 227.1 [M-100+Hr.
[00143] Step 2: synthesis of compound BB-3-4
[00144] A solution of compound BB-3-3 (20.00 g, 61.29 mmol, 1.00 eq) and wet
Pd/C (5.00 g,
5% purity) in methanol (200.00 mL) was stirred at 20 C under hydrogen
atmosphere (15 psi)
for 5 hours. After the completion of the reaction, the reaction solution was
filtered, and the
27
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
filtrate was concentrated under reduced pressure to give compound BB-3-4. LCMS
m/z =
297.1 [M+Hr.
[00145] Step 3: synthesis of compound BB-3-5
[00146] To a solution of compound BB-3-4 (10.00 g, 33.75 mmol, 1.00 eq) and
N,N-diisopropylethylamine (4.36 g, 33.75 mmol, 5.89 mL, 1.00 eq) in DMSO
(100.00 mL)
was added HATU (12.83 g, 33.75 mmol, 1.00 eq). The reaction was stirred at 20
C for 2 hours.
After the completion of the reaction, water (200 mL) and ethyl acetate (200
mL) were added to
the reaction solution, and the layers were separated. The organic phase was
concentrated under
reduced pressure to give a crude product. The crude product was purified by
silica gel column
chromatography (petroleum ether: ethyl acetate = 10:1 - 1:1) to give compound
BB-3-5. LCMS
m/z = 223.1 [M-56+H]t
[00147] Step 4: synthesis of compound BB-3-6
[00148] To a dry 250 mL three-necked flask were added compound BB-3-5 (6.00 g,
21.56mmo1, 1.00 eq), DMF (60.00 mL) and cesium carbonate (10.54 g, 32.34 mmol,
1.50 eq),
and iodomethane (3.06 g, 21.56 mmol, 1.34 mL, 1.00 eq) was then added
dropwise. The
internal temperature was controlled below 20 C. The reaction was stirred at
16 C for 16 hours.
After the completion of the reaction, water (100 mL) and ethyl acetate (100
mL) were added to
the system, and the layers were separated. The organic phase was washed with
saturated brine
(100 mL * 2), dried over magnesium sulfate, and filtered. The filtrate was
concentrated under
reduced pressure to give compound BB-3-6. LCMS m/z = 237.1 [M-56+11r.
[00149] Step 5: synthesis of compound BB-3-7
[00150] To a solution of phosphorus pentasulfide (760.35 mg, 3.42 mmol, 363.80
L, 5 eq) in
THF (10 mL) was added sodium carbonate (362.57 mg, 3.42 mmol, 5 eq) at 20 C,
and the
mixture was stirred for another 0.5 hours. BB-3-6 (0.2 g, 684.16 mol, 1 eq)
was then added,
and the reaction solution was placed in an oil bath at 70 C and stirred for
9.5 hours. A target
signal appeared by LCMS monitoring. 20 mL of ethyl acetate was added to the
reaction
solution, and the mixture was filtered. The resulting filtrate was
concentrated under reduced
pressure to give compound BB-3-7. LCMS m/z = 253.1 [M-56+Hr.
[00151] Step 6: synthesis of compound BB-3
[00152] To BB-3-7 (630.84 mg, 2.05 mmol, 1 eq) was added a solution of
hydrochloric acid in
28
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
ethyl acetate (4 M, 20.00 mL, 39.11 eq), and the mixture was stirred at 23 C
for 1 hour. By
LCMS monitoring, the raw materials were completely consumed, and a target
signal appeared.
The reaction solution was concentrated under reduced pressure to give a crude
product, and 30
mL of saturated aqueous sodium bicarbonate solution was then added. The
mixture was
extracted with ethyl acetate (15 mL * 3). The organic phases were combined,
dried over
anhydrous sodium sulfate, and filtered. The filtrate was concentrated under
reduced pressure to
give compound BB-3. 114 NMR (400 MHz, CDC13) 6 = 7.21 - 7.32 (m, 3 H), 7.15 -
7.19 (m, 1
H), 4.40 (dd, J= 9.92, 6.62 Hz, 1 H), 4.10 (dd, J= 11.36, 9.81 Hz, 1 H), 3.77 -
3.94 (m, 4 H);
LCMS miz = 209.1 [M+111+.
[00153] Reference example 4: Fragment BB-4
NNrµJ
S
[00154] Route for synthesis:
NHBoc
BocHN BocHN
OH
0
CXIBB-3-2
__________________ I \
N NO2 OH OH
N NO2 N--NNH2
BB-4-1 BB-4-2 BB-4-3
0) 0 0
..NHBoc ________________ f'INHBoc _________________ 1NHBoc __
N N N N
BB-4-4 BB-4-5 BB-4-6
0
,,NH2
/ S
BB-4
[00155] Step 1: synthesis of compound BB-4-2
[00156] To a solution of BB-3-2 (13.13 g, 63.98 mmol, 1 eq) in DMF (100 mL)
was added
NaH (5.12 g, 127.96 mmol, 60% purity, 2 eq) at 0 C, and the mixture was
stirred for another 1
hour. BB-4-1 (10 g, 70.38 mmol, 1.1 eq) was then added, and the mixture was
stirred at 28 C
for 9 hours. A target signal appeared by LCMS monitoring. The reaction
solution was added to
29
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
1000 mL of water, and the mixture was extracted with ethyl acetate (300 mL *
4). The resulting
aqueous phase was adjusted to a pH of about 5 with 2 N hydrochloric acid, and
then extracted
with ethyl acetate (300 mL * 5). The organic phases were combined, dried over
anhydrous
sodium sulfate, and filtered. The filtrate was concentrated under reduced
pressure to give
compound BB-4-2. LCMS m/z = 326.0 [M-1-11-.
[00157] Step 2: synthesis of compound BB-4-3
[00158] To a solution of BB-4-2 (20.00 g, 61.11 mmol, 1 eq) in methanol (200
mL) was added
wet Pd/C (10 g, 30.55 mmol, 5 % purity) at 23 C. The mixture was stirred
under hydrogen
atmosphere (15 psi) for 10 hours. By LCMS monitoring, the raw materials were
completely
consumed, and a target signal appeared. The reaction solution was filtered,
and the resulting
filtrate was concentrated under reduced pressure to give compound BB-4-3. LCMS
m/z --
298.1 [M+H]t
[00159] Step 3: synthesis of compound BB-4-4
[00160] To a solution of BB-4-3 (16.00 g, 53.82 mmol, 1 eq) in ethyl acetate
(400 mL) were
added N,N-diisopropylethylarnine (20.87 g, 161.45 mmol, 28.12 mL, 3 eq) and
tri-n-butyl
phosphoric anhydride (68.49 g, 107.63 mmol, 64.01 mL, 50% purity in ethyl
acetate, 2 eq) at
23 C. The mixture was stirred for another 2 hours. By LCMS monitoring, the raw
materials
were completely consumed, and a target signal appeared. The reaction solution
was washed
with saturated brine (200 mL * 2). The organic phase was dried over anhydrous
sodium sulfate,
and filtered, and the filtrate was concentrated under reduced pressure to give
a crude product.
The crude product was purified by silica gel column chromatography (petroleum
ether:ethyl
acetate= 10:1 - 1:1) to give compound BB-4-4. LCMS m/z = 224.1 [M-56+H]t
[00161] Step 4: synthesis of compound BB-4-5
[00162] To a solution of BB-4-4 (1 g, 3.58 mmol, 1 eq) in DMF (30 mL) were
added cesium
carbonate (1.40 g, 4.30 mmol, 1.2 eq) and iodomethane (609.86 mg, 4.30 mmol,
267.48 1tL, 1.2
eq) at 20 C. The mixture was stirred for another 1 hour. By LCMS monitoring,
the raw
materials were completely consumed, and a target signal appeared. The reaction
solution was
added to 100 mL of water, and the mixture was extracted with ethyl acetate (30
mL * 5). The
organic phases were combined and washed with 50 mL of saturated brine. The
organic phase
was dried over anhydrous sodium sulfate, and filtered, and the filtrate was
concentrated under
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
reduced pressure to give compound BB-4-5. LCMS m/z = 238.1 [M-56+H]t
[00163] Step 5: synthesis of compound BB-4-6
[00164] To a solution of phosphorus pentasulfide (3.79 g, 17.05 mmol, 10 eq)
in THF (30 mL)
was added sodium carbonate (1.81 g, 17.05 mmol, 10 eq) at 20 C, and the
mixture was stirred
for another 0.5 hours. BB-4-5 (0.5 g, 1.70 mmol, 1 eq) was then added, and the
reaction
solution was placed in an oil bath at 70 C and stirred for 9.5 hours. The raw
materials were
substantially consumed by LCMS monitoring, and a target signal appeared. The
reaction
solution was filtered to give a filtrate. 50 mL of ethyl acetate was added to
the filtrate and the
mixture was washed with 30 mL of saturated brine. The organic phase was dried
over
anhydrous sodium sulfate, and filtered, and the filtrate was concentrated
under reduced
pressure to give a crude product. The crude product was purified by silica gel
column
chromatography (petroleum ether: ethyl acetate = 10:1 ¨ 1:1) to give compound
BB-4-6. LCMS
m/z = 310.3 [M+H]t
[00165] Step 6: synthesis of compound BB-4.
[00166] To BB-4-6 (0.6 g, 1.94 mmol, 1 eq) was added a solution of
hydrochloric acid in ethyl
acetate (4 M, 20 mL, 41.25 eq), and the mixture was stirred at 23 C for 1
hour. By LCMS
monitoring, the raw materials were completely consumed, and a target signal
appeared. The
reaction solution was concentrated under reduced pressure to give a crude
product, and 30 mL
of saturated sodium bicarbonate solution was added. The mixture was extracted
with ethyl
acetate (20 mL * 3). The organic phases were combined, dried over anhydrous
sodium sulfate,
and filtered. The filtrate was concentrated under reduced pressure to give
compound BB-4.
LCMS m/z = 210.1 [M+H]
[00167] Reference example 5: Fragment BB-5
.,NH2 HCI
N N
D3C S
[00168] Route for synthesis:
31
Date recue / Date received 2021-11-30
CA 03142360 2021 - 11 - 30
0 -
= = C C
.,NHBoc ,,NHBoc ,,NHBoc
N N N N N N
H 0 D36 D36 S
BB-4-4 BB-5-1 BB-5-2
0
HCI
(T\1N
1)36 S
BB-5
[00169] Step 1: synthesis of compound BB-5-1
[00170] To a solution of BB-4-4 (0.1 g, 358.05 timol, 1 eq) in tetrahydrofuran
(5 mL) were
added deuterated iodomethane (101.64 mg, 716.10 timol, 43.62 pt, 2 eq) and
cesium
carbonate (349.98 mg, 1.07 mmol, 3 eq) at 25 C, and the mixture was stirred
for another 2
hours. Ethyl acetate (20 mL) was added to the reaction solution, and the
mixture was then
washed with saturated brine (10 mL), and filtered. The filtrate was
concentrated under reduced
pressure to give a crude product. The crude product was purified by slurrying
with methyl
tert-butyl ether (5 mL) to give compound BB-5-1. LCMS m/z = 297.2 [M-FH]+.
[00171] Step 2: synthesis of compound BB-5-2
[00172] To a solution of phosphorus pentasulfide (2.25 g, 10.12 mmol, 1.08 mL,
10 eq) in THF
(10 mL) was added sodium carbonate (1.07 g, 10.12 mmol, 10 eq) at 30 C, and
the mixture
was stirred for 0.5 hours. BB-5-1(0.3 g, 1.01 mmol, 1 eq) was then added, and
the reaction
solution was stirred in an oil bath at 70 C for 10 hours. Ethyl acetate (20
mL) was added to the
reaction solution. The mixture was filtered through Celite, and the filtrate
was concentrated
under reduced pressure to give a crude product. The crude product was purified
by column
chromatography (petroleum ether: ethyl acetate = 10:1 ¨ 1:1) to give compound
BB-5-2. LCMS
m/z = 312.9 [M+Hr.
[00173] Step 3: synthesis of compound BB-5
[00174] HC1/Et0Ac (4 M, 5.69 mL, 59.27 eq) was added to BB-5-2 (0.12 g, 384.12
timol, 1 eq)
at 28 C, and the mixture was stirred for 1 hour. The reaction solution was
concentrated under
reduced pressure to give compound BB-5. LCMS m/z = 213.1 [M+Hr.
[00175] Reference example 6: Fragment BB-6
32
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
0 N
HO
[00176] Route for synthesis:
0 N
\_07 NH \-C? "
Ho =
BB-6-1 BB-6-2 BB-6
[00177] Step 1: synthesis of compound BB-6-2
[00178] To a solution of BB-6-1 (2 g, 14.27 mmol, 1 eq) and Cs2CO3 (5.11 g,
15.70 mmol, 1.1
eq) in DMF (20 mL) was added benzyl bromide (2.44 g, 14.27 mmol, 1.70 mL, 1
eq) at 25 C,
and the mixture was stirred for another 3 hours. By LCMS monitoring, the raw
materials were
completely consumed, and a target MS appeared. The reaction solution was added
to water
(100 mL), and the mixture was extracted with ethyl acetate (30 mL*5). The
organic phase was
dried over anhydrous sodium sulfate, and filtered, and the filtrate was
concentrated under
reduced pressure. The crude product was purified by flash silica gel column
chromatography
(petroleum ether:ethyl acetate = 10:1 - 1:1) to give BB-6-2. 1H NMR (400 MHz,
CDC13) 6 =
7.58 (d, J= 1.00 Hz, 1 H), 7.55 (s, 1 H), 7.33 - 7.40 (m, 3 H), 7.14- 7.20 (m,
2 H), 5.13 (s, 2 H),
4.34 (q, J= 7.20 Hz, 2 H), 1.36 (t, J= 7.20 Hz, 3 H); LCMS m/z = 231.1 [M+1] .
[00179] Step 2: synthesis of compound BB-6
[00180] To a solution of BB-6-2 (1.50 g, 6.51 mmol, 1 eq) in tetrahydrofiffan
(26 mL) was
added a solution of lithium hydroxide monohydrate (2.19 g, 52.11 mmol, 8 eq)
in water (26 mL)
at 28 C, and the mixture was stirred for another 12 hours. By LCMS monitoring,
the raw
materials were completely consumed, and a target MS appeared. The reaction
solution was
concentrated under reduced pressure. After removing the solvent, water (20 mL)
was added,
and the mixture was adjusted to a pH of about 2 with 2 N hydrochloric acid.
The precipitated
solid was then filtered to give BB-6. 1H NMR (400 MHz, DMSO-d6) ö = 7.87 (d,
J= 2.20 Hz,
2 H), 7.27 - 7.43 (m, 5 H), 5.24 (s, 2 H); LCMS m/z = 201.1 [M-1]-.
[00181] Reference example 7: Fragment BB-7
101 0..
N OH
[00182] Route for synthesis:
33
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
0
CI 1110 0 ¨Io-
la OH CI 0-N/ 0
CI
BB-7-1 BB-7-2 BB-7-3
0 N o¨\ 0.7N/ 00H
BB-7-4 BB-7
[00183] Step 1: synthesis of compound BB-7-2
[00184] To a solution of BB-7-1 (5 g, 29.65 mmol, 1 eq) in toluene (70 mL) was
added diethyl
oxalate (4.77 g, 32.62 mmol, 4.45 mL, 1.1 eq) and sodium ethoxide (2.62 g,
38.55 mmol, 1.3 eq)
at 0 C, and the mixture was reacted at 20 C for 12 hours. By LCMS analysis,
the raw
materials were completely consumed, and a target signal appeared. The reaction
solution was
concentrated under reduced pressure, diluted with ethyl acetate (200 mL), and
washed with
saturated brine (200 mL). The organic phase was dried over anhydrous sodium
sulfate, and
filtered, and the filtrate was concentrated under reduced pressure to give a
crude product,
which was directly used in the next step without purification. Compound BB-7-2
was obtained.
11-1 NMR (400 MHz, CDC13) 6 = 6.87 - 7.19 (m, 4 H), 5.78 (br s, 1 H), 4.04 (br
s, 2 H), 2.92 -
3.44 (m, 2 H), 1.18 (br s, 3 H); LCMS m/z = 269.11M+1r.
[00185] Step 2: synthesis of compound BB-7-3
[00186] To a solution of BB-7-2 (7 g, 26.05 mmol, 1 eq) in ethanol (200 mL)
was added
hydroxylamine hydrochloride (1.81 g, 26.05 mmol, 1 eq), and the mixture was
reacted at 80 C
for 12 hours. By LCMS analysis, the raw materials were completely consumed,
and a target
signal appeared. The reaction solution was concentrated under reduced pressure
to give BB-7-3.
1H NMR (400 MHz, CDC13) 6 = 7.33 (m, 2 H); 7.20 (m, 2 H), 6.35 (s, 1 H), 4.41 -
4.47 (m, 2 H),
4.13 (q, J = 7.20 Hz, 2 H), 1.30- 1.33 (t, 3 H); LCMS m/z = 266.1[M+1] .
[00187] Step 3: synthesis of compound BB-7-4
[00188] To a solution of BB-7-3 (4 g, 15.06 mmol, 1 eq) in ethanol (100 mL)
was added Pd/C
(4 g, 5% purity), and the mixture was reacted at 30 C under H2 atmosphere (30
psi) for 12
hours. By LCMS analysis, the raw materials were completely consumed, and a
target signal
appeared. The reaction solution was filtered through Celite, and the filtrate
was concentrated
34
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
under reduced pressure to give a crude product. The crude product was purified
by silica gel
column chromatography (dichloromethane:methanol = 10:1) to give compound BB-7-
4.
LCMS m/z = 232.1[M+1]+.
[00189] Step 4: synthesis of compound BB-7
[00190] To a solution of BB-7-4 (0.5 g, 2.16 mmol, 1 eq) in tetrahydrofuran
(15 mL) and water
(5 mL) was added lithium hydroxide monohydrate (453.17 mg, 10.80 mmol, 5 eq),
and the
mixture was reacted at 30 C for 2 hours. The raw materials were completely
consumed and a
new spot appeared by TLC (petroleum ether:ethyl acetate = 5:1) monitoring. The
reaction
solution was concentrated under reduced pressure to remove the organic
solvent, and 2 M
hydrochloric acid solution was added to adjust pH to about 2. A white solid
precipitated. The
mixture was filtered, and the filter cake was collected to give BB-7. 1H NMR
(400 MHz,
DMSO-d6) ö = 7.24 - 7.41 (m, 5 H), 6.57 (s, 1 H), 4.22 (s, 2 H).
[00191] Reference example 8: Fragment BB-8
¨N 0
N /<
OH
[00192] Route for synthesis:
N 0
L"--N\/ ¨ ________________ 1101 1110 NLõ:"
OH
BB-8-1 BB-8-2 BB-8
[00193] Step 1: synthesis of compound BB-8-2
[00194] To a solution of BB-8-1(2 g, 15.74 mmol, 1 eq) in DMF (32 mL) were
added cesium
carbonate (6.67 g, 20.46 mmol, 1.3 eq) and benzyl bromide (3.23 g, 18.88 mmol,
2.24 mL, 1.2
eq), and the mixture was stirred at 20 C for 2 hours. By LCMS monitoring, the
raw materials
were completely consumed, and a target signal appeared. Water (30 mL) and
ethyl acetate (30
mL) were added to the reaction solution, and the layers were separated. The
organic phase was
washed with saturated brine, dried over anhydrous sodium sulfate, and
filtered. The filtrate was
concentrated under reduced pressure to give a crude product. The crude product
was purified
by flash silica gel column chromatography (petroleum ether:ethyl acetate =
10:1-3:1) to give
BB-8-2. 11-1NMR (400 MHz, CDC13) 6 = 8.11 (s, 1 H), 7.34 - 7.43 (m, 3 H), 7.27
- 7.33 (m, 2 H),
5.43 (s, 2 H), 4.00 (s, 3 H); LCMS m/z = 218.1 [M+1]+.
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00195] Step 2: synthesis of compound BB-8
[00196] BB-8-2 (0.3 g, 1.38 mmol, 1 eq) was dissolved in tetrahydrofuran (12
mL) and water
(4 mL), and lithium hydroxide monohydrate (173.85 mg, 4.14 mmol, 3 eq) was
added. The
reaction was stirred at 25 C for 12 hours. By LCMS monitoring, the raw
materials were
completely consumed, and a target signal peak appeared. Ethyl acetate (10 mL)
was added to
the reaction solution, and the aqueous phase was adjusted to a pH of 3-4 with
1 M hydrochloric
acid. Solid precipitated. The mixture was filtered to give BB-8. NMR (400 MHz,
DMSO-d6)
6=13.25 (br s, 1 H), 8.78 (s, 1 H), 7.27 - 7.40 (m, 5 H), 5.47 (s, 2 H); LCMS
m/z = 204.1
[M+1]-F.
[00197] Reference example 9: Fragment BB-9
NC
0
41111
______________________________________ 0H
[00198] Route for synthesis:
NC
HN-N /0
401
H2N N
0
BB-9-1 BB-9-2 BB-9-3
NC
..N 0
* N
OH
BB-9
[00199] Step 1: synthesis of compound BB-9-2
[00200] NaNO2 (662.86 mg, 9.60 mmol, 1.5 eq) was added to a solution of BB-9-1
(1 g, 6.40
mmol, 1 eq) in H2504 (1 M, 12.80 mL, 2 eq) and water (10 mL) at 0 C, and the
mixture was
stirred at 0 C for 0.5 hours. CuC12 (1.72 g, 12.80 mmol, 2 eq) was dissolved
in concentrated
hydrochloric acid (15 mL), and the solution was added to the above mixture.
The obtained
mixture was stirred at 0 C for 1.5 hours. By LCMS monitoring, the raw
materials were
completely consumed, and a target signal peak appeared. Ethyl acetate (10 mL)
was added to
the reaction solution, and the aqueous phase was extracted with ethyl acetate
(15 mL*2). The
organic phase was washed with saturated brine, dried over anhydrous sodium
sulfate, and
filtered. The filtrate was concentrated under reduced pressure. The crude
product was purified
36
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
by flash silica gel column chromatography (petroleum ether:ethyl acetate =
10:1 - 1:2) to give
BB-9-2. 1H NMR (400 MHz, CDC13) = 4.46 (q, J= 21.60 Hz, 2 H), 1.38 (t, J=
14.40 Hz, 3 H);
LCMS m/z = 176.0 [M+1]+.
[00201] Step 2: synthesis of compound BB-9-3
[00202] To a solution of BB-9-2 (760.78 mg, 4.33 mmol, 1 eq) in DMF (5 mL) was
added
cesium carbonate (1.84 g, 5.63 mmol, 1.3 eq) and 3-cyanobenzyl bromide (889.31
mg, 5.20
mmol, 617.58 pL, 1.2 eq), and the reaction was stirred at 20 C for 2 hours. By
LCMS
monitoring, the raw materials were completely consumed, and a target signal
peak appeared.
Water (10 mL) was added to the reaction solution, and the mixture was
extracted with ethyl
acetate (10 mL*2). The organic phase was washed with saturated brine, dried
over anhydrous
sodium sulfate, and filtered. The filtrate was concentrated under reduced
pressure, and the
crude product was purified by flash silica gel column chromatography
(petroleum ether: ethyl
acetate = 20:1 - 2:1) to give BB-9-3. LCMS m/z = 291.0 [M+1J+.
[00203] Step 3: synthesis of compound BB-9
[00204] BB-9-3 (0.08 g, 301.10 Ind, 1 eq) was dissolved in tetrahydrofuran (6
mL) and water
(2 mL), and lithium hydroxide monohydrate (37.90 mg, 903.29 pmol, 3 eq) was
added. The
mixture was reacted at 2 C for 12 hours. By LCMS monitoring, the raw materials
were
completely consumed, and a target signal peak appeared. Ethyl acetate (5 mL)
was added to the
reaction solution. The aqueous phase was adjusted to a pH of about 6 with 1 M
hydrochloric
acid, and lyophilized to give BB-9. LCMS m/z = 263.1 [M+11+.
[00205] Reference example 10: Fragment BB-10
r\LoN
[00206] Route for synthesis:
0
110 N'NH2 -N..
0 N 4110 I
0 0 0
"N
BB-1-1 BB-10-1 BB-10
[00207] Step 1: synthesis of compound BB-10-1
[00208] To a solution of BB-1-1 (3 g, 19.98 mmol, 1 eq) in dichloromethane (90
mL) was
added triethylamine (6.06 g, 59.93 mmol, 8.34 mL, 3 eq). Ethyl
chlorooxoacetate (3.55 g,
37
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
25.97 mmol, 2.91 mL, 1.3 eq) was added, and the mixture was stirred at 25 C
for 5 hours. By
LCMS analysis, the raw materials were completely consumed, and a target signal
appeared.
The reaction solution was quenched by adding water (60 mL) and extracted with
dichloromethane (60 mL*3). The organic phase was dried over anhydrous sodium
sulfate, and
filtered, and the filtrate was concentrated under reduced pressure. The crude
product was
purified by flash silica gel column chromatography (petroleum ether: ethyl
acetate = 5:1-1:1) to
give BB-10-1. 111 NMR (400 MHz, DMSO-d6) 6 = 10.73 (br s, 1 H), 10.30 (br s, 1
H), 7.22 -
7.34 (m, 5 H), 4.26 (q, J= 7.00 Hz, 2 H), 3.51 (s, 2 H), 1.27 (t, J= 7.10 Hz,
3 H); LCMS m/z =
251.1[M+1]+.
[00209] Step 2: synthesis of compound BB-10
[00210] To a solution of BB-10-1 (529.69 mg, 2.12 mmol, 1 eq) in acetonitrile
(15 mL) was
added phosphorus oxychloride (486.82 mg, 3.17 mmol, 295.04 pL, 1.5 eq). The
reaction was
stirred at 90 C for 2 hours. The reaction solution was added to saturated
sodium bicarbonate
solution (20 mL), and the mixture was stirred vigorously for 5 minutes. The
mixture was
extracted twice with ethyl acetate (20 mL). The organic phases were combined,
washed with
saturated brine, dried over anhydrous sodium sulfate, and filtered. The
filtrate was
concentrated under reduced pressure to give BB-10. 1H NMR (400MHz, CDC13) 6 =
7.23 -
7.10 (m, 5H), 4.36 - 4.29 (m, 2H), 4.12 (s, 2H), 1.34- 1.23 (m, 3H); LCMS m/z
= 233.1[M+1]4.
[00211] Reference example 11: Fragment BB-11A, BB-11B
o o
NN---o
N
BB-11A BB-11B
[00212] Route for synthesis:
38
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
0 0
0 BacHN H2N,
0
BB-11-1 BB-11-2 BB-11-3
0 0 0
0P.0 0
, NH2
N
0
BB-114 B6414 13641A BB41B
1002131 Step 1: synthesis of compound BB-11-2
[00214] To a solution of BB-11-1 (5 g, 26.01 mmol, 1 eq) in glacial acetic
acid (39 mL) and
tetrahydrofuran (150 mL) was added tert-butyl carbazate (17.19 g, 130.07 mmol,
5 eq), and the
mixture was reacted at 55 C for 12 hours. The mixture was cooled to room
temperature (25 C),
and NaBH3CN (8.17 g, 130.07 mmol, 5 eq) was added in batches. The mixture was
heated to
55 C, and reacted for another 12 hours. The reaction solution was cooled to
room temperature,
and saturated sodium bicarbonate solution was added to the reaction solution
to adjust pH to
7-8. The mixture was extracted with ethyl acetate (150 mL*2). The organic
phases were
combined, washed with saturated brine, dried over anhydrous sodium sulfate,
and filtered. The
filtrate was concentrated under reduced pressure to give BB-11-2. LCMS m/z =
221.1
[M-56+11+.
[00215] Step 2: synthesis of compound BB-11-3
1002161 11-2 (7 g, 25.33 mmol, 1 eq) was added to HC1/Et0Ac (4 M, 60 mL), and
the mixture
was reacted at 25 C for 2 hours. The reaction solution was concentrated under
reduced
pressure to give a crude product. To the crude product was added saturated
sodium bicarbonate
solution to adjust pH to 7-8. The mixture was extracted with ethyl acetate (50
mL*2). The
organic phases were combined, washed with saturated brine, dried over
anhydrous sodium
sulfate, and filtered. The filtrate was concentrated under reduced pressure to
give crude product
BB-11-3. LCMS m/z = 177.1 [M+1] .
[00217] Step 3: synthesis of compound BB-11-4.
[00218] To a solution of BB-11-3 (4 g, 22.70 mmol, 1 eq) in ethanol (50 mL)
was added ethyl
2-ethoxy-2-iminoacetate (16.47 g, 113.50 mmol, 5 eq), and the mixture was
reacted at 85 C for
39
Date recue / Date received 2021-11-30
12 hours. The reaction solution was concentrated under reduced pressure to
give a crude product.
The crude product was purified by column chromatography
(dichloromethane:methanol = 10:0 to
5:1) to give BB-11-4. LCMS m/z = 276.2 [M+1]+.
1002191 Step 4: synthesis of compound BB-11-5
[00220] BB-11-4 (1.3 g, 4.72 mmol, 1 eq) was added to phosphorous oxychloride
(30 mL) at
25 C, and the mixture was reacted at 120 C for 3 hours. The reaction solution
was cooled to room
temperature, and then slowly poured into warm water (150 mL). The mixture was
adjusted to a pH
of 7-8 with saturated sodium bicarbonate, and then extracted with ethyl
acetate (100 mL*2). The
organic phases were combined, washed with saturated brine, dried over
anhydrous sodium sulfate,
and filtered. The filtrate was concentrated under reduced pressure to give a
crude product. The
crude product was purified by column chromatography (dichloromethane:methanol
= 10:0 to 10:1)
to give BB-11-5. 11-1 NMR (400 MHz, DMSO-d6) ö= 7.34 - 7.43 (m, 3 H), 7.21 -
7.28 (m, 2 H),
5.58 (br t, J= 7.12 Hz, 1 H), 4.27 (br dd, J= 6.80, 5.04 Hz, 2 H), 2.88 - 128
(m, 4 H), 1.26 (br t,
J= 7.12 Hz, 3 H). LCMS m/z = 258.2 [M+1].
[00221] Step 5: synthesis of compound BB-11A and BB-11B
[00222] The compound BB-11 was analyzed by supercritical fluid chromatography
(ChiralcelTM
AD-3 3[Em, 0.46cm id x 15mL; Mobile phase: A for SFC CO2 and B for
Me0H(0.05%IPAm);
Gradient: B in A from 10% to 40% in 6 minutes; Flow rate: 4.0mL/min;
Wavelength: 220nm), and
it was shown that retention times of BB-11A and BB-11B were 2.217 min and
2.427 min,
respectively. BB-11A and BB-11B were obtained by separation upon supercritical
fluid
chromatography (Column: DAICEL CHIRALPAKTm AD (250mm*50mm, 10 m); Mobile
phase:
[0.1%NH3H20 MEOH]; Me0H%: 30%-30%, 2.56min). The compound BB-11A was analyzed
by
supercritical fluid chromatography (ChiralcelTm AD-3 3pm, 0.46cm id x 15mL;
Mobile phase: A
for supercritical carbon dioxide, B for methanol (containing 0.05% IPAm);
Gradient: B from 10%
to 40% in 6 minutes; Flow rate: 4.0mL/min; Wavelength: 220nm), and it was
shown that retention
time of BB-11A was 2.235 min, and retention time of BB-11B was 2.439 min.
1002231 Reference example 12: Fragment BB-12
FI
NH2
[00224] Route for synthesis:
Date Recite/Date Received 2023-04-14
CA 03142360 2021-11-30
40 N., 40 N.,
BB-124 BB-12
[00225] Step 1: synthesis of compound BB-12.
[00226] To a solution of BB-12-1 in ethanol (100 mL) were added 12 (11.40 g,
44.92 mmol,
9.05 mL, 1 eq) and Ag2SO4 (14.01 g, 44.92 mmol, 7.61 mL, 1 eq) at 25 C, and
the mixture was
stirred for another 12 hours. The reaction solution was filtered through
Celite. Water (150 mL)
and ethyl acetate (150 mL) were added to the filtrate, and the layers were
separated. The
aqueous phase was extracted with ethyl acetate (50 mL*2). The organic phases
were combined,
washed with saturated brine, dried over anhydrous sodium sulfate, and
filtered. The filtrate was
concentrated under reduced pressure to give a crude product. The crude product
was dissolved
in ethyl acetate, and hydrochloric acid/ethyl acetate (4 M) was added. The
mixture was stirred
at room temperature for 0.5 h, and then filtered. The filter cake was
collected. Ethyl acetate (50
mL) was added to the cake, and saturated sodium bicarbonate was added to
adjust pH to 8-9.
The layers were separated. The aqueous phase was extracted with ethyl acetate
(25 mL*2). The
organic phases were combined, washed with saturated brine, dried over
anhydrous sodium
sulfate, and filtered. The filtrate was concentrated under reduced pressure
(water pump, 45 C)
to give a crude product, and the crude product was purified by column
chromatography
(petroleum ether:ethyl acetate = 10:1 ¨ 1:1) to give BB-12. 1H NMR (400 MHz,
CDC13) 5 =
7.22 (dt, J= 7.68, 2.37 Hz, 1 H), 6.83 (ddd,J 10.85, 8.22, 2.76 Hz, 1 H), 3.97
(br s,2 H).
[00227] Reference example 13: Fragment BB-13
_N 0
N __
[00228] Route for synthesis:
=HN 0 0 N_Isl 0
OH
BB-9-2 BB-13A BB-13
[00229] Step 1: synthesis of compound BB-13-1
[00230] To a solution of BB-9-2 (760.78 mg, 4.33 mmol, 1 eq) in DMF (5 mL)
were added
cesium carbonate (1.84 g, 5.63 mmol, 1.3 eq) and benzyl bromide (889.31 mg,
5.20 mmol,
41
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
617.581AL, 1.2 eq), and the reaction was stirred at 20 C for 2 hours. By LCMS
monitoring, the
raw materials were completely consumed, and a target signal peak appeared.
Water (10 mL)
was added to the reaction solution, and the mixture was extracted with ethyl
acetate (10 mL*2).
The organic phase was washed with saturated brine, dried over anhydrous sodium
sulfate, and
filtered. The filtrate was concentrated under reduced pressure. The crude
product was purified
by flash silica gel column chromatography (petroleum ether:ethyl acetate =
20:1-2:1) to give
BB-13-1. NMR (400 MHz, CDC13) 6=7.34 - 7.41 (m, 3 H), 7.29 - 7.34 (m, 2 H),
5.42 (s, 2
H), 4.47 (q, J = 22.40 Hz, 2 H), 1.43 (t, J= 15.60 Hz, 3 H); LCMS m/z = 266.0
[M+1] .
[002311 Step 2: synthesis of compound BB-13
[00232] BB-13-1 (0.08 g, 301.10 lamol, 1 eq) was dissolved in tetrahydrofuran
(6 mL) and
water (2 mL), and lithium hydroxide monohydrate (37.90 mg, 903.29 Rmol, 3 eq)
was added.
The mixture was reacted at 25 C for 12 hours. By LCMS monitoring, the raw
materials were
completely consumed, and a target signal peak appeared. 5 rilL of ethyl
acetate was added to
the reaction solution. The aqueous phase was adjusted to a pH of about 6 with
1 M hydrochloric
acid, and lyophilized to give BB-13. NMR (400 MHz, DMSO-d6) S= 7.32 - 7.42 (m,
3 H),
7.25 - 7.30 (m, 2 H), 5.48 (s, 2 H); LCMS m/z = 238.1 [M+1]+.
[00233] Example 1: VVX001
0, N io
s
1002341 Route for synthesis:
0 N =HOIN
0 BB1 0 0 \ N 1110
1101 ,,NH2 -
3. </N-N
/ S
/ S
BB-3 WX0131
1002351 Step 1: synthesis of compound WX001
[00236] Compound BB-3 (0.58 g, 2.78 mmol, 1 eq), compound BB-1 (849 mg, 4.18
mmol, 1.5
eq), N,N-diisopropylethylamine (1.26 g, 9.75 mmol, 1.70 mL, 3.5 eq) were
dissolved in ethyl
acetate (10 mL), and then tri-n-butyl phosphoric anhydride (4.43 g, 6.96 mmol,
4.14 mL, 50%
purity in ethyl acetate, 2.5 eq) was added dropwise. After the completion of
addition, the
42
Date recue / Date received 2021-11-30
mixture was stiffed at 25 C for 12 hours. 20 mL of water was added to the
reaction solution and
the mixture was extracted with ethyl acetate (5 mL * 2). The organic phases
were combined and
washed with saturated brine (10 mL). The organic phase was dried over
anhydrous sodium sulfate,
and filtered, and the filtrate was concentrated under reduced pressure to give
a crude product. The
crude product was purified by silica gel column, and then separated by SFC
(ChiralcelTM OJ-3,
3um, 0.46cm id x 5cm L; Mobile phase: A for supercritical carbon dioxide, B
for methanol
(containing 0.05% IPAm); Gradient: B from 10% to 40% in 5 minutes; Flow rate:
4.0mL/min;
Wavelength h: 220nm) to give compound WX001. NMR (400 MHz, CDC13) i = 8.71 (d,
J=
7.53 Hz, 1H), 7.20-7.38 (m, 9H), 5.15 - 5.25 (m, 1H), 4.67 (dd, J= 6.53, 9.54
Hz, 1H), 4.29 (dd,
J= 9.79, 10.79 Hz, 1H), 4.21 (s, 2H), 3.89 (s, 3H); LCMS m/z = 394.1 [M+H]+.
By analyzing with
supercritical fluid chromatography (Chiral column: Column: ChiralpakTM OD -3,
3 m, 0.46cm id
x 5cm L; Mobile phase: A: CO2, B: Me0H (0.05% IPAm); Gradient: B/A = 10% - 40%
in 3
minutes; Flow rate: 4.0 mL/min; Wavelength: 220nm), ee % was equal to 96.36 %.
[00237] Example 2: VVX002
CN
0 N
L.
,,NH WIN
/ S
[00238] Route for synthesis:
CN
0 N
HOcj CN
ON 0 N
BB-2
NH 2
/ S
/ S
BB-3 VVX002
[00239] Step 1: synthesis of compound VVX002
[00240] To a solution of BB-3 (0.06 g, 288.07 mmol, 1 eq) and BB-2 (131.48 mg,
576.15 mol, 2
eq) in DMF (10 mL) were added tri-n-butyl phosphoric anhydride (458.30 mg,
720.19 gmol,
428.32 L, 50 % purity in ethyl acetate, 2.5 eq) and N,N-diisopropylethylamine
(111.69 mg,
864.22 mot, 150.53 iuL, 3 eq), and the mixture was stirred at 25 C for 10
hours. By LCMS
monitoring, the raw materials were completely consumed, and a target signal
appeared. 20 mL of
ethyl acetate was added to the reaction solution and the mixture was washed
with 15 mL of
43
Date Recite/Date Received 2023-04-14
saturated brine. The organic phase was dried over anhydrous sodium sulfate,
and filtered, and the
filtrate was concentrated under reduced pressure to give a crude product. The
crude product was
purified by preparative HPLC (Column: Xtimate C18 150mm*25mm*5 gm; Mobile
phase: [water
(10mM NH4HCO3)-ACN]; acetonitrile%: 35%-65%, 10.5min) to give compound WX002.
1H
NMR (400 MHz, DMSO-d6) 6 = 8.60 (br d, J= 8.16 Hz, 1 H), 7.69 - 7.81 (m, 2 H),
7.51 - 7.65
(m, 3 H), 7.36 - 7.46 (m, 2 H), 7.25 - 7.33 (m, 1 H), 4.97 (dt, J= 10.58, 7.72
Hz, 1 H), 4.35 - 4.52
(m, 2 H), 4.21 (s, 2 H), 3.79 (s, 3 H); LCMS m/z = 419.1 [M+H]t By analyzing
with supercritical
fluid chromatography (Chiral column: Column: ChiralpakTM OD-3, 3 m, 0.46cm id
x 5cm L;
Mobile phase: A: CO2, B: Me0H (0.05% IPAm); Gradient: B/A = 10% - 40% in 3
minutes; Flow
rate: 4.0 mL/min; Wavelength: 220nm), ee % was equal to 100 %.
[00241] Example 3: VVX003
0 N
rµ?,\H
N
co
/ S
[00242] Route for synthesis:
0, N /10
_IN
HO N
0 0 N
,NH2 BB -1 /0 j\Fi
1j, H
/ S
BB-4 WX003
[00243] Step 1: synthesis of compound VVX003
[00244] To a solution of BB-4 (60 mg, 286.71 mol, 1 eq) and BB-1 (87.39 mg,
430.07
1.5 eq) in DMF (10 mL) were added tri-n-butyl phosphoric anhydride (456.13 mg,
716.78
tunol, 426.29 L, 50% purity in ethyl acetate, 2.5 eq) and N,N-
diisopropylethylamine (111.16
mg, 860.13 wnol, 149.82 L, 3 eq), and the mixture was stirred at 25 C for 10
hours. By LCMS
monitoring, the raw materials were completely consumed, and a target signal
appeared. 30 mL
of ethyl acetate was added to the reaction solution and the mixture was washed
with 20 mL of
saturated brine. The organic phase was dried over anhydrous sodium sulfate,
and filtered, and
the filtrate was concentrated under reduced pressure to give a crude product.
The crude product
was purified by preparative HPLC (Column: Xtimate C18 150mm*25mm*5pin; Mobile
phase:
[water (10mM NH4HCO3)-ACN]; acetonitrile%: 35%-65%, 10.5min) to give compound
44
Date Recite/Date Received 2023-04-14
VVX003. NMR (400 MHz, DMSO-d6) ö = 8.63 (br s, 1 H), 8.46 (dd, J= 4.63,
1.54 Hz, 1 H),
7.79 (d, Jr 7.94 Hz, 1 H), 7.48 (dd, J= 8.05, 4.74 Hz, 1 H), 7.23 - 7.37 (m, 5
H), 5.01 (dt, J-
10.80, 7.28 Hz, 1 H), 4.43 - 4.72 (m, 2 H), 4.14 (br s, 2 H), 3.80 (s, 3 H);
LCMS m/z = 395.2
[M+H]t By analyzing with supercritical fluid chromatography (Chiral column:
Column:
ChiralpakTm OD -3, 311m, 0.46cm id x 5cm L; Mobile phase: A: CO2, B: Me0H
(0.05% IPAm);
Gradient: B/A = 10% - 40% in 3 minutes; Flow rate: 4.0 mL/min; Wavelength:
220nm), ee % was
equal to 96.3%.
[00245] Example 4: VVX004
CN
0 N
/ S
[00246] Route for synthesis:
CN
0 N
HO CN' N_L
0 0, N as
NH2 BB-2 _
"
I ...NH WIN
NN/N s
/ S
BB-4 INX004
[00247] Step 1: synthesis of compound VVX004
[00248] To a solution of BB-4 (60 mg, 286.71 mol, 1 eq) and BB-2 (130.86 mg,
573.43 mol,
2 eq) in DMF (10 mL) were added tri-n-butyl phosphoric anhydride (456.13 mg,
716.78 mol,
426.29 L, 50% purity in ethyl acetate, 2.5 eq) and N,N-diisopropylethylamine
(111.16 mg,
860.14 mol, 149.82 L, 3 eq), and the mixture was stirred at 25 C for 10
hours. By LCMS
monitoring, the raw materials were completely consumed, and a target signal
appeared. 30 mL
of ethyl acetate was added to the reaction solution and the mixture was washed
with 20 mL of
saturated brine. The organic phase was dried over anhydrous sodium sulfate,
and filtered, and
the filtrate was concentrated under reduced pressure to give a crude product.
The crude product
was purified by preparative HPLC (Column: Xtimate C18 15 mm*25mm*5 pm; Mobile
phase:
[water (10mM NH4HCO3)-ACN]; acetonitrile%: 35%-65%, 10.5min) to give compound
WX004. 1H NMR (400 MHz, DMSO-d6) = 8.73 (br s, 1 H), 8.46 (d, J= 4.85 Hz, 1
H), 7.69
-7.86 (m, 3 H), 7.44 -7.65 (m, 3 H), 5.01 (dt, J= 11.08, 7.14 Hz, 1 H), 4.48 -
4.68 (m, 2 H),
4.22 (s, 2 H), 3.80 (s, 3 H); LCMS m/z = 420.1 [M+H]t By analyzing with
supercritical fluid
Date Recite/Date Received 2023-04-14
chromatography (Chiral column: Column: ChiralpakTM OD -3, 3 m, 0.46cm id x 5cm
L; Mobile
phase: A: CO2, B: Me0H (0.05% IPAm); Gradient: B/A = 10% - 40% in 3 minutes;
Flow rate: 4.0
mL/min; Wavelength: 220nm), ee % was equal to 100 %.
[00249] Example 5: VVX005
0 ox
co
N N
D36 S
[00250] Route for synthesis:
,1 40HO < N-N
0 N is
NtH /1\1-1µ1
I .,NH2 HCI BB-1 I "
ThµINN N H
D36 S N036 S
BB-5 WX005
[00251] Step 1: synthesis of compound VVX005
[00252] To a solution of BB-5 (100 mg, 471.06 ttrnol, 1 eq) and BB-1 (130.86
mg, 573.43 ttmol,
1.2 eq) in DMF (10 mL) were added tri-n-butyl phosphoric anhydride (599.53 mg,
942.12 mai,
560.31 pL, 50 % purity in ethyl acetate, 2.5 eq) and N,N-diisopropylethylamine
(182.64 mg, 1.41
mmol, 246.15 L, 3 eq), and the mixture was stirred at 25 C for 10 hours. By
LCMS monitoring,
the raw materials were completely consumed, and a target signal appeared.
Ethyl acetate (30 mL)
was added to the reaction solution, and the mixture was washed with saturated
brine (20 mL). The
organic phase was dried over anhydrous sodium sulfate, and filtered, and the
filtrate was
concentrated under reduced pressure to give a crude product. The crude product
was purified by
preparative HPLC (Column: Phenomenex Luna C18 150mm*30mm*5p.m; Mobile phase:
[water
(0.05%HC1)-ACN]; acetonitrile%: 20%-50%, 12min) to give compound WX005. 1H NMR
(400
MHz, DM50-d6) i = 8.62 (br s, 1H), 8.46 (dd,J= 1.75, 4.82 Hz, 1H), 7.79 (dd,J=
1.32, 7.89 Hz,
1H), 7.48 (dd, J= 4.82, 7.89 Hz, 1H), 7.20-7.37 (m, 5H), 5.01 (td, Jr 7.34,
11.18 Hz, 1H), 4.60
(br s, 1H), 4.49-4.55 (m, 1H), 4.14 (br s, 2H); LCMS m/z = 398.2 [M+H]. By
analyzing with
supercritical fluid chromatography (Chiral column: Column: ChiralpakTM OD -3,
3 m, 0.46cm id
x 5cm L; Mobile phase: A: CO2, B: Me0H (0.05% IPAm); Gradient: B/A = 10% - 40%
in 3
minutes; Flow rate: 4.0 mL/min; Wavelength: 220nm), ee % was equal to 100 %.
46
Date Recite/Date Received 2023-04-14
[00253] Example 6: VVX006
J) ao
r=r'N
S
[00254] Route for synthesis:
Clij 40
NH2
HO BB
/s NC)\
I "
Th\IN TheN
/ S / S
BB-4 WX006
[00255] Step 1: synthesis of compound WX006
[00256] To a solution of BB-4 (10 mg, 47.79 p.mol, 1 eq) and BB-1 (11.60 mg,
57.34 ttmol, 1.2
eq) in DMF (1 mL) were added tri-n-butyl phosphoric anhydride (60.82 mg, 95.57
timol, 56.84
IIIõ 50 % purity in ethyl acetate, 2.5 eq) and N,N-diisopropylethylamine
(18.53 mg, 143.36 mol,
24.97 L, 3 eq), and the mixture was stirred at 25 C for 10 hours. By LCMS
monitoring, the raw
materials were completely consumed, and a target signal appeared. The reaction
solution was
directly purified by preparative HPLC (Column: Phenomenex Luna C18
150mm*30mm*51.1m;
Mobile phase: [water (0.05%HC1)-ACN]; acetonitrile%: 20%-50%, 12min) to give
compound
WX006. IHNMR (400 MHz, CDC13) 6 = 9.01 (br s, 1H), 8.34-8.46 (m, 2H), 7.51-
7.64 (m, 2H),
7.43 (br s, 3H), 7.28-7.31 (m, 2H), 7.22-7.26 (m, 1H), 5.29 (br s, 2H), 5.20
(br d, J= 7.02 Hz, 1H),
4.58-4.69 (m, 2H), 3.91 (s, 3H); LCMS m/z = 394.2 [M+H]t By analyzing with
supercritical fluid
chromatography (Chiral column: Column: ChiralpakTM OD -3, 31.1m, 0.46cm id x
5cm L; Mobile
phase: A: CO2, B: Me0H (0.05% IPAm); Gradient: B/A = 10% - 40% in 3 minutes;
Flow rate: 4.0
mL/min; Wavelength: 220nm), ee % was equal to 100 %.
[00257] Example 7: WX007
o
N
S
[00258] Route for synthesis:
47
Date Recite/Date Received 2023-04-14
0\\
\ 1101
HO N"'" 0
BB-7
reNN
S / S
BB-4 WX007
[00259] Step 1: synthesis of compound WX007
[00260] To a solution of BB-4 (10 mg, 47.79 mol, 1 eq) and BB-7 (11.65 mg,
57.35 mol, 1.2
eq) in DMF (1 mL) were added tri-n-butyl phosphoric anhydride (60.82 mg, 95.57
prnol, 56.84
50 % purity in ethyl acetate, 2.5 eq) and N,N-diisopropylethylamine (18.53 mg,
143.36 mot,
24.97 L, 3 eq), and the mixture was stirred at 25 C for 10 hours. By LCMS
monitoring, the raw
materials were completely consumed, and a target signal appeared. The reaction
solution was
directly purified by preparative HPLC (Column: Phenomenex Luna C18
150mm*30mm*5 m;
Mobile phase: [water (0.05%HC1)-ACN]; acetonitrile%: 20%-50%, 12min) to give
compound
WX007. NMR (400 MHz, DMSO-d6) 6 = 8.98 (d, J= 8.33 Hz, 1H), 8.46 (dd, J= 1.32,
4.82
Hz, 1H), 7.77 (dd, J= 1.75, 7.89 Hz, 1H), 7.47 (dd, J= 4.60, 8.11 Hz, 1H),
7.22-7.40 (m, 5H),
6.54 (s, 1H), 5.00 (td, J= 7.45, 11.40 Hz, 1H), 4.59-4.70 (m, 1H), 4.48-
4.56(m, 1H), 4.22 (s, 2H),
3.79 (s, 3H); LCMS m/z = 395.1 [M+H]. By analyzing with supercritical fluid
chromatography
(Chiral column: Column: ChiralpakTM OD -3, 3 m, 0.46cm id x 5cm L; Mobile
phase: A: CO2, B:
Me0H (0.05% IPAm); Gradient: B/A = 10% - 40% in 3 minutes; Flow rate: 4.0
mL/min;
Wavelength: 220nm), ee % was equal to 100 %.
[00261] Example 8: VVX008
CN
CI
[00262] Route for synthesis:
CN
0 N-lq
HO, N ci CN
0 0 40BB-9
,INH2 _______________________________ a. "NH NI:INci
N N NNNJ
/ S S
BB-4 1A00008
[00263] Step 1: synthesis of compound WX008
[00264] To a solution of BB-4 (10 mg, 47.79 tunol, 1 eq) and BB-8 (15.06 mg,
57.35 mol, 1.2
48
Date Recite/Date Received 2023-04-14
eq) in DMF (1 mL) were added tri-n-butyl phosphoric anhydride (60.82 mg, 95.57
pmol, 56.84
!IL, 50 % purity in ethyl acetate, 2.5 eq) and N,N-diisopropylethylamine
(18.53 mg, 143.36 pmol,
24.97 pL, 3 eq), and the mixture was stirred at 25 C for 10 hours. By LCMS
monitoring, the raw
materials were completely consumed, and a target signal appeared. The reaction
solution was
directly purified by preparative HPLC (Column: Phenomenex Luna C18
150mm*30mm*51..tm;
Mobile phase: [water (0.05%HC1)-ACN]; acetonitrile%: 20%-50%, 12min) to give
compound
VVX008. IHNMR (400 MHz, DMSO-d6) = 8.85 (d, J= 7.89 Hz, 1H), 8.46 (d, Jr 3.07
Hz, 1H),
7.75-7.89 (m, 3H), 7.61 (d, J= 4.82 Hz, 2H), 7.48 (dd, J= 4.82, 7.89 Hz, 1H),
5.58 (s, 2H), 4.94-
5.06 (m, 1H), 4.65 (t, J = 10.74 Hz, 1H), 4.45-4.57 (m, 1H), 3.80 (s, 3H);
LCMS m/z = 454.1
[M+H]. By analyzing with supercritical fluid chromatography (Chiral column:
Column:
ChiralpakTm OD -3, 3p.m, 0.46cm id x 5cm L; Mobile phase: A: CO2, B: Me0H
(0.05% IPAm);
Gradient: B/A = 10% - 40% in 3 minutes; Flow rate: 4.0 mL/min; Wavelength:
220nm), ee % was
equal to 100 %.
[00265] Example 9: VVX009
0 NN
0
"NH
leNN
/ S
[00266] Route for synthesis:
Nrjq io
HO N-
O
,NH2 BB-8 ,0
N1-4-NN Mµ1NN
S / S
BB-4 INX009
[00267] Step 1: synthesis of compound WX009
[00268] To a solution of BB-4 (10 mg, 47.79 p.mol, 1 eq) and BB-9 (11.65 mg,
57.35
1.2 eq) in DMF (1 mL) were added tri-n-butyl phosphoric anhydride (60.82 mg,
95.57 pinol,
56.84 FL, 50 % purity in ethyl acetate, 2.5 eq) and N,N-diisopropylethylamine
(18.53 mg,
143.36 j.tmol, 24.97 pL, 3 eq), and the mixture was stirred at 25 C for 10
hours. By LCMS
monitoring, the raw materials were completely consumed, and a target signal
appeared. The
reaction solution was directly purified by preparative HPLC (Column:
Phenomenex Luna C18
150mm*30mm*5p.m; Mobile phase: [water (0.05%HC1)-ACN]; acetonitrile%: 20%-50%,
49
Date Recite/Date Received 2023-04-14
12min) to give compound WX009. 1H NMR (400 MHz, DMSO-d6) ö = 8.84 (s, 1H),
8.71 (d, J=
7.89 Hz, 1H), 8.46 (dd,J= 1.53, 4.60 Hz, 1H), 7.79 (dd, J= 1.53, 8.11 Hz, 1H),
7.48 (dd, J= 4.82,
7.89 Hz, 1H), 7.26-7.42 (m, 5H), 5.49 (s, 2H), 4.94-5.08 (m, 1H), 4.48-4.63
(m, 2H), 3.80 (s, 3H);
LCMS m/z = 395.1 [M+H]t By analyzing with supercritical fluid chromatography
(Chiral
column: Column: ChiralpakTm OD -3, 3 m, 0.46cm id x 5cm L; Mobile phase: A:
CO2, B: Me0H
(0.05% IPAm); Gradient: B/A = 10% - 40% in 3 minutes; Flow rate: 4.0 mL/min;
Wavelength:
220nm), ee % was equal to 100 %.
[00269] Example 10: WX010
0
OCN %NH
/ S
[00270] Route for synthesis:
1-:)---<:11\1
o) o¶.:Z
NH2 INX010-1
0
1'
S N N
/ S
BB-4 =ow
[00271] Step 1: synthesis of compound WX010
[00272] To a solution of BB-4 (10 mg, 47.79 tunol, 1 eq) and WX010-1 (11.65
mg, 57.35 gmol,
1.2 eq) in DMF (1 mL) were added tri-n-butyl phosphoric anhydride (60.82 mg,
95.57 pmol,
56.84 L, 50% purity in ethyl acetate, 2.5 eq) and N,N-diisopropylethylamine
(18.53 mg, 143.36
timol, 24.97 !IL, 3 eq), and the mixture was stirred at 25 C for 10 hours. By
LCMS monitoring,
the raw materials were completely consumed, and a target signal appeared. The
reaction solution
was directly purified by preparative HPLC (Column: Phenomenex Luna C18
150mm*30mm*5p.m; Mobile phase: [water (0.05%HC1)-ACN]; acetonitrile%: 20%-50%,
12min) to give compound WX010. 1H NMR (400 MHz, DMSO-d6) ö= 8.75 (d, Jr 8.33
Hz,
1H), 8.69(s, 1H), 8.46 (dd, J= 1.53, 4.60 Hz, 1H), 7.79 (dd, J= 1.53, 8.11 Hz,
1H), 7.48 (dd, J
= 4.82, 7.89 Hz, 1H), 7.30-7.41 (m, 5H), 5.65 (s, 2H), 4.97-5.10 (m, 1H), 4.58-
4.68 (m, 1H),
4.47-4.57 (m, 1H), 3.80 (s, 3H); LCMS m/z = 395.1 [M+H]t By analyzing with
supercritical
fluid chromatography (Chiral column: Column: ChiralpakTM OD -3, 31.1m, 0.46cm
id x 5cm L;
Mobile phase: A: CO2, B: Me0H (0.05% IPAm); Gradient: B/A = 10% - 40% in 3
minutes;
Date Recite/Date Received 2023-04-14
Flow rate: 4.0 mL/min; Wavelength: 220nm), ee % was equal to 100 %.
[00273] Example 11: WX011
ci
0).4.N1
N N
/ S
[00274] Route for synthesis:
HO N CI CI
0 0 0).--4j BB-13 1
.,NH2 INH N
N
S N N
/ S
BB-4 INX011
[00275] Step 1: synthesis of compound WX011
[00276] To a solution of BB-4 (10 mg, 47.79 mot 1 eq) and BB-13 (14.76 mg,
62.13 mot 1.2
eq) in DMF (1 mL) were added tri-n-butyl phosphoric anhydride (60.82 mg, 95.57
pm ol, 56.84
ttL, 50 % purity in ethyl acetate, 2.5 eq) and N,N-diisopropylethylamine
(18.53 mg, 143.36 mot
24.97 L, 3 eq), and the mixture was stirred at 25 C for 10 hours. By LCMS
monitoring, the raw
materials were completely consumed, and a target signal appeared. The reaction
solution was
directly purified by preparative HPLC (Column: Phenomenex Luna C18
150mm*30mm*51.im;
Mobile phase: [water (0.05%HC1)-ACN]; acetonitrile%: 20%-50%, 12min) to give
compound
WX011. IHNMR (400 MHz, DMS0- d6) 6 = 8.83 (d, J= 7.89 Hz, 1H), 8.41-8.49 (m,
1H), 7.77
(dd, Jr 1.32, 7.89 Hz, 1H), 7.46 (dd, Jr 4.82, 7.89 Hz, 1H), 7.30-7.42 (m,
3H), 7.26 (d, J= 7.02
Hz, 2H), 5.48 (s, 2H), 4.98 (td, J= 7.13, 11.62 Hz, 1H), 4.59-4.67 (m, 1H),
4.49 (dd, J= 6.80, 9.87
Hz, 1H), 3.78 (s, 3H); LCMS miz = 429.0 [M+H]t By analyzing with supercritical
fluid
chromatography (Chiral column: Column: ChiralpakTM OD -3, 3 m, 0.46cm id x 5cm
L; Mobile
phase: A: CO2, B: Me0H (0.05% IPAm); Gradient: B/A = 10% - 40% in 3 minutes;
Flow rate: 4.0
mL/min; Wavelength: 220nm), ee % was equal to 100 %.
[00277] Example 12: WX012
0, 0
,NH N-11
/ S
5].
Date Recite/Date Received 2023-04-14
CA 03142360 2021-11-30
[00278] Route for synthesis:
r 0 N-N
0
0 0 y4 BB-10
N N N N
S S
BB-4 WX012
[00279] Step 1: synthesis of compound WX012
[00280] To a solution of BB-4 (15 mg, 71.68 pmol, 1 eq) and BB-10 (33.29 mg,
143.36 mot,
2 eq) in toluene (3 mL) was added trimethyl aluminum (2 M, 53.76 pL, 1.5 eq),
and the mixture
was then stirred at 25 C for 1 hour. By LCMS monitoring, the raw materials
were completely
consumed, and a target signal appeared. The reaction solution was directly
purified by
preparative HPLC (Column: Phenomenex Luna C18 150nun*30mm*511m; Mobile phase:
[water (0.05%HC1)-ACI=I]; acetonitrile%: 20%-50%, 12min) to give compound
WX012.
LCMS m/z = 396.2 [M+111 .
[00281] Example 13: WX013
N
0 N
..INH
N
S
[00282] Route for synthesis:
\-0 N HO N
_________________________ o>/ ,o
11.
N N
S
BB-11B WX013-1 VVX013
[00283] Step 1: synthesis of compound WX013-1
[00284] Li011-1420 (245.59 mg, 5.85 mmol, 3 eq) was added to a solution of BB-
11B (501.93
mg, 1.95 mmol, 1 eq) in tetrahydrofuran (9 mL) and water (3 mL), and the
mixture was reacted
at 25 C for 2 hours. Water (10 mL) and ethyl acetate (10 mL) were added to
the reaction
solution, and the layers were separated. The aqueous phase was extracted with
ethyl acetate (10
mL*2). The resulting aqueous phase was adjusted to a pH of 5-6 with 1 M HC1,
and extracted
with ethyl acetate (10 mL*2). The organic phases were combined, washed with
saturated brine,
dried over anhydrous sodium sulfate, and filtered. The filtrate was
concentrated under reduced
52
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
pressure (water pump, 45 C) to give VVX013-1. LCMS m/z = 230.2 [M+1] .1H NMR
(400
MHz, DMSO-d6) 5 = 12.75 - 13.57 (m, 1 H), 7.33 -7.44 (m, 3 H), 7.18 - 7.28 (m,
2 H), 5.57 (dd,
J= 7.97, 6.21 Hz, 1 H), 3.06 - 3.22 (m, 2 H), 2.94 - 3.03 (m, 1 H), 2.53 -
2.61 (m, 1 H).
[00285] Step 2: synthesis of compound WX013
[00286] N,N-diisopropylethylamine (23.16 mg, 179.20 umol, 31.21 pi, 2.5 eq)
and WX013-1
(24.65 mg, 107.52 mol, 1.5 eq) were added to a solution of BB-1 (15 mg, 71.68
gmol, 1 eq) in
DMF (1.5 mL), and propylphosphonic anhydride (T3P, 68.42 mg, 107.52 umol,
63.944, 50%
purity, 1.5 eq) was then added. The mixture was reacted at 25 C for 1 hour.
The reaction
solution was filtered, and the filtrate was collected. The collected filtrate
was purified by
preparative HPLC (Column: Phenomenex Luna C18 150mm*30mm*5 m; Mobile phase:
[water (0.05%HC1)-ACN]; acetonitrile%: 20%-50%, 12min) to give VVX013. LCMS
m/z
42 1.1 [M+1] .1H NMR (400 MHz, DMSO-do) 6 = 8.68 (d, J= 8.04 Hz, 1 H), 8.46
(dd, J= 4.72,
1.32 Hz, 1 H), 7.78 (dd, J= 8.04, 1.38 Hz, 1 H), 7.47 (dd, J= 8.04, 4.64 Hz, 1
H), 7.32 -7.43 (m,
3 H), 7.24 (br d, J= 6.65 Hz, 2 H), 5.44 - 5.68 (m, 1 H), 5.00 (dt, J= 11.40,
7.40 Hz, 1 H), 4.42
- 4.68 (m, 2 H), 3.79 (s, 3 H), 2.90 - 3.23 (m, 4 H).
[00287] Example 14: WX014
0, N
= .,NH N
H S
[00288] Route for synthesis:
53
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
NHBoc
0 0 0
OH 0 0 0
NHBoc NHBoc NHBoc NH,
WX014-1 WX014-2 WX014-3 WX014-4
NHBoc
OH
dNHBoc ..NHBoc
0
NH2
F H 0 H S
WX014-5 WX014-6 WX014-7
0 N
1110
NH, _______________________________
N-
N
H S
H S
WX014-8
WX014
[00289] Step 1: synthesis of compound VVX014-2
[00290] WX014-1 was dissolved in a solution of THF (100 mL) and IVIe0H (100
mL), and the
reaction flask was placed in an ice water bath (0 C). Trimethylsilyl
diazomethane (2 M, 47.89
mL, 2.1 eq) was added to the flask, and the mixture was allowed to warm to 25
C and stirred
for 2 hours. Glacial acetic acid was added dropwise until the reaction
solution turned pale
yellow. The reaction solution was concentrated under reduced pressure to give
compound
WX014-2.
[00291] Step 2: synthesis of compound VVX014-3
[00292] Triphenylphosphine (14.30 g, 54.53 mmol, 1.2 eq) and imidazole (3.71
g, 54.53 mmol,
1.2 eq) were dissolved in dichloromethane (120 mL) at 25 C, and 12 (13.84 g,
54.53 mmol,
10.98 mL, 1.2 eq) was slowly added to the above mixture solution. The mixture
solution was
stirred for 10 minutes, and a solution of WX014-2 in DCM (80 mL) was added to
the above
solution. The mixture was reacted at 25 C for 12 hours. The reaction solution
was filtered, and
the filtrate was concentrated under reduced pressure to give a crude product.
The crude product
was purified by column chromatography (petroleum ether:ethyl acetate = 10:1 ¨
1:1) to give
VVX014-3. LCMS m/z = 244.1 [M-100+1] .1H NMR (400 MHz, CDC13) 6 = 5.10 (br d,
J=
4.82 Hz, 1 H), 4.35 (br d, J= 3.96 Hz, 1 H), 3.77 (s, 3 H), 3.18 (t, J= 7.46
Hz, 2 H), 2.30 -2.49
(m, 1 H), 2.18 (dq, J= 14.32, 7.22 Hz, 1 H), 1.43 - 1.47 (m, 9 H).
54
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00293] Step 3: synthesis of compound VVX014-4
[00294] 1,2-Dibromoethane (82.12 mg, 437.12 gmol, 32.98 ILL. 0.3 eq) was added
to zinc
powder (285.83 mg, 4.37 mmol, 3 eq) in DMF (2 mL). The mixture was stirred at
60 C for 30
minutes, and then cooled to room temperature (25 C). Trimethylchlorosilane
(9.50 mg, 87.42
ttmol, 11.10 pt, 0.06 eq) was added into the reaction flask, and the mixture
was stirred at 25 C
for 30 minutes. A solution of WX014-2 in DMF (2 mL) was added to the above
solution, and
the mixture was reacted at 25 C for 30 minutes, and then allowed to stand for
30 minutes. The
upper emulsion was taken out and slowly added to a solution of
tris(dibenzylideneacetone)dipalladium (44.08 mg, 48.14 [tmol, 0.05 eq),
tri-o-methylphenylphosphine (58.61 mg, 192.55 gmol, 0.2 eq), and BB-12 in DMF
(2 mL), and
the mixture was reacted at 20 C for 1 hour. Water (5 mL) and methyl tert-butyl
ether (5 mL)
were added to the reaction solution, and the layers were separated. The
aqueous phase was
extracted with methyl tert-butyl ether (5 mL*2). The organic phases were
combined, washed
with saturated brine, dried over anhydrous sodium sulfate, and filtered. The
filtrate was
concentrated under reduced pressure to give VVX014-4. LCMS m/z = 289.1 N-56+11
.
[00295] Step 4: synthesis of compound WX014-5
[00296] Li011-1-120 (219.33 mg, 5.23 mmol, 3 eq) was added to a solution of
VVX014-4 in
tetrahydrofuran (15 mL) and water (15 mL), and the mixture was reacted at 25 C
for 2 hours.
mL of Water and 10 mL of ethyl acetate were added to the reaction solution,
and the layers
were separated. The aqueous phase was extracted with ethyl acetate (10 mL*2).
The resulting
aqueous phase was adjusted to a pH of 5-6 with 1 M HC1, and extracted with
ethyl acetate (10
mL*2). The organic phases were combined, washed with saturated brine, dried
over anhydrous
sodium sulfate, and filtered. The filtrate was concentrated under reduced
pressure to give
WX014-5. LCMS m/z = 275.1 [M-56+1] .
[00297] Step 5: synthesis of compound WX014-6
[00298] Propylphosphonic anhydride (895.80 mg, 1.41 mmol, 837.20 uL, 50%
purity, 1.5 eq)
was added to a solution of N,N-diisopropylethylamine (303.22 mg, 2.35 mmol,
408.65111õ 2.5
eq) and WX014-5 in DMF (20 mL), and the mixture was reacted at 25 C for 2
hours. Water (15
mL) and ethyl acetate (15 mL) were added to the reaction solution, and the
layers were
separated. The aqueous phase was extracted with ethyl acetate (15 mL*2). The
organic phases
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
were combined, washed with saturated brine, dried over anhydrous sodium
sulfate, and filtered.
The filtrate was concentrated under reduced pressure to give a crude product.
The crude
product was purified by column chromatography (petroleum ether: ethyl acetate
= 10:1 - 1:1)
to give WX014-6. 1H NMR (400 MHz, CDC13) ö= 7.40 (br s, 1 H), 6.76 - 6.87 (m,
2 H), 5.46
(br d,J= 7.46 Hz, 1 H), 4.22 - 4.37 (m, 2 H), 2.88 -3.03 (m, 1 H), 2.63 -2.73
(m, 2 H), 1.42 (s,
9H).
[00299] Step 6: synthesis of compound VVX014-7
[00300] Lawsson's reagent (77.70 mg, 192.12 tunol, 1.5 eq) was added to a
solution of
VVX014-6 (40 mg, 128.08 i.imol, 1 eq) in toluene (5 mL) at 20 C, and the
mixture was reacted
at 70 C for 12 hours. The reaction solution was concentrated under reduced
pressure to give a
crude product. The crude product was purified by column chromatography
(petroleum
ether:ethyl acetate = 10:1 - 1:1) to give WX014-7. LCMS m/z = 273.1 [M-56+1] .
[00301] Step 7: synthesis of compound WX014-8
[00302] HC1/Et0Ac (4M, 2 mL) was added to a solution of WX014-7 in ethyl
acetate (3 mL),
and the mixture was reacted at 25 C for 2 hours. The reaction solution was
concentrated under
reduced pressure (water pump, 40 C) to give a crude product WX014-8. LCMS m/z
= 229.2
[M+1]+.
[003031 Step 8: synthesis of compound WX014
[00304] DIPEA (18.31 mg, 141.66 gmol, 24.67 t.LL, 2.5 eq) and T3P (54.09 mg,
84.99 mot,
50.55 pL, 50% purity, 1.5 eq) were added to a solution of VVX014-8 (15 mg,
56.66 prnol, 1 eq,
HC1) and BB-1 (14.97 mg, 73.66 lamol, 1.3 eq) in DMF (2 mL), and the mixture
was reacted at
25 C for 2 hours. Water (5 mL) and ethyl acetate (5 mL) were added to the
reaction solution,
and the layers were separated. The aqueous phase was extracted with ethyl
acetate (5 mL*2).
The organic phases were combined, washed with saturated brine, dried over
anhydrous sodium
sulfate, and filtered. The filtrate was concentrated under reduced pressure to
give a crude
product. The crude product was purified by preparative HPLC (Column:
Phenomenex Luna
C18 150mm*30mm*51.1m; Mobile phase: [water (0.05%HC1)-ACN]; acetonitrile%: 20%-
50%,
12min) to give VVX014. LCMS m/z = 414.2 [M+1]+.1H NMR (400 MHz, CD30D) 5 =
7.21 -
7.37 (m, 5 H), 6.97 - 7.13 (m, 2 H), 4.71 (br d, J= 4.14 Hz, 1 H), 4.18 (br
s,2 H), 2.84 - 2.96 (m,
1 H), 2.64 - 2.83 (m, 2 H), 2.17 (td, J= 11.67, 7.78 Hz, 1 H).
56
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00305] Example 15: WX015
0 N -N
1110
S
[00306] Route for synthesis:
).,NH2
0 1:)'> 1111
0 Al 5 BB-3
KO 'N _____________________ 11. 40 ).,N1I-1 __
/ S
BB-14 INX015
[00307] Step 1: synthesis of compound VVX015
[00308] To a round bottom flask containing N,N-dimethylfounamide (10 mL) were
added
BB-3 (20 mg, 96.02 gmol, 1.1 eq) and DIPEA (23.69 mg, 183.32 mot, 31.93 !IL,
2.1 eq).
After dissolved, BB-14 (21.24 mg, 87.30 gmol, 1 eq) and T3P (55.55 mg, 87.30
gmol, 51.92
50% purity, 1 eq) were added, and then the mixture was reacted with stirring
at 25 C for 12
hours. LCMS showed that the raw materials were basically consumed. The
reaction solution
was concentrated under reduced pressure to about 5 mL. HPLC (Column: Welch
Xtimate C18
150*25mm*5 m; Mobile phase: [water (0.225%FA)-ACN]; acetonitrile%: 35%-65%,
8min)
was used for purification to give product VVX015. 111 NMR (400MHz, CDC13) o=
8.78 (br d,
J=7.5 Hz, 1H), 7.43 - 7.35 (m, 5H), 7.35 - 7.26 (m, 4H), 5.82 (s, 2H), 5.21
(td, J=6.9, 11.0 Hz,
1H), 4.71 (dd, J=6.5, 9.5 Hz, 1H), 4.33 - 4.21 (m, 1H), 3.87 (s, 3H); LCMS m/z
= 395.1
[M+1].
[00309] Example 16: WX016
N
S
[00310] Route for synthesis:
)Ler,iti cylLyAN CC
N--zcN N
/ 5
WXM6-1 WX016-2 WXM6-3 MMO16
[00311] Step 1: synthesis of compound VVX016-2
57
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
1003121 To a round bottom flask was added DMSO (10 mL), and then WX016-1 (1.31
g, 8.44
mmol, 1 eq), K2CO3 (1.40 g, 10.13 mmol, 1.2 eq) and benzyl bromide (1.59 g,
9.29 mmol, 1.10
mL, 1.1 eq) were slowly added. The mixture was continuously stirred at 25 C
for 12 hours.
After the completion of the reaction, water (50 mL) was added to the reaction
solution, and the
mixture was extracted twice with ethyl acetate (30 mLx2). The organic phases
were combined,
washed with saturated brine (5 mLx2), and concentrated under reduce pressure
to give a crude
product. The crude product was purified by column chromatography (petroleum
ether:ethyl
acetate = 100:1-1:1) to give VVX016-2.1H NMR (400MHz, CDC13) ö = 7.39 - 7.30
(m, 3H),
7.19 (dd, J=1.8, 7.6 Hz, 2H), 5.39 (s, 2H), 4.49 (q, J=7.1 Hz, 2H), 2.43 (s,
3H), 1.44 (t, J=7.1
Hz, 3H); LCMS m/z = 246.1 [m+i]t
[00313] Step 2: synthesis of compound VVX016-3
[00314] To a round bottom flask were added THF (7.5 mL) and H20 (2.5 mL), and
then
VVX016-2 (1 g, 4.08 mmol, 1 eq) and Li01-1=1420 (513.26 mg, 12.23 mmol, 3 eq)
were slowly
added. The mixture was reacted with stirring at 25 C for 2 hours. The reaction
solution was
concentrated under reduced pressure, and 2N hydrochloric acid was added
dropwise to adjust
pH to acidic. The mixture was filtered to give a filter cake which was the
target compound
VVX016-3. 1H NMR (400MHz, CDC13) 6 = 7.42 - 7.28 (m, 3H), 7.25 - 7.19 (m, 2H),
5.40 (s,
2H), 2.56 (s, 3H); LCMS m/z = 217.9 [m+11.
[00315] Step 3: synthesis of compound VVX016
[00316] To a round bottom flask were added N,N-dimethylformamide (1 mL), WX016-
3 (80
mg, 368.28 ttmol, 1 eq) and BB-4 (77.07 mg, 368.28 ttmol, 1 eq), and then T3P
(351.54 mg,
552.43 ttmol, 328.55 ttL, 50% purity, 1.5 eq) and DIPEA (142.79 mg, 1.10 mmol,
192.45 ttL, 3
eq) were added. The mixture was continuously stirred at 25 C for 5 hours, and
then
concentrated to give a crude product. The crude product was purified by
preparative HPLC
(Column: Welch Xtimate C18 150*25mm*5ttm; Mobile phase: [water (0.225%FA)-
ACN];
acetonitrile%: 35%-65%, 8min) to give compound WX016. 1H NMR (400MHz, CDC13) =
8.72 (br d, J=7.3 Hz, 1H), 8.37 (dd, J=1.4, 4.6 Hz, 1H), 7.56 (dd, J=1.3, 8.0
Hz, 1H), 7.38 - 7.27
(m, 4H), 7.18 (br d, J=6.0 Hz, 2H), 5.36 (s, 2H), 5.23 (td, J=6.8, 11.0 Hz,
1H), 4.78 (dd, J=6.5,
9.5 Hz, 1H), 4.32 (dd, J=9.8, 11.0 Hz, 1H), 3.93 (s, 3H), 2.41 (s, 3H); LCMS
m/z = 409.1
[N4+1].
58
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00317] Example 17: WX017
0 o,
.2
S
[00318] Route for synthesis:
0 0 -N
¨0 N':"I BB.8.1
*
0
WX017-1 WX017-2 YVX017-3
0
0 N-NF N B:4 s CX F
Nj-
N N
S
WX017-4 WX017-5 1NX017
[00319] Step 1: synthesis of compound WX017-2
[00320] To a reaction flask were added lithium aluminum hydride (629.99 mg,
16.60 mmol, 2
eq) and THF (5 mL) at 25 C, and then a solution of WX017-1 (1.08 g, 8.30 mmol,
1 eq) in THF
(5 mL) was slowly added dropwise. After the completion of addition, the
mixture was heated to
35 C, and continuously stirred for 1 hour. The reaction was quenched by adding
6 nil. of
saturated aqueous Na2SO4 solution. The mixture was filtered, and washed with
ethyl acetate
(10 mL x3 times). The organic phases were combined, dried over anhydrous
MgSO4, and
filtered. The filtrate was concentrated under reduced pressure. The crude
product was purified
by silica gel column chromatography (petroleum ether:ethyl acetate=100:1-5:1)
to give
compound VVX017-2. 1H NMR (400MHz, CDC13) 6 = 3.84 (s, 2H), 2.01 (d, J=2.5 Hz,
6H).
[00321] Step 2: synthesis of compound VVX017-3
[00322] To a reaction flask were added WX017-2, DCM (10 mL), and pyridine
(1.40 g, 17.70
mmol, 1.43 mL, 4.11 eq), and then p-toluenesulfonyl chloride (1.23 g, 6.46
mmol, 1.5 eq) was
slowly added. The mixture was heated to 40 C and reacted for 24 hours. A new
spot (Rf=0.7)
appeared by TLC (petroleum ether:ethyl acetate=5:1) monitoring. The reaction
solution was
directly concentrated under reduced pressure, and the crude product was
purified by silica gel
column chromatography (petroleum ether:ethyl acetate-100:1-30:1) to give
compound
VVX017-3. 1H NMR (400MHz, CDC13) 6 = 7.78 (d, J=8.3 Hz, 2H), 7.35 (d, J=8.0
Hz, 2H), 4.24
59
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
(s, 2H), 2.46 (s, 3H), 1.99 (d, J=2.3 Hz, 6H).
[00323] Step 3: synthesis of compound WX017-4
[00324] To an eggplant-shaped bottle, acetonitrile (10 mL), VVX017-3 (500 mg,
L85 mmol,
1.1 eq) and BB-8-1 (213.72 mg, 1.68 mmol, 1 eq) were added at 25 C, and then
K2CO3 (278.88
mg, 2.02 mmol, 1.2 eq) was added. The mixture was heated to 70 C and reacted
for 48 hours.
The reaction solution was concentrated, and the crude product was purified by
silica gel
column (eluent: petroleum ether:ethyl acetate=100:1-1:2) to give compound
WX017-4. 1-11
NMR (400MHz, CDC13) ö = 8.12 (s, 1H), 4.57 (s, 2H), 4.01 (s, 3H), 2.05 (d,
J=2.5 Hz, 6H).
[00325] Step 4: synthesis of compound WX017-5
[00326] To a round bottom flask containing THF (2 mL) was added WX017-4 (100
mg,
444.01 mol, 1 eq) at 25 C. After dissolved, a solution of Li011.1120 (55.90
mg, 1.33 mmol, 3
eq) in Me0H (1 mL) was added aropwise, and the mixture was reacted at 25 C for
5 hours. The
mixture was concentrated under reduced pressure and the residue was dissolved
in
tetrahydrofuran (5 mi.). 1N dilute hydrochloric acid was added to adjust pH to
4, and toluene (5
mL) was then added. The mixture was mixed well, and the solvent was then
evaporated to
dryness under reduced pressure to give a crude product of WX017-5, which was
directly used
in the next step without purification.
[00327] Step 5: synthesis of compound WX017
[00328] To a reaction flask were added ethyl acetate (10 mL), WX017-5 (207 mg,
588.09
mol, 1 eq), and BB-4 (143.52 mg, 588.09 mol, 1 eq) at 25 C. After dissolved,
T3P (1.12 g,
1.76 mmol, 1.05 mL, 50% purity, 3 eq) and DIPEA (228.02 mg, 1.76 mmol, 307.30
L, 3 eq)
were added, and the mixture was reacted at 25 C for 8 hours. After the
completion of the
reaction, ethyl acetate (10 mL) was added. The organic phase was washed with
water (10
mI.x3 times), followed by saturated brine (10 mL xl time), and concentrated
under reduced
pressure to give a crude product. The crude product was purified by
preparative HPLC
(Column: Welch Xtimate C18 150*25mm*5 m; Mobile phase: [water
(0.05%NH3H20)-ACN]; acetonitrile%: 35%-65%, 8min) to give compound WX017.
41NMR
(400MHz, CDC13) 5 = 8.83 (br d, J=6.8 Hz, 1H), 8.37 (dd, J=1.4, 4.6 Hz, 1H),
8.08 (s, 1H),
7.57 (dd, J=1.3, 8.0 Hz, 1H), 7.29 (dd, J=4.8, 8.0 Hz, 1H), 5.20 (td, J=6.7,
11.2 Hz, 1H), 4.80
(dd, J=6.4, 9.4 Hz, 1H), 4.54 (s, 2H), 4.33 (dd, J=9.8, 11.0 Hz, 1H), 3.94 (s,
3H), 2.05 (d, J=2.3
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
Hz, 6H); LCMS m/z = 403.2 [M+1] .
[00329] Example 18: WX018
0 0\ zN-N /1110
IN)F1
S
[00330] Route for synthesis:
0
= .NIH2 _ Os _,,
N N BB
/ S < 7
KC D NN
Mµ1N
Is
BB-14 WX01 8
[00331] Synthesis of compound WX018
[00332] To a round bottom flask containing N,N-dimethylformamide (10 mL) were
added
BB-4 (200 mg, 955.71 mol, 1.1 eq) and DIPEA (235.80 mg, 1.82 mmol, 317.80 L,
2.1 eq).
After dissolved, BB-14 (210.50 mg, 868.83 mol, 1 eq) and T3P (552.89 mg,
868.83 mot,
516.72 L, 50% purity, 1 eq) were added, and the mixture was then stirred at
25 C for 12 hours.
The reaction solution was concentrated under reduced pressure to about 5 mL.
HPLC (Column:
Welch Xtimate C18 150*25mm*5 m; Mobile phase: [water (0.225%FA)-ACN];
acetonitrile%:
35%-65%, 8min) was used for purification to give compound VVX018. 1HNMR
(400MHz,
CDC13) 6 = 8.86 (br d, J=6.8 Hz, 1H), 8.38 (dd, J=1.6, 4.6 Hz, 1H), 7.69 -
7.27 (m, 7H), 5.83 (s,
2H), 5.20 (td, J=6.7, 11.2 Hz, 1H), 4.78 (dd, J=6.3, 9.5 Hz, 1H), 4.33 (dd,
J=9.7, 11.2 Hz, 1H),
3.93 (s, 3H); LCMS miz = 396.1 [M+11+.
[00333] Example 19: WX019
0 N-N
0) _______________________________
N
N N
S
[00334] Route for synthesis:
61
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
0
.NH2
N N BB-4
0 / 0 N Illp
)\qq-N 0/11 _____________________________ 0
HO
/ S
BB-15 WX019
[00335] Step 1: synthesis of compound VVX019
1003361 To a round bottom flask containing N,N-dimethylformamide (10 mL) were
added
BB-15 (156.11mg, 745.97 mol, 1.1 eq), BB-4 (150 mg, 678.16 gmol, 1 eq), T3P
(431.55 mg,
678.16 gmol, 403.32 j.tL, 50% purity, 1 eq), and DIPEA (184.06 mg, 1.42 mmol,
248.06
2.1 eq), and then stirring was started. The mixture was reacted with stirring
at 25 C for 12
hours. After the completion of the reaction, the reaction solution was
concentrated under
reduced pressure to about 5 mL. HPLC (Column: Welch Xtimate C18 150*25mm*5m;
Mobile phase: [water (0.225%FA)- ACN]; acetonitrile%: 35%-65%, 8min) was used
for
purification to give product WX019. 1H NMR (400MHz, CDC13) E.= 8.81 (br d,
J=7.3 Hz, 1H),
8.37(dd, J=1.5, 4.8 Hz, 1H), 8.14 (s, 1H), 7.56 (dd, J=1.5, 8.0 Hz, 1H), 7.41 -
7.27 (m, 3H), 7.21
-7.06 (m, 2H), 5.45 (s, 2H), 5.20(td, J=6.7, 11.2 Hz, 1H), 4.78 (dd, J=6.5,
9.5 Hz, 1H), 4.31 (dd,
J=9.5, 11.0 Hz, 1H), 3.93 (s, 3H); 19F NMR (376MHz, CDC13) E.= -109.59 - -
130.05 (m, 1F);
LCMS m/z = 413.1 [M+1]+.
[00337] Example 20: VVX020
0 N-N
..,NH F
/ S
[00338] Route for synthesis:
Cf) NH,
F 1.1-N BEt-4 t:/N N
F hi 00)._<õNN .22
F
..NH F
1111 N N
I S
WX020-1 WX020-2 WX020-3 WX020
[00339] Step 1: synthesis of compound VVX020-2
[00340] To acetonitrile (15 mL) were added VVX020-1 (3 g, 23.60 mmol, 1 eq),
2,6-difluorobenzyl bromide (5.37 g, 25.96 mmol, 1.1 eq), and K2CO3 (3.91 g,
28.32 mmol, 1.2
eq), and then stifling was started. The mixture was reacted at 50 C for 12
hours. After the
62
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
reaction was completed by TLC monitoring, the reaction solution was filtered
to remove
IC2CO3, and the filter cake was washed three times with ethyl acetate (15 mL).
Saturated brine
(50 mL) was added to the filtrate, and then an organic phase was obtained
after extraction. The
aqueous phase was extracted with EA (30 mL) again. The organic phases were
combined, and
concentrated under reduced pressure to give a crude product. The crude product
was purified
by silica gel column (eluent: petroleum ether:ethyl acetate = 100:1-100:100)
to give
compound WX020-2. 1H NMR (400MHz, CDC13) 6= 8.17 (s, 1H), 7.46 - 7.33 (m, 1H),
7.04-
6.91 (m, 2H), 5.51 (s, 2H), 4.13 - 3.85 (m, 3H).
[00341] Step 2: synthesis of compound WX020-3
[00342] To a round bottom flask containing THF (30 mL) was added VVX020-2 (1
g, 3.95
mmol, 1 eq). After dissolved, a solution of LiOH=1120 (331.43 mg, 7.90 mmol, 2
eq) in H20 (5
mi.) was added, and the mixture was reacted with stirring at 20 C for 2 hours.
The reaction
solution was adjusted to a pH of 6 with 1M diluted hydrochloric acid, and the
mixture was then
concentrated under reduced pressure to remove the solvent to give a crude
product WX020-3;
LCMS m/z = 239.9 [M+1]+.
[00343] Step 3: synthesis of compound WX020
[00344] To a round bottom flask containing N,N-dimethylfounamide (10 mL) were
added
BB-4 (192.49 mg, 919.82 mot, 1.1 eq), WX020-3 (200 mg, 836.20 mot, 1 eq),
T3P(532.12
mg, 836.20 mol, 497.31 L, 50% purity, 1 eq), and DIPEA (226.95 mg, 1.76
mmol, 305.86
tit, 2.1 eq), and the mixture was reacted with stirring at 25 C for 12 hours.
The reaction
solution was concentrated under reduced pressure to about 5 mL, and the
residue was purified
by preparative HPLC (Column: Welch Xtimate C18 150*25mm*5 m; Mobile phase:
[water
(0.225%FA)-ACN]; acetonitrile%: 35%-65%, 8min) to give compound WX020. 1H NMR
(400MHz, CDC13) 5 = 8.79 (hr d, J=7.0 Hz, 1H), 8.36 (dd, J=1.5, 4.8 Hz, 1H),
8.14 (s, 1H), 7.55
(dd, J=1.5, 8.0 Hz, 1H), 7.43 -7.26 (m, 2H), 6.97 (t, J=7.9 Hz, 2H), 5.49 (s,
2H), 5.19 (td, J=6.7,
11.1 Hz, 1H), 4.77 (dd, J=6.3, 9.5 Hz, 1H), 4.30 (dd, J=9.7, 10.9 Hz, 1H),
3.92 (s, 3H); 19F
NMR (376MHz, CDC13) 5 = -104.74 - -120.36 (m, 1F); LCMS m/z =431.1 [M+11+.
[00345] Example 21: VVX021
63
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
0 N-N
=,,NH N
N N
/ s
[00346] Route for synthesis:
NHBoc NHBoc oarx0
I ..,NHBoc I 1NHBoc
N N N N
N NH2 N NH2 H 0 / 0
BB-4-3 WX021-1 WX021-2 WX021-3
0)N'4.11 .N
CI 0
HO s*1 0 N_N is
c'r('),INHBoc B4 --
,NH
N N N N
S S N N
/ s
WX021-4 WX021-5 WX021
[00347] Step 1: synthesis of compound WX021-1
[00348] To a round bottom flask containing DCM (20 mL) was added BB-3-4 (2 g,
6.73mmo1,
1 eq), and the mixture was stirred at 40 C. NCS (988.11 mg, 7.40 mmol, 1.1 eq)
was slowly
added, and then the reaction was continuously stirred at 40 C for 5 hours. The
reaction solution
was concentrated under reduced pressure to give a crude product. The crude
product was
purified by silica gel column (eluent: DCM:Me0H=100:1-100:10) to give compound
VVX021-1. 1H NMR (400MHz, CD30D) 6= 7.54 (d, J=1.5 Hz, 1H), 7.34 (d, J=1.8 Hz,
1H),
6.95 - 6.77 (m, 1H), 5.49 (s, 2H), 4.70 - 4.60 (m, 2H), 4.53 (br dd, J=4.3,
9.5 Hz, 1H), 4.39 -
4.26 (m, 1H), 1.46 (s, 9H). LCMS m/z = 331.9 [M+1] .
[00349] Step 2: synthesis of compound VVX021-2
[00350] To around bottom flask containing DCM (10 mL) were added WX021-1 (1.60
g, 4.82
mmol, 1 eq), T3P (6.14 g, 9.65 mmol, 5.74 mL, 50% purity, 2 eq), and DIPEA
(1.87 g, 14.47
mmol, 2.52 mL, 3 eq), and the mixture was reacted at 20 C for 3 hours. The
reaction solution
was poured into saturated brine (300 mL), and the layers were separated to
give an organic
phase. The aqueous phase was extracted twice with ethyl acetate (100 mL). The
organic phases
were combined and concentrated under reduced pressure to give a crude product.
The crude
product was purified by silica gel column (petroleum ether:ethyl
acetate=100:20-100:100) to
give compound WX021-2. 1H NMR(400MHz, CDC13) 8= 8.22 (br s, 1H), 8.04 (d,
J=2.0 Hz,
1H), 7.41(d, J=2.3 Hz, 1H), 5.59 (br s, 1H), 4.71 - 4.46 (m, 2H), 4.23 - 4.05
(m, 1H), 1.46 (s,
9H); LCMS m/z = 257.8 [M-56+1r.
64
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00351] Step 3: synthesis of compound VVX021-3
[00352] To a round bottom flask containing N,N-dimethylacetamide (10 mL) were
added
VVX021-2 (200 mg, 637.48 p.mol, 1 eq), iodomethane (1.17 g, 8.24 mmol, 513.16
L, 12.93
eq), and cesium carbonate (415.41 mg, 1.27 mmol, 2 eq). The mixture was
reacted with stirring
at 25 C under nitrogen for 1 hour. After the completion of the reaction, the
reaction solution
was poured into saturated brine (20 mL), and the mixture was extracted three
times with ethyl
acetate (15 ml). The organic phases were combined and concentrated under
reduced pressure
to give a crude product. The crude product was dissolved in ethyl acetate (2
mL), and purified
by preparative TLC (petroleum ether:ethyl acetate=3:1) to give a product WX021-
3. 1H NMR
(400MHz, CDC13) 6= 8.23 (d, J=2.3 Hz, 1H), 7.47 (d, J=2.0 Hz, 1H), 5.55 (br s,
1H), 4.82 -
4.49 (m, 2H), 4.35 - 4.14 (m, 1H), 3.47 (s, 3H), 1.41 (s, 9H).
[00353] Step 4: synthesis of compound VVX021-4
[00354] To a round bottom flask containing toluene (10 mL) were added VVX021-3
(177 mg,
540.02 mot, 1 eq) and Lawsson's reagent (327.63 mg, 810.04 p.mol, 1.5 eq) at
25 C, and the
mixture was slowly heated to 110 C and reacted for 12 hours. The reaction
solution was poured
into saturated brine (100 mL), and the mixture was extracted three times with
ethyl acetate (30
mL). The organic phases were combined, and concentrated under reduced pressure
to give a
crude product. The crude product was purified by preparative TLC (petroleum
ether:ethyl
acetate =3:1) to give compound WX021-4. LCMS m/z = 287.8 [M-56+1] .
[00355] Step 5: synthesis of compound VVX021-5
[00356] To a round bottom flask containing dichloromethane (5 mL) was added
WX021-4 (35
mg, 101.80 p.mol, 1 eq) at 25 C. Trifluoroacetic acid (174.10 mg, 1.53 mmol,
113.06 uL, 15 eq)
was added dropwise with stirring, and the mixture was continuously reacted for
2 hours. The
reaction solution was evaporated to dryness under reduced pressure to give a
crude product of
VVX021-5, which was used directly in the next step.
[00357] Step 6: synthesis of compound WX021
[00358] To a round bottom flask containing N,N-dimethylacetarnide (5 mL) were
added
WX021-5 (20 mg, 82.06 p.mol, 1 eq), BB-8 (16.68 mg, 82.06 mot, 1 eq), T3P
(52.22 mg,
82.06 p.mol, 48.81 pL, 50% purity, 1 eq), and DIPEA (22.27 mg, 172.33 p.mol,
30.02 pL, 2.1
eq), and the mixture was reacted at 25 C for 5 hours. Saturated brine (30 mL)
was added, and
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
the mixture was extracted with ethyl acetate (30 mLx3). The organic phase was
concentrated
under reduced pressure to give a crude product. The crude product was purified
by HPLC
(formic acid system) (Column: Xtimate C18 100*30mm*3gm; Mobile phase [water
(0.225%FA)-ACN]; acetonitrile%: 40%-70%, 8min) to give compound WX021. 1H NMR
(400MHz, CDC13) 6= 8.77 (hr d, J=7.3 Hz, 1H), 8.32 (d, J=2.3 Hz, 1H), 8.04 (s,
1H), 7.57 (d,
J=2.0 Hz, 1H), 7.44 - 7.34 (m, 3H), 7.32 - 7.27 (m, 2H), 5.40 (s, 2H), 5.26 -
5.16 (m, 1H), 4.77
(dd, J=6.3, 9.5 Hz, 1H), 4.39 - 4.27 (m, 1H), 3.90 (s, 3H); LCMS m/z = 429.0
[M+11+.
[00359] Example 22: WX022
CIO
/ S
[00360] Route for synthesis:
HO </%-.N 0
C 11-15
I NH2 ____________________ 0) IC3),\ __ NIJN
N I ,INH N
S Th\IN IS
WX021-5 WX022
[00361] Step 1: synthesis of compound WX022
[00362] To N,N-dimethylacetamide (5 mL) were added WX021-5 (20 mg, 82.06 gmol,
1 eq),
BB-15 (18.15 mg, 82.06 gmol, 1 eq), T3P (52.22 mg, 82.06 gmol, 48.81 gL, 50%
purity, 1 eq),
and DIPEA (22.27 mg, 172.33 mot, 30.02 gL, 2.1 eq), and the mixture was
reacted at 25 C
for 5 hours. 30 mL of saturated brine was added, and the mixture was extracted
with ethyl
acetate (30 mLx3) to give an organic phase. The organic phase was concentrated
under reduced
pressure to give a crude product. The crude product was purified by
preparative HPLC
(Column: Xtimate C18 100*30mm*3 m; Mobile phase: [water (0.225%FA)-ACN];
acetonitrile%: 42%-72%, 8min) to give compound WX022. 1H NMR (400MHz, CDC13)
6=
8.77 (br d, J=6.5 Hz, 1H), 8.32 (d, J=2.0 Hz, 1H), 8.14 (s, 1H), 7.57 (d,
J=2.3 Hz, 1H), 7.41 -
7.31 (m, 2H), 7.20 - 7.07 (m, 2H), 5.45 (s, 2H), 5.30 - 5.08 (in, 1H), 4.76
(dd, J=6.3, 9.5 Hz,
1H), 4.32 (t, J=10.3 Hz, 1H), 3.93 - 3.87 (m, 1H); 19F NMR (376MHz, CDC13) 6= -
110.66 -
-127.90 (m, 1F); LCMS m/z = 447.1[M+1].
66
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00363] Example 23: VVX023
o -N is
Br,o) ,
H N
N
/ S
[00364] Route for synthesis:
N_JHBoc NHBoc Brn0 Br I 0
0 ' 0 0 ,NHBoc ____ x N H Bo c
OH OH N N N N
N NH2 N NH2 H 0 / 0
BB-4-3 WX023-1 WX023-2 INX023-3
0 Br 0
Brici .,NHBoc Bry ()
N N N N
S S N N
/ s
WX023-4 WXO 23-5 WX023
[00365] Step 1: synthesis of compound VVX023-1
[00366] BB-4-3 (3.00 g, 10.09 mmol, 1 eq) and N-bromosuccinimide (1.98 g,
11.10 mmol,
1.1eq) were slowly added to DCM (30 mL) at 25 C, and the reaction solution was
continuously
stirred at 25 C under nitrogen for 12 hours. The reaction solution was slowly
poured into water
(100 mL), and the mixture was extracted with dichloromethane (100 mLx2). The
organic
phases were combined and washed successively with water (100 mL) and saturated
brine (100
mL) to give an organic phase. The organic phase was concentrated under reduced
pressure. The
crude product was purified by silica gel column chromatography
(dichloromethane:methanol --
100:1-100:5) to give compound VVX023-1.
[00367] Step 2: synthesis of compound VVX023-2
[00368] To a round bottom flask was added ethyl acetate (100 mL) at 25 C.
WX023-1 (5.60 g,
14.89 mmol, 1 eq), T3P (14.21 g, 22.33 mmol, 13.28 mL, 50% purity, 1.5eq) and
DIPEA (3.85
g, 29.77 mmol, 5.19 mL, 2 eq) were then slowly added. The reaction solution
was continuously
stirred at 25 C under nitrogen for 1 hour. The reaction solution was slowly
poured into water
(200 mL), and the mixture was extracted with ethyl acetate (200 mL x2). The
organic phases
were combined and washed successively with water (200 mL) and saturated brine
(200 mL) to
give an organic phase. The organic phase was concentrated under reduced
pressure. The crude
product was purified by silica gel column chromatography (petroleum
ether:ethyl acetate
=100:1-1:1) to give compound VVX023-2.
67
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00369] Step 3: synthesis of compound VVX023-3
[00370] To a round bottom flask was added N,N-dimethylfoiniamide (10 ml.) at
25 C.
VVX023-2 (L80 g, 5.03 mmol, 1 eq), iodomethane (5.71 g, 40.23 mmol, 2.50 mL,
8.01 eq) and
cesium carbonate (3.60g, 11.06 mmol, 2.2 eq) were then slowly added. The
reaction solution
was continuously stirred at 25 C under nitrogen for 1 hour. The reaction
solution was slowly
poured into water (100 mL), and the mixture was extracted with ethyl acetate
(100 mLx2). The
organic phases were combined and washed successively with water (100 mL) and
saturated
brine (100 mL). The organic phase was concentrated under reduced pressure to
give a crude
product. The crude product was purified by silica gel column chromatography
(petroleum
ether:ethyl acetate=100:1-3:1) to give compound WX023-3. NMR (400MHz, CDC13) 6
=
8.32 (d, J=2.0 Hz, 1H), 7.61 (d, J=2.3 Hz, 1H), 5.55 (brd, J=4.8 Hz, 1H), 4.79
- 4.44 (m, 2H),
4.34 -4.11 (m, 111), 3.46 (s, 3H), 1.40 (s, 911).
[00371] Step 4: synthesis of compound WX023-4
[00372] To a round bottom flask was added toluene (50 mi.) at 25 C, and then
WX023-3 (1.35
g, 3.63 mmol, 1 eq) and Lawsson's reagent (2.20 g, 5.44 mmol, 1.5eq) were
slowly added. The
reaction solution was continuously stirred at 110 C under nitrogen for 11
hours. The reaction
solution was slowly poured into water (100 mL), and the mixture was extracted
with ethyl
acetate (100 mLx2). The organic phases were combined and washed successively
with water
(100 mL) and saturated brine (100 mL). The organic phase was concentrated
under reduced
pressure to give a crude product. The crude product was purified by silica gel
column
chromatography (petroleum ether:ethyl acetate=100:1-1:1) to give compound
WX023-4. 1H
NMR (400MHz, CDC13) 6 = 8.38 (d, J=2.0 Hz, 111), 7.65 (d, J=2.3 Hz, 1H), 6.10
(br d, J=7.3
Hz, 1H), 4.81 -4.67 (m, 1H), 4.58 (dd, J=6.1, 9.4 Hz, 1H), 4.23 (dd, J=9.5,
11.3 Hz, 1H), 3.87
(s, 311), 1.41 (s, 911).
[00373] Step 5: synthesis of compound WX023-5
[00374] To a round bottom flask was added dichloromethane (40 mL) at 25 C, and
then
WX023-4 (980 mg, 2.52 mmol, 1 eq) and trifluoroacetic acid (6.16 g, 54.02
mmol, 4, 21.40eq)
were slowly added. The reaction solution was continuously stirred at 25 C
under nitrogen for
11 hours. The reaction solution was slowly poured into saturated aqueous
sodium bicarbonate
solution (100 mL), and the mixture was extracted twice with dichloromethane
(100 mLx2).
68
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
The organic phases were combined and washed successively with water (100 mL)
and
saturated brine (100 mL). The organic phase was concentrated under reduced
pressure to give a
crude compound WX023-5, which was used directly in the next step without
purification. 1H
NMR (400MHz, CDC13) 6 = 8.32 (d, J=2.0 Hz, 1H), 7.59 (d, J=2.3 Hz, 1H), 4.40
(dd, j=6.3,
10.0 Hz, 1H), 4.10 (t, J=10.8 Hz, 1H), 3.88 - 3.71 (m, 4H).
[00375] Step 6: synthesis of compound WX023
[00376] To a round bottom flask was added N,N-dimethylacetamide (5 mL) at 25
C.
WX023-5 (288 mg, 999.43 limo!, 1 eq), T3P (954.00 mg, 1.50 mmol, 891.59 1tL,
50% purity,
1.5 eq), BB-8 (406.16 mg, 2.00 mmol, 2 eq) and DIPEA (387.50 mg, 3.00 mmol,
522.24 L, 3
eq) were then slowly added. The reaction solution was continuously stirred at
25 C under
nitrogen for 2 hours. The reaction solution was slowly poured into water (100
mL), and the
mixture was extracted with ethyl acetate (100 mLx2). The organic phases were
combined and
washed successively with water (100 mL) and saturated brine (100 mL). The
organic phase
was concentrated under reduced pressure to give a crude product. The crude
product was
purified by preparative HPLC (Column: Xtimate C18 100*30mm*31.1m; Mobile
phase: [water
(0.225%FA)-ACN]; acetonitrile%: 42%-72%, 8min) to give compound WX023. 1H NMR
(400MHz, CDC13) 6 = 8.77 (hr d, J=7.0 Hz, 1H), 8.42 (d, J=2.0 Hz, 1H), 8.04
(s, 1H), 7.71 (d,
J=2.0 Hz, 1H), 7.45 - 7.33 (m, 3H), 7.33 - 7.27 (m, 2H), 5.40 (s, 2H), 5.21
(td, J=6.7, 11.3 Hz,
1H), 4.77 (dd, J=6.3, 9.5 Hz, 1H), 4.33 (dd, J=9.8, 11.0 Hz, 1H), 3.90 (s,
3H); LCMS m/z
=475.0 [M+11+.
[00377] Example 24: WX024
N-
H0yOINHN 110
0 i S
[00378] Route for synthesis:
69
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
NHBoc
NHBoc NHBoc
F OOH
NO2 B6-3-2 ,0 NO2 ip NH
0 0
WX024-1 WX024-2 WX024-3
0 0 0 0
0 ip ..NHBoc 0 ...NFIESoc (0NHBo,(.1
0
WX024-4 WX024-5 WX024- 6 WX024-7
H 00H,NN:ji
, _N 1110
BB-8 .,N c)H_</N iNN:j 111 ---4.
0 HO
0 0 S
WX024-13 WX024
[00379] Step 1: synthesis of compound VVX024-2
[00380] To a round bottom flask was added THF (100 mL). VVX024-1 (10 g, 50.22
mmol, 1
eq), BB-3-2 (11.34 g, 55.24 mmol, 1.1 eq) and cesium carbonate (29.45 g, 90.39
mmol, 1.8 eq)
were then slowly added. The mixture was continuously stirred at 65 C for 16
hours. The
reaction solution was poured into water (300 mL), and 2 M diluted hydrochloric
acid was then
added dropwise to adjust pH to 3. The mixture was extracted with ethyl acetate
(500 mL x2).
The organic phases were combined and washed with saturated brine (50 mL x2).
The organic
phase was concentrated under reduced pressure to give compound WX024-2. 1H
=NMR
(400MHz, CDC13) 6= 8.46 (d, J=1.8 Hz, 1H), 8.20 (dd, J=2.0, 8.8 Hz, 1H), 7.12
(d, J=8.8 Hz,
1H), 5.62 (br d, J=8.0 Hz, 1H), 4.83 - 4.61 (m, 2H), 4.45 (dd, J=3.0, 9.3 Hz,
1H), 3.93 (s, 3H),
1.45 (s, 10H).
[00381] Step 2: synthesis of compound VVX024-3
[00382] To a hydrogenation bottle was added Me0H (300 mL). VVX024-2 (25.8 g,
67.13
mmol, 1 eq) and Pd/C (2.6 g, 26.02 mmol, 10% purity) were then slowly added.
The
atmosphere was replaced three times with argon gas, and the mixture was
continuously stirred
at 30 C under H2 (40 Psi) atmosphere for 24 hours. A new spot appeared by TLC
(petroleum
ether:ethyl acetate:acetic acid=1:1:0.1) monitoring. The reaction solution was
filtered through
Celite, and the filtrate was concentrated under reduced pressure to give
compound WX024-3.
1H NMR (400MHz, CDC13) 6 = 7.50 - 7.44 (m, 1H), 7.39 (br s, 1H), 6.70 (d,
J=8.5 Hz, 1H),
6.53 (br s, 2H), 6.00 (br d, J=7.5 Hz, 1H), 4.73 (br d, J=7.0 Hz, 1H), 4.43
(br d, J=8.5 Hz, 1H),
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
4.31 -4.24 (m, 1H), 3.85 (s, 3H), 1.41 (s, 9H).
[00383] Step 3: synthesis of compound WX024-4
[00384] To a round bottom flask was added ethyl acetate (200 mL). VVX024-3,
T3P (33.67 g,
52.91 mmol, 31.47 mL, 50% purity, 1.5 eq), and DIEA (13.68 g, 105.83 mmol,
18.43 mL, 3 eq)
were then slowly added, and the mixture was continuously stirred at 25 C for
2 hours. The
reaction solution was extracted with water (200 mL), and the layers were
separated. The
aqueous phase was extracted with ethyl acetate (200 mL x2). The organic phases
were
combined, washed with saturated brine (100 mLx2), and concentrated under
reduced pressure.
The crude product was purified by silica gel column chromatography (petroleum
ether:ethyl
acetate=100:1-1:1) to give compound WX024-4. 1H NMR (400MHz, CDC13) 8= 8.15
(br s,
1H), 7.80 (dd, J=2.0, 8.5 Hz, 1H), 7.73 (d, J=2.0 Hz, 1H), 7.13 (d, J=8.3 Hz,
1H), 5.62 (br d,
J=5.3 Hz, 1H), 4.71 - 4.59 (m, 2H), 4.33 - 4.23 (m, 1H), 3.95 - 3.89 (m, 3H),
1.43 (s, 9H).
[00385] Step 4: synthesis of compound WX024-5
[00386] To a round bottom flask was added N,N-dimethylformamide (200 mL).
WX024-4 (17
g, 50.54 mmol, 1 eq), cesium carbonate (49.40 g, 151.63 mmol, 3 eq) and
iodomethane (21.52
g, 151.63 mmol, 9.44 mL, 3 eq) were then slowly added, and the mixture was
continuously
stirred at 25 C for 2 hours. Water (300 mL) was added to the reaction
solution, and the mixture
was extracted with ethyl acetate (300mL x2). The organic phases were combined,
washed with
saturated brine (100 mL x2), and concentrated under reduced pressure. The
crude product was
purified by silica gel column chromatography (petroleum ether:ethyl
acetate=100:1-1:1) to
give compound VVX024-5. 1H NMR (400MHz, CDC13) 6= 7.92 - 7.83 (m, 2H), 7.18
(d, J=8.4
Hz, 1H), 5.50 (br d, J=6.1 Hz, 1H), 4.72 - 4.52 (m, 2H), 4.28 - 4.17 (m, 1H),
3.92 (s, 3H), 3.42
(s, 3H), 1.38 (s, 9H).
[00387] Step 5: synthesis of compound VVX024-6
[00388] To a round bottom flask was added toluene (40 mL). WX024-5 (4.01 g,
11.45 mmol, 1
eq), Lawsson's reagent (5.09 g, 12.59 mmol, 1.1 eq) and Boc20 (10.60 g, 48.55
mmol, 11.15
mL, 4.24 eq) were then slowly added. The mixture was heated to 110 C, and
stirred for 12
hours. The reaction solution was slowly poured into saturated brine (30 mL),
and the mixture
was extracted with ethyl acetate (100mL x2). The organic phases were combined,
washed with
saturated brine (30 mL x2), and concentrated under reduced pressure to give a
crude product.
71
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
The crude product was purified by silica gel column chromatography (petroleum
ether:ethyl
acetate=100:1-1:1) to give compound WX024-6. 1H NMR (400MHz, CDC13) 8= 7.99 -
7.92
(m, 2H), 7.21 (d, J=8.3 Hz, 1H), 6.02 (br d, J=7.8 Hz, 1H), 4.80 - 4.69 (m,
1H), 4.53 (dd, J=6.3,
9.5 Hz, 1H), 4.22 (dd, J=9.5, 11.3 Hz, 1H), 3.94 (s, 3H), 3.86 (s, 3H), 1.46 -
1.33 (m, 9H).
[00389] Step 6: synthesis of compound VVX024-7
[00390] To a round bottom flask was added ethyl acetate (10 mL). WX024-6 (500
mg, 1.36
mmol, 1 eq) and HCl/ethyl acetate (4 M, 10 mL, 29.31 eq) were then slowly
added, and the
mixture was continuously stirred at 25 C for 2 hours. The reaction solution
was concentrated
under reduced pressure to give compound VVX024-7. 1H NMR (400MHz, CDC13) 5=
8.04 -
7.89 (m, 2H), 7.28 (br s, 1H), 4.93 (br s, 1H), 4.63 (br s, 1H), 4.44 (br s,
1H), 3.93 (s, 3H), 3.88
- 3.85 (m, 1H), 3.81 (s, 3H).
[00391] Step 7: synthesis of compound VVX024-8
[00392] To a round bottom flask was added N,N-dimethylformamide (5 mL). WX024-
7 (245
mg, 809.18 timol, 1 eq, HC1), BB-8 (164.42 mg, 809.18 timol, 1 eq), HATU
(461.51 mg, 1.21
mmol, 1.5 eq) and DIPEA (313.74 mg, 2.43 mmol, 422.83 j.tL, 3 eq) were then
slowly added,
and the mixture was continuously stirred at 25 C for 2 hours. The reaction
solution was poured
into water (20 mL), and the mixture was extracted with ethyl acetate (20
mLx2). The organic
phases were combined, washed with saturated brine (5 mL x2), and concentrated
under reduced
pressure to give a crude product. The crude product was purified by silica gel
column
chromatography (petroleum ether:ethyl acetate=100:1-1:100) to give compound
VVX024-8.
1H NMR (400MHz, CDC13) 8= 8.70 (br d, J=7.3 Hz, 1H), 8.02 - 7.94 (m, 3H), 7.42
- 7.34 (m,
3H), 7.31 - 7.28 (m, 2H), 5.39 (s, 2H), 5.20 (td, J=6.8, 11.0 Hz, 1H), 4.72
(dd, J=6.5, 9.4 Hz,
1H), 4.31 (t, J=10.3 Hz, 1H), 3.95 (s, 3H), 3.89 (s, 3H).
[00393] Step 8: synthesis of compound VVX024
[00394] To a round bottom flask were added THF (4 mL) and H20 (1 mL). VVX024-8
(50 mg,
110.74 mot, 1 eq) and Li01-1=1120 (4.65 mg, 110.74 mol, 12.79 L, 1 eq) were
then slowly
added, and the mixture was continuously stirred at 25 C for 2 hours. The
reaction solution was
separated by HPLC (Column: Phenomenex Gemini-NX 80*40mm*3 m; Mobile phase:
[water
(0.05% NH3-1120 + 10mM NII4HCO3) -ACN]; acetonitrile%:11%-31%, 8min) to give
compound WX024. 1H NMR (400MHz, CDC13) 8= 8.78 (br s, 1H), 8.18 - 7.82 (m,
3H), 7.36
72
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
(br s, 5H), 5.64 - 5.32 (m, 2H), 5.26 (br s, 1H), 4.72 (br s, 1H), 4.32 (br s,
1H), 3.86 (br s, 3H);
LCMS m/z = 438.1 [M+11+.
[00395] Example 25: VVX025
o 40
,
N--;j
S
[00396] Route for synthesis:
NHBo
NHBoc NHBoc o 0
N NH2 OH 0 OH
____________ ,
BB-3-2 .,NHBoc ...NHBoc
NO2 N 0
NO2
WX025-1 WX025-2 WX025-3 WX025-4 WX025-5
0,47 410
0
, 0 HO N- 0 C.1_17 =
,NHBoc ia, .'N H2 BB-8-1
N
S s
I S
WX025-6 WX025-7 WX025
[0039'7] Step 1: synthesis of compound VVX025-2
[00398] NaH (2.78 g, 69.38 mmol, 60% purity, 2.2 eq) was added to a solution
of BB-3-2 (7.12
g, 34.69 mmol, 1.1 eq) in N,N-dimethylformamide (80 mL) at 0 C under nitrogen,
and the
mixture was reacted for 2 hours. The reaction solution was placed in an ice-
water bath, and
VVX025-1 (5 g, 31.54 mmol, 1 eq) was added to the above solution. The reaction
solution was
heated to 25 C and reacted for 12 hours. The reaction solution was slowly
added to ice water
(100 mL), and the mixture was extracted with ethyl acetate (150 mL x2). The
aqueous phase
was adjusted to a pH of 5-6 with 1 M HCl, and extracted with ethyl acetate
(150 mL x2). The
organic phases were combined, washed with saturated brine, dried over
anhydrous sodium
sulfate, and filtered. The filtrate was concentrated under reduced pressure to
give compound
VVX025-2. LCMS m/z = 328.1 [M+1]+.
[00399] Step 2: synthesis of compound VVX025-3
[00400] Pd/C (3 g, 5% purity) was added to a solution of VVX025-2 (9 g, 27.50
mmol, 1 eq) in
ethyl acetate (60 mL) and methanol (30 mL). The atmosphere was replaced three
times with H2,
and the mixture was reacted at 25 C under H2 (15 Psi) atmosphere for 12 hours.
The reaction
solution was filtered through Celite, and the filtrate was concentrated under
reduced pressure to
73
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
give compound WX025-3. LCMS m/z = 298.1 [M+1]+.
[00401] Step 3: synthesis of compound WX025-4
[00402] T3P (20.87 g, 32.79 mmol, 19.50 mL, 50% purity, 1.5 eq) was added to a
solution of
DIPEA (7.06 g, 54.66 mmol, 9.52 mL, 2.5 eq) and WX025-3 (6.5 g, 21.86 mmol, 1
eq) in
N,N-dimethylformamide (200 mL), and the mixture was reacted at 25 C for 3
hours. Water
(200 mL) was added to the reaction solution in an ice bath, and the mixture
was extracted with
ethyl acetate (200mL x2). The organic phases were combined, washed with
saturated brine,
dried over anhydrous sodium sulfate, and filtered. The filtrate was
concentrated under reduced
pressure to give a crude product. The crude product was purified by column
chromatography
(petroleum ether:ethyl acetate= 10:1-1:2) to give compound VVX025-4. 1H NMR
(400 MHz,
CDC13) 8 = 8.37 (br s, 1 H), 8.20 - 8.31 (m, 2 H), 6.97 (d, J = 5.70 Hz, 1 H),
5.69 (br d, J = 4.38
Hz, 1 H), 4.54 - 4.71 (m, 2 H), 4.22 - 4.35 (m, 1 H), 1.45 - 1.52 (m, 9 H);
LCMS m/z =
280.1[M+1]+.
[00403] Step 4: synthesis of compound WX025-5
[00404] Iodomethane (384.21 mg, 2.71 mmol, 168.51 [iL, 1.05 eq) was added to a
solution of
VVX025-4 (0.72 g, 2.58 mmol, 1 eq) and cesium carbonate (1.01 g, 3.09 mmol,
1.2 eq) in
tetrahydrofuran (14 mL), and the mixture was reacted at 20 C for 12 hours.
Water (25 mL) and
ethyl acetate (25 mL) were added to the reaction solution, and the layers were
separated. The
aqueous phase was extracted with ethyl acetate (25 mLx2). The organic phases
were combined,
washed with saturated brine, dried over anhydrous sodium sulfate, and
filtered. The filtrate was
concentrated under reduced pressure to give a crude product. The crude product
was purified
by column chromatography (dichloromethane:methanol = 10:0-10:1) to give
compound
VVX025-5. 1H NMR (400 MHz, CDC13) = 8.50 (s, 1 H), 8.39 (d, J = 5.27 Hz, 1 H),
7.06 (d, J
= 5.40 Hz, 1 H), 5.54 (br d, J = 6.02 Hz, 1 H), 4.56 - 4.73 (m, 2 H), 4.25 -
4.37 (m, 1 H), 3.47 (s,
3 H), 1.41 (s, 9 H); LCMS m/z = 294.1 [M+1] .
[00405] Step 5: synthesis of compound WX025-6
[00406] Lawsson's reagent (110.32 mg, 272.74 innol, 0.8 eq) was added to a
solution of
WX025-5 (0.1 g, 340.93 pmol, 1 eq) in toluene (2 mL) at 20 C, and the mixture
was reacted at
90 C for 12 hours. Ethyl acetate (5 mL) was added to the reaction solution.
The mixture was
filtered, and the ante was concentrated under reduced pressure to give a crude
product. The
74
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
crude product was purified by column chromatography (petroleum ether:ethyl
acetate=
10:1-1:2) to give compound WX025-6. LCMS m/z = 310.1 [M+11+.
[00407] Step 6: synthesis of compound VVX025-7
[00408] HCl/ethyl acetate (3 mL) was added to a solution of WX025-6 (53 mg,
171.31 gmol, 1
eq) in ethyl acetate (3 mL), and the mixture was reacted at 25 C for 2 hours.
The reaction
solution was concentrated under reduced pressure to give compound WX025-7.
LCMS m/z =
210.1 [MA]'.
[00409] Step 7: synthesis of compound VVX025
[00410] DIPEA (77.82 mg, 602.10 limo!. 104.87 !IL, 3 eq) and T3P (127.72 mg,
401.40 pmol,
119.36 jiL, 2 eq) were added to a solution of WX025-7 (42 mg, 200.70 mol, 1
eq) and BB-8
(61.17 mg, 301.05 mot, 1.5 eq) in N,N-dimethylformamide (3 mL), and the
mixture was
reacted at 25 C for 2 hours. Water (5 mL) and ethyl acetate (5 mL) were added
to the reaction
solution, and the layers were separated. The aqueous phase was extracted with
ethyl acetate (5
mI.x 2). The organic phases were combined, washed with saturated brine, dried
over anhydrous
sodium sulfate, and filtered. The filtrate was concentrated under reduced
pressure to give a
crude product. The crude product was separated by preparative HPLC (Column:
Phenomenex
Luna C18 150mm*30mm*5 m; Mobile phase: [water (0.05%HC1)-ACN1; acetonitrile%:
20%-50%, 12min) to give compound WX025. 1H NMR (400 MHz, DMSO-d6) = 8.83 (d, J
=
8.16 Hz, 2 H), 8.64 - 8.65 (m, 1 H), 8.67 (d, J = 7.72 Hz, 1 H), 8.54 (d, J =
5.28 Hz, 1 H), 7.26
-7.42 (m, 6 H), 5.49 (s, 2 H), 5.04 (dt, J = 11.24, 6.84 Hz, 1 H), 4.44-
4.64(m, 2 H), 3.83 (s, 3
H); LCMS m/z = 395.2 [MA]'.
[00411] Example 26: VVX026
0 N
0 34,
/ s
[00412] Route for synthesis:
0
)...1-1,
N N N
0 N
N
BB-4
0 ../* sr ,0 , 3 CI \I?
0
N N 0 I*
0 0 0 S
WX026-1 WX026-2 WX026-3 INX026
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00413] Step 1: synthesis of compound VVX026-2
[00414] To a solution of VVX026-1 (1 g, 4.63 mmol, 1 eq) and phenol (871.27
mg, 9.26 mmol,
814.27 pL, 2 eq) in N,N-dimethylformamide (10 mL) were added potassium
carbonate (1.28 g,
9.26 mmol, 2 eq), cuprous bromide (66.40 mg, 462.89 pmol, 14.10 pt, 0.1 eq),
and
acetylacetone (23.17 mg, 231.45 mol, 23.77 pL, 0.05 eq), and the mixture was
stirred at 90 C
for another 10 hours. Water (100 mL) was added to the reaction solution, and
the mixture was
extracted with ethyl acetate (30 mLx3). The organic phases were combined,
dried over
anhydrous sodium sulfate, and filtered, and the filtrate was concentrated
under reduced
pressure to give compound WX026-2. LCMS m/z = 230.2 [M+1]+.
[00415] Step 2: synthesis of compound VVX026-3
[00416] To a solution of WX026-2 (0.45 g, 1.96 mmol, 1 eq) in tetrahydrofuran
(5 mL) was
added a solution of Li011-1120 (164.76 mg, 3.93 mmol, 2 eq) in water (1 mL),
and the mixture
was stirred at 18 C for 1 hour. Ethyl acetate (20 mL) was added to the
reaction solution, and the
mixture was adjusted to a pH of 2 with 2 N hydrochloric acid. The organic
phase was dried over
anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to
give compound
VVX026-3. LCMS m/z = 216.1 [m+1].
[00417] Step 3: synthesis of compound VVX026
[00418] To a solution of BB-4 (0.3 g, 679.40 pmol, 1 eq) in N,N-
dimethylfotmamide (2 mL)
were added VVX026-3 (153.52 mg, 713.37 grnol, 1.05 eq), DIPEA (263.42 mg, 2.04
mmol,
355.01 tiL, 3 eq), and T3P (648.52 mg, 1.02 mmol, 606.09 pL, 50% purity, 1.5
eq) at 18 C, and
the mixture was stirred for 1 hour. The reaction solution was purified by HPLC
(Column:
Phenomenex Luna C18 150mm*30mm*5pm; Mobile phase: [water (0.05%HC1)-ACN];
acetonitrile%: 20%-50%, 12min) to give compound VVX026. 1H NMR (400 MHz, DMSO-
d6)
= 8.84 (s, 1H), 8.60 (d, J= 7.89 Hz, 1H), 8.36 (dd, J= 1.32, 4.82 Hz, 1H),
7.70 (dd, J= 1.53,
8.11 Hz, 1H), 7.25-7.46 (m, 5H), 5.49 (s, 2H), 4.85 (td, J= 7.67, 11.40 Hz,
1H), 4.63-4.75 (in,
1H), 4.51 (dd, J= 7.45, 9.65 Hz, 1H), 4.03 (br s, 3H); LCMS m/z = 407.1 [M+1]
.
[00419] Example 27: VVX027
76
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
o
0 N-N
cj
S
[00420] Route for synthesis:
ov
ao).,NH2
N N
/ s
0 BB-4 0 </N, N
HO /N-INI NH
N N
/ S
BB-16 WX027
[00421] Step 1: synthesis of compound VX027
[00422] To a round bottom flask was added N,N-dimethylacetamide (5 mL) at 25
C. BB-4 (20
mg, 45.29 gmol, 1 eq), T3P (43.23 mg, 67.94 mot, 40.41 pL, 50% purity, 1.5
eq), BB-16
(15.85 mg, 67.94 gmol, 1.5 eq) and DIPEA (17.56 mg, 135.88 Ltmol, 23.67 pL, 3
eq) were then
slowly added, and the reaction solution was continuously stirred at 25 C
under nitrogen for 2
hours. The reaction solution was slowly poured into water (100 mL), and the
mixture was
extracted with ethyl acetate (100 mL x 2). The organic phases were combined,
washed
successively with water (100 mI.) and saturated brine (100 mL), and
concentrated under
reduced pressure to give a crude product. The crude product was seperated by
preparative
HPLC (Column: Xtimate C18 100*30mm*311m; Mobile phase: [water (0.225%FA)-ACN];
acetonitrile%: 42%-72%, 8min) to give compound VX027. 1H NMR (400MHz, CDC13) 6
=
8.78 (br d, J=7.0 Hz, 1H), 8.47 - 8.25 (m, 1H), 8.08 (s, 1H), 7.60 - 7.50 (m,
1H), 7.35 (t, J=7.9
Hz, 1H), 7.32 - 7.26 (m, 2H), 6.96 (t, J=7.4 Hz, 1H), 6.91 (d, J=8.0 Hz, 1H),
5.38 (s, 2H), 5.20
(td, J=6.7, 11.4 Hz, 1H), 4.77 (dd, J=6.3, 9.5 Hz, 1H), 4.38 - 4.23 (m, 1H),
3.92 (s, 3H), 3.84 (s,
3H); LCMS miz =425.1 [M+11+.
[00423] Example 28: WX028
0
0
=.11\JH N-- 0
NN/N s
[00424] Route for synthesis:
77
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
40,
_ N _ NBr
-
or-izbdr ________
Br-4 N
N-
__________________________________________ Br rTh
N-
WX028-1 WX028-2 WX028-3 WX028-4
0 0N 'NH2
1-1 Ho S BI34, r) ..N/Fi \IC 0
/ s
WX028-5 WX028-6 WX028
1004251 Step 1: synthesis of compound VVX028-2
[00426] To a round bottom flask was added MeCN (80 mi.), and VX028-1 (4 g,
17.63 mmol,
1 eq) was then slowly added. After dissolved, 2-(2-bromoethoxy)tetrahydropyran
(4.42 g,
21.16 mmol, 3.21 mL, 1.2 eq) and DIPEA (2.51 g, 19.40 mmol, 3.38 mL, 1.1 eq)
were added,
and the mixture was heated to 90 C and continuously stirred for 3 hours.
Water (100 mL) was
added to the reaction solution, and the mixture was extracted with ethyl
acetate (100inLx2).
The organic phases were combined, washed with saturated brine (30 mLx2), and
concentrated
under reduced pressure to give a crude product. The crude product was purified
by silica gel
column chromatography (petroleum ether:ethyl acetate-100:1-1:1) to give
compound
VVX028-2. 11-1 NMR (400MHz, CDC13) 6= 4.55 (br s, 1H), 4.34 (t, J=5.3 Hz, 2H),
4.12 - 4.06
(m, 1H), 3.79 (td, J-5.4, 10.8 Hz, 1H), 3.64 - 3.53 (m, 1H), 3.50 - 3.41 (m,
1H), 1.76 - 1.58 (m,
2H), 1.57 - 1.43 (m, 4H).
1004271 Step 2: synthesis of compound WX028-3
1004281 To a round bottom flask was added THF (50 mL), and WX028-2 (4.99 g,
14.06 mmol,
1 eq) was then slowly added. The mixture was cooled to -78 C and n-
butyllithium (2.5 M, 6.75
mL, 1.2 eq) was added. The mixture was stirred for 1 hour, and benzaldehyde
(2.98 g, 28.11
mmol, 2.84 mL, 2 eq) was slowly added. The mixture was stirred at -78 C for
0.5 hours, and
then heated to -50 C and stirred for another 0.5 hours. After the completion
of the reaction, the
reaction solution was poured into a mixed solution of saturated ammonium
chloride (200 mL)
and ethyl acetate (200 mL), and the layers were separated. The aqueous phase
was extracted
with ethyl acetate (200 mL). The organic phases were combined, washed with
saturated brine
(50 mLx2), and concentrated under reduced pressure to give a crude product.
The crude
78
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
product was purified by silica gel column chromatography (petroleum
ether:ethyl
acetate=100:1-1:1) to give compound WX028-3. 1H NMR (400MHz, CDC13) 6= 7.45 -
7.29
(m, 5H), 6.09 (d, J=5.8 Hz, 1H), 4.51 (br s, 1H), 4.34 (ddq, J=3.5, 5.5, 7.2
Hz, 1H), 4.26 - 4.15
(m, 1H), 4.07- 3.97 (m, 1H), 3.78 - 3.56 (m, 2H), 3.47 (dt, J=5.9, 10.7 Hz,
1H), 1.85 - 1.64 (m,
2H), 1.52 (br d, J=6.3 Hz, 4H).
1004291 Step 3: synthesis of compound WX028-4
[00430] To a round bottom flask was added toluene (50 mL). VVX028-3 (4.7 g,
12.30 mmol, 1
eq) and Ts0H-1120 (3.04 g, 15.98 mmol, 1.3 eq) were then slowly added, and the
mixture was
continuously stirred at 110 C for 5 hours. Water (50 mL) was added to the
reaction solution,
and the mixture was extracted with ethyl acetate (50mLx2). The organic phases
were
combined, washed with saturated brine (20 mLx2), and concentrated under
reduced pressure.
The crude product was purified by silica gel column chromatography (petroleum
ether:ethyl
acetate=100:1-1:1) to give compound VVX028-4. 1H NMR (400MHz, CDC13) 6= 7.45 -
7.34
(m, 5H), 5.87 (s, 1H), 4.33 - 4.27 (m, 2H), 4.19 - 4.06 (m, 2H).
[00431] Step 4: synthesis of compound VVX028-5
[00432] To an autoclave was added Et0H (20 mL). VVX028-4 (500 mg, 1.78 mmol, 1
eq),
Pd(dppf)C12 (261.21 mg, 356.99 timol, 0.2 eq) and TEA (1.81 g, 17.85 mmol,
2.48 mL, 10 eq)
were then slowly added. The atmosphere was replaced three times with argon
gas, and the
mixture was continuously stirred at 100 C under CO (1 MPa) atmosphere for 24
hours. Water
(50 mL) was added to the reaction solution, and the mixture was extracted with
ethyl acetate
(50mLx2). The organic phases were combined, washed with saturated brine (10
mLx2), and
concentrated under reduced pressure to give a crude product. The crude product
was seperated
by preparative HPLC (Column: Xtimate C18 100*30mm*3m; Mobile phase: [water
(0.225%FA)-ACN]; acetonitrile%: 42%-72%, 8min) to give compound VVX028-5. 114
NMR
(400MHz, CDC13) ö = 7.47 -7.31 (m, 5H), 6.02 - 5.93 (m, 1H), 4.54 -4.38 (m,
4H), 4.34 - 4.25
(m, 1H), 4.19 - 4.10 (m, 1H), 1.42 (t, J=7.1 Hz, 3H).
[00433] Step 5: synthesis of compound WX028-6
[00434] To a round bottom flask were added THF (4 mL) and H20(1 mL). WX028-5
(260 mg,
951.38 gmol, 1 eq) and Li0H-1420 (119.77 mg, 2.85 mmol, 3 eq) were then slowly
added. The
mixture was continuously stirred at 25 C for 1 hour. The reaction solution was
concentrated to
79
Date recue / Date received 2021-11-30
dryness by rotary evaporation under reduced pressure to remove THE 1 M aqueous
HC1 solution
was added dropwise to adjust pH to 3, and the mixture was filtered to give a
product WX028-6.
1HNMR (400MHz, DMSO-d6) 6= 7.40 (s, 5H), 6.00 (s, 1H), 4.50 - 4.40 (m, 1H),
4.40 - 4.29 (m,
2H), 4.26 - 4.11 (m, 1H).
[00435] Step 6: synthesis of compound WX028-7
[00436] To a round bottom flask was added N,N-dimethylformamide (1 mL). WX028-
6 (30 mg,
122.33 gmol, 1 eq), BB-4 (54.02 mg, 122.33 gmol, 1 eq), T3P (116.77 mg, 183.50
gmol, 109.13
;IL, 50% purity, 1.5 eq) and DIPEA (47.43 mg, 366.99 p.mol, 63.92 jiL, 3 eq)
were then slowly
added, and the mixture was continuously stirred at 25 C for 2 hours. The
reaction solution was
separated by preparative HPLC (Column: Xtimate C18 100*30 mm*311m; Mobile
phase: [water
(0.225%EA)-ACN]; acetonitrile%: 35%-65%, 8min) to give a racemate of compound
WX028,
which was then resolved by chiral SFC (Column: DAICEL CHIRALCELTM OD
(250mm*30mm,
10gm); Mobile phase: [Neu-ET011]; ethanol %: 45%-45%, min) to give the active
isomer WX028.
NMR (400MHz, CDC13) 8= 8.65 (br d, J=7.1 Hz, 1H), 8.37 (br d, J=3.3 Hz, 1H),
7.56 (br d,
J=7.8 Hz, 1H), 7.48 - 7.36 (m, 5H), 7.32 - 7.27 (m, 1H), 5.99 (s, 1H), 5.33 -
5.16 (m, 1H), 4.74
(dd, J=6.4, 9.5 Hz, 1H), 4.40 (br d, J=4.3 Hz, 2H), 4.36 -4.24 (m, 2H), 4.19 -
4.07 (m, 1H), 3.92
(s, 3H); LCMS m/z = 437.1 [M+1]+.
[00437] Example 29: WX029
0 N
0 -
Thq-N
S
[00438] Route for synthesis:
C;IPs.,NH2
N N
CL/iN
<iNN F 0 )......</NN.2 F W34
rj(õ,o N'j '11r
N N
WX029-1 WX029-2 WX029-3 WX029
[00439] Step 1: synthesis of compound WX029-2
[00440] To a round bottom flask was added MeCN (20 mL) at 25 C, and WX029-1
(2.02 g, 15.89
mmol, leq), K2CO3 (4.39 g, 31.79 mmol, 2 eq) and 3-fluorobenzyl chloride (2.76
g, 19.07 mmol,
2.28 mL, 1.2 eq) were then slowly added. The reaction solution was
continuously stirred at 60 C
under nitrogen for 12 hours. The reaction solution was slowly poured into
water
Date Recite/Date Received 2023-04-14
CA 03142360 2021-11-30
(100 mL) and the mixture was extracted with ethyl acetate (100 mLx 2). The
organic phases
were combined, washed successively with water (100 mL) and saturated brine
(100 mL), and
concentrated under reduced pressure to give a crude product. The crude product
was purified
by silica gel column chromatography (petroleum ether:ethyl acetate=100:20-
100:75) to give
compound WX029-2. 1H NMR (400MHz, CDC13) 3= 8.14(s, 1H), 7.36 (dt, J=5.9, 8.0
Hz, 1H),
7.11 - 7.03(in, 2H), 6.99 (br d, J=9.0 Hz, 1H), 5.42 (s, 2H), 4.14 - 3.89 (m,
3H).
[00441] Step 2: synthesis of compound WX029-3
[00442] To a round bottom flask were added THF (14 mL) and H20 (2 mL) at 25 C,
and
VVX029-2 and UO111120 (642.21 mg, 15.31 mmol, 3 eq) were then slowly added.
The
reaction solution was continuously stirred at 25 C under nitrogen for 1 hour.
The reaction
solution was adjusted to a pH of 6-7 with diluted hydrochloric acid (1 M), and
the precipitate
was filtered and dried to give compound WX029-3.
[00443] Step 3: synthesis of compound WX029
[00444] To a round bottom flask was added N,N-dimethylacetamide (5 mI.) at 25
C, and
WX029-3 (15.03 mg, 67.94 umol, 1.5 eq), T3P (43.23 mg, 67.94 pinol, 40.41 L,
50% purity,
1.5 eq), BB-4 (15.03 mg, 67.94 mot, 1.5 eq) and DIPEA (17.56 mg, 135.87 mol,
23.67 L, 3
eq) were then slowly added. The reaction solution was continuously stirred
under nitrogen for 2
hours. The reaction solution was slowly poured into water (100 mL), and the
mixture was
extracted with ethyl acetate (100 mL x 2). The organic phases were combined,
washed
successively with water (100 mL) and saturated brine (100 mL), and
concentrated under
reduced pressure to give a crude product. The crude product was purified by
preparative HPLC
(Column: Xtimate C18 100*30 mm*3p.m; Mobile phase: [water (0.225%FA)-ACN];
acetonitrile%: 35%-65%, 8min) to give a product VVX029. 1H NMR (400MHz, CDC13)
6
8.83 (br d, J=7.0 Hz, 1H), 8.37 (d, J=3.8 Hz, 1H), 8.10 (s, 1H), 7.57 (d,
J=8.0 Hz, 1H), 7.40 -
7.27 (m, 2H), 7.15 - 6.87 (m, 3H), 5.40 (s, 2H), 5.29 - 5.07 (m, 1H), 4.79
(dd, J=6.3, 9.3 Hz,
1H), 4.32 (t, J=10.3 Hz, 1H), 3.93 (s, 3H); 19F NMR (376MHz, CDC13) (3= -
111.33 (s, 1F);
LCMS m/z =413.0 [M+1].
[00445] Example 30: WX030
81
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
0 N_m
1 3) \ __________________________ = 0/
''teNN
I S
[00446] Route for synthesis:
0 N_NH A ¨ ,N _N
0</N1 07¨</No -310-
VVX030-1 INX030-2 VVX030-3
CX:)-INH2
N N
/s 0 N...1
BB-4 o,
,..NH
N N
S
WX030
[00447] Step 1: synthesis of compound VVX030-2
[00448] To a round bottom flask was added MeCN (20 mL) at 25 C, and VVX030-1
(2.04 g,
16.05 mmol, leq), K2CO3 (4.44 g, 32.10 mmol, 2 eq) and 4-methoxybenzyl
chloride (3.02 g,
19.26 mmol, 2.62 mL, 1.2 eq) were then slowly added. The reaction solution was
continuously
stirred at 60 C under nitrogen for 12 hours. The reaction solution was slowly
poured into water
(100 mL), and the mixture was extracted with ethyl acetate (100 mL x 2). The
organic phases
were combined, washed successively with water (100 mL) and saturated brine
(100 mL), and
concentrated under reduced pressure to give a crude product. The crude product
was purified
by silica gel column chromatography (petroleum ether:ethyl acetate=100:20-
100:75) to give
compound WX030-2. 1H NMR (400MHz, CDC13) 6 = 8.05 (s, 1H), 7.27 (d, J=8.8 Hz,
2H),
6.98 - 6.87 (m, 2H), 5.43 - 5.26 (m, 2H), 4.03 - 3.97 (m, 3H), 3.82 (s, 3H).
[00449] Step 2: synthesis of compound VVX030-3
[00450] To a round bottom flask were added THF (14 mL) and H20 (2 mL) at 25 C,
and
VVX030-2 (1.5 g, 6.07 mmol, 1 eq) and Li011-1-120 (763.68 mg, 18.20 mmol, 3
eq) were then
slowly added. The reaction solution was continuously stirred at 25 C under
nitrogen for 1 hour.
The reaction solution was adjusted to a pH of 6-7 with diluted hydrochloric
acid (1 M), and the
precipitate was filtered and dried to give compound WX030-3.
[00451] Step 3: synthesis of compound VVX030
[00452] To a round bottom flask was added N,N-dimethylacetamide (5 mL) at 25
C, and
82
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
VVX030-3 (15.84 mg, 67.94 mol, 1.5 eq), T3P (43.23 mg, 67.94 mol, 40.41 1.õ
50% purity,
1.5 eq), BB-4 (15.84 mg, 67.94 mot, 1.5 eq) and DIPEA (17.56 mg, 135.87 mot,
23.67 L, 3
eq) were then slowly added, and the reaction solution was continuously stirred
at 25 C under
nitrogen for 2 hours. The reaction solution was slowly poured into water (100
mL), and the
mixture was extracted with ethyl acetate (100 mL x 2). The organic phases were
combined,
washed successively with water (100 mL) and saturated brine (100 mL), and
concentrated
under reduced pressure to give a crude product. The crude product was
seperated by
preparative HPLC (Column: Xtimate C18 100*30 mm*3 m; Mobile phase: [water
(0.225%
FA)- ACN]; acetonitrile%: 35%-65%, 8min) to give a product WX030. 1-11 NMR
(400MHz,
CDC13) 6 = 8.80 (br s, 1H), 8.37 (br s, 1H), 7.98 (br s, 1H), 7.56 (brs, 1H),
7.38 - 7.28 (m, 1H),
7.26 (br s, 2H), 6.91 (br s, 2H), 5.41 - 5.10 (m, 3H), 4.78 (br s, 1H),
4.31(br s, 1H), 3.98 - 3.73
(m, 6H); LCMS m/z =425.1 [M+1]+.
[00453] Example 31: AVX031
o IN
N N
s
[00454] Route for synthesis:
N,
0,4J H
-0 NOLF-1 HO
F
WX031-1 WX031-2 WX031-3
(n,NH2
N N
/ S 0 0\ N,N
BB-4
N N
/ S
WX031
[00455] Step 1: synthesis of compound WX031-2
[00456] To a round bottom flask was added MeCN (20 mL). WX031-1 (1.5 g, 11.80
mmol, 1
eq), K2CO3 (2.45 g, 17.70 mmol, 1.5 eq) and 4-fluorobenzyl chloride (1.88 g,
12.98 mmol, 1.55
mL, 1.1 eq) were then added, and the mixture was continuously stirred at 50 C
for 12 hours.
The reaction solution was poured into water (50 mL) and the mixture was
extracted with ethyl
acetate (50 mLx2). The organic phases were combined, washed with saturated
brine (10
83
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
mLx2), and concentrated under reduced pressure to give a crude product. The
crude product
was purified by silica gel column chromatography (petroleum ether:ethyl
acetate =-
100:1-1:100) to give compound VVX031-2. NMR (400MHz, CDC13) 6= 8.09 (s, 1H),
7.30
(dd, J=5.3, 8.3 Hz, 2H), 7.08 (t, J=8.5 Hz, 2H), 5.39 (s, 2H), 4.00 (s, 3H).
[00457] Step 2: synthesis of compound VVX031-3
[00458] To a round bottom flask were added THF (8 mL) and H20 (2 mL). WX031-2
(1.06 g,
4.52 mmol, 1 eq) and Li0H.H20 (569.16 mg, 13.56 mmol, 3 eq) were then added,
and the
mixture was continuously stirred at 25 C for 2 hours. The reaction solution
was concentrated
under reduced pressure to remove THF. 1 M diluted hydrochloric acid solution
was added
dropwise to the reaction solution to adjust pH to less than 3, and the mixture
was filtered to give
compound VVX031-3. 1H NMR (400MHz, DMSO-d6) 6= 8.79 (s, 1H), 7.39 (dd, J=5.5,
8.8 Hz,
2H), 7.25 - 7.17 (m, 2H), 5.47 (s, 211).
[00459] Step 3: synthesis of compound WX031
[00460] To a round bottom flask was added N,N-dimethylfoimamide (1 mL). WX031-
3
(18.03 mg, 81.53 pmol, 1.2 eq), BB-4 (30 mg, 67.94 mol, 1 eq), DIPEA (26.34
mg, 203.82
pmol, 35.50 pL, 3 eq) and T3P (64.85 mg, 101.91 mot 60.61 L, 50% purity, 1.5
eq) were
then slowly added, and the mixture was continuously stirred at 25 C for 2
hours. The reaction
solution was directly separated by HPLC (Column: Xtimate C18 100*30mm*3 m;
Mobile
phase: [water (0.225%FA)-ACN]; acetonitrile%: 40%-70%, 8min) to give compound
WX031.
1H NMR (400MHz, CDC13) 6= 8.81 (br d, J=7.3 Hz, 111), 8.37 (dd, J=1.4, 4.6 Hz,
1H), 8.06 (s,
1H), 7.56 (dd, J=14, 7.9 Hz, 1H), 7.33 - 7.27 (m, 3H), 7.07 (t, J=8.5 Hz, 2H),
5.37 (s, 2H), 5.20
(td, J=6.7, 11.2 Hz, 1H), 4.78 (dd, J=6.4, 9.4 Hz, 111), 4.32 (dd, J=9.7, 10.9
Hz, 111), 3.93 (s,
3H); LCMS miz = 413.1 pvid-1r.
[00461] Example 32: VVX032
CN
0 N,N
N
S
[00462] Route for synthesis:
84
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
0 N 0
CN op CN
HO
WX032-1 WX032-2 VVX032-3
0
'NH, CN
N N NN 011
/ S BB-4 ,./C)
)"NH
NN
WX032
1004631 Step 1: synthesis of compound VVX032-2
[00464] To MeCN (20 mL) were added VX032-1 (1.5 g, 11.80 mmol, 1 eq), 3-
chloromethyl
benzonitrile (1.97 g, 12.98 mmol, 1.72 mL, 1.1 eq) and K2CO3 (2.45 g, 17.70
mmol, 1.5 eq),
and the reaction solution was continuously stirred at 50 C for 12 hours.
Water (50 mL) was
added to the reaction solution and the mixture was extracted with ethyl
acetate (50 mL x2). The
organic phases were combined, washed with saturated brine (20 mL x2), and
concentrated
under reduced pressure to give a crude product. The crude product was purified
by silica gel
column chromatography (petroleum ether: ethyl acetate=100:1-1:100) to give
compound
VVX032-2. 1H NMR (400MHz, CDC13) 5= 8.21 (s, 1H), 7.67 (t, J=4.3 Hz, 1H), 7.58
(s, 1H),
7.52 (d, J=4.8 Hz, 2H), 5.47 (s, 2H), 4.01 (s, 3H).
1004651 Step 2: synthesis of compound VVX032-3
[00466] To a round bottom flask were added THF (8 mL) and H20 (2 mL). VVX032-2
(1.4 g,
5.78 mmol, 1 eq) and UO114120 (727.53 mg, 17.34 mmol, 3 eq) were then added,
and the
reaction solution was continuously stirred at 25 C for 2 hours. The reaction
solution was
concentrated under reduced pressure to remove THF. 1 M diluted hydrochloric
acid solution
was added dropwise to the reaction solution to adjust pH to less than 3, and
the mixture was
filtered to give the target compound WX032-3. 1H NMR (400MHz, DMSO-do) 5= 8.83
- 8.80
(m, 1H), 7.86 - 7.80 (m, 2H), 7.68 - 7.57 (in, 2H), 5.59 - 5.52 (m, 2H).
[00467] Step 3: synthesis of compound VVX032
[00468] To a round bottom flask was added N,N-dimethylfonnamide (1 mL). VVX032-
3
(15.50 mg, 67.94 timol, 1 eq), BB-4 (30 mg, 67.94 1,111101, 1 eq), DIPEA
(26.34 mg, 203.82
gmol, 35.50 pL, 3 eq) and T3P (64.85 mg, 101.91 gmol, 60.61 j.tL, 50% purity,
1.5 eq) were
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
then slowly added, and the mixture was continuously stirred at 25 C for 2
hours. The reaction
solution was directly seperated by HPLC (Column: Xtimate C18 100*30mm*31.1m;
Mobile
phase: [water (0.225%FA)-ACN]; acetonitrile%: 35%-65%, 8min) to give compound
WX032.
1H NMR (400MHz, CDC13) 6= 8.85 (br d, J=7.3 Hz, 1H), 8.37 (d, J=3.3 Hz, 1H),
8.17 (s, 1H),
7.65 (br d, J=2.8 Hz, 1H), 7.60 - 7.55 (m, 2H), 7.53 - 7.47 (m, 2H), 7.29 (dd,
J=4.6, 7.9 Hz, 1H),
5.45 (s, 2H), 5.26 - 5.15 (m, 1H), 4.79 (dd, J=6.3, 9.5 Hz, 1H), 4.38 - 4.28
(m, 1H), 3.93 (s, 3H);
LCMS m/z = 420.1 [M+11+.
[00469] Example 33: VVX033
0
..NH Nrj
N N
S
[00470] Route for synthesis:
o
P-NH A N
HO N- 411
WX033-1 WX033-2 WX033-3
,,INH20 N-N
N N 0 7/ 00
/ s BB-4 c.j.
NH N-
x I '
N N
S
INX033
[00471] Step 1: synthesis of compound VVX033-2
[00472] To a round bottom flask was added MeCN (20 mL). VVX033-1(1.5 g, 11.80
mmol, 1
eq), 3-methylbenzyl chloride (1.83 g, 12.98 mmol, 1.72 mL, 1.1 eq) and K2CO3
(2.45 g, 17.70
mmol, 1.5 eq) were added, and the mixture was continuously stirred at 50 C
for 12 hours.
Water (50 mL) was added to the reaction solution and the mixture was extracted
with ethyl
acetate (50 mLx 2). The organic phases were combined, washed with saturated
brine (10
mLx2), and concentrated under reduced pressure to give a crude product. The
crude product
was purified by silica gel column chromatography (petroleum ether:ethyl
acetate=100:1-1:100)
to give compound VVX033-2. 1H NMR (400MHz, CDC13) 6= 8.08 (s, 1H), 7.33 - 7.27
(m, 1H),
7.18 (cl, J=7.6 Hz, 1H), 7.10 (br d, J=1.8 Hz, 2H), 5.38 (s, 2H), 4.05 - 3.97
(m, 3H), 2.38 -2.31
(m, 3H).
86
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00473] Step 2: synthesis of compound VVX033-3
[00474] To a round bottom flask were added THF (8 mL) and H20 (2 mL). WX033-2
(1.6 g,
6.92 mmol, 1 eq) and Li011-1-120 (870.95 mg, 20.76 mmol, 3 eq) were then
added, and the
mixture was continuously stirred at 25 C for 2 hours. The reaction solution
was concentrated
under reduced pressure to remove THF. 1 M diluted hydrochloric acid solution
was added
dropwise to the reaction solution to adjust pH to less than 3, and the mixture
was filtered to give
compound VVX033-3. 11-1 NMR (400MHz, DMSO-d6)43= 13.28 (hr s, 1H), 8.79 (s,
1H), 7.30 -
7.23 (m, 1H), 7.17 - 7.07 (m, 3H), 5.43 (s, 2H), 2.29 (s, 3H).
[00475] Step 3: synthesis of compound VVX033
[00476] To a round bottom flask was added N,N-dimethylformamide (1 mL). VVX033-
3
(17.71 mg, 81.53 mot, 1.2 eq), BB-4 (30 mg, 67.94 mot, 1 eq), DIPEA (26.34
mg, 203.82
jtmol, 35.50 L, 3 eq) and T3P (64.85 mg, 101.91 mot, 60.61 L, 50% purity,
1.5 eq) were
then slowly added, and the mixture was continuously stirred at 25 C for 2
hours. The reaction
solution was directly seperated by HPLC (Column: Xtimate C18 100*30mm*3 m;
Mobile
phase: [water (0.225%FA)-ACN]; acetonitrile%: 37%-67%, 8min) to give compound
WX033.
ITINMR (400MHz, CDC13) 5 = 8.81 (br d, J=7.0 Hz, 1H), 8.37 (d, J=3.3 Hz, 1H),
8.03 (s, 1H),
7.57 (d, J=6.8 Hz, 1H), 7.31 -7.27 (m, 2H), 7.20 - 7.15 (m, 1H), 7.11 -7.07
(m, 2H), 5.36 (s,
2H), 5.22 (td, J=6.8, 11.5 Hz, 1H), 4.79 (dd, J=6.4, 9.4 Hz, 1H), 4.36 - 4.27
(m, 1H), 3.93 (s,
3H), 2.34 (s, 3H); LCMS m/z = 409.1 [M+1]+.
[00477] Example 34: VVX034
N
/ S
[00478] Route for synthesis:
87
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
0 0
> F \._4\1,N
0 N_NH
HO
-0 N-
WX034-2 VVX034-3
WX034-1
N N
S 0 N_N BB-4 0111
,,NH N-rj
N N
S
WX034
1004791 Step 1: synthesis of compound VVX034-2.
[00480] To a single-neck bottle was added MeCN (20
mL).
1-Chloromethy1-3,5-difluorobenzene (2.11 g, 12.98 mmol, 573.45 tL, 1.1 eq),
WX034-1 (1.5
g, 11.80 mmol, 1 eq) and K2CO3 (2.45 g, 17.70 mmol, 1.5 eq) were then added,
and the mixture
was continuously stirred at 50 C for 12 hours. A new spot appeared by TLC
(petroleum
ether:ethyl acetate=1:2) monitoring. Water (50 mL) was added to the reaction
solution and the
mixture was extracted with ethyl acetate (50 mL x2). The organic phases were
combined,
washed with saturated brine (20 mL x2), and concentrated under reduced
pressure to give a
crude product. The crude product was purified by silica gel column
chromatography
(petroleum ether: ethyl acetate=100:1-1:100) to give compound VVX034-2. 1H NMR
(400MHz,
CDC13) 6= 8.22 (s, 1H), 6.92 - 6.77 (m, 3H), 5.50 - 5.38 (m, 2H), 4.11 - 3.99
(m, 3H).
[00481] Step 2: synthesis of compound VVX034-3
[00482] To a round bottom flask were added THF (8 mL) and H20 (2 mL). WX034-2
(1 g,
3.95 mmol, 1 eq) and Li0H-1120 (497.15 mg, 11.85 mmol, 3 eq) were then added,
and the
mixture was continuously stirred at 25 C for 2 hours. The reaction solution
was concentrated
under reduced pressure to remove THF. 1 M diluted hydrochloric acid solution
was added
dropwise to the remaining solution to adjust pH to less than 3, and the
mixture was filtered to
give compound VVX034-3. 1H NMR (400MHz, DMSO-d6) 6= 8.80 (s, 1H), 7.24 (br t,
J=9.4 Hz,
1H), 7.07 (br d, J=6.3 Hz, 2H), 5.52 (s, 2H).
[00483] Step 3: synthesis of compound VVX034.
[00484] To a round bottom flask was added N,N-dimethylfonnamide (1 mL). WX034-
3
(19.50 mg, 81.53 Ltmol, 1.2 eq), BB-4 (30 mg, 67.94 gmol, 1 eq), DIPEA (26.34
mg, 203.82
88
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
mol, 35.50 L, 3 eq) and T3P (64.85 mg, 101.91 mot, 60.61 L, 50% purity, 1.5
eq) were
then slowly added, and the mixture was continuously stirred at 25 C for 2
hours. The reaction
solution was directly seperated by HPLC (Column: Xtimate C18 100*30mm*31,1m;
Mobile
phase: [water (0.225%FA)-ACN]; acetonitrile%: 37%-67%, 8min) to give compound
WX034.
1H NMR (400MHz, CDC13) 6 = 8.85 (br d, J=7.0 Hz, 1H), 8.37 (dd, J=1.5, 4.6 Hz,
1H), 8.16 (s,
1H), 7.57 (dd, J=1.5, 8.0 Hz, 1H), 7.29 (dd, J=4.7, 7.9 Hz, 1H), 6.85 - 6.73
(m, 3H), 5.38 (s,
2H), 5.21 (td, J=6.6, 11.2 Hz, 1H), 4.79 (dd, J=6.4, 9.5 Hz, 1H), 4.33 (dd,
J=9.6, 11.0 Hz, 1H),
3.93 (s, 3H); LCMS m/z = 431.1 [M+1] .
[00485] Example 35: VVX035
O-.-.\ (3\,\ ______________________ /./N-N
\rµi
/ s
1004861 Route for synthesis:
0
-0 N HO
WX035-1 WX035-2 WX035-3
0
N N-__NH2 </NN 0111
4
s "4 eNN
WX035
[0048'7] Step 1: synthesis of compound VVX035-2
[00488] To MeCN (20 mL) were added VVX035-1 (1.5 g, 11.80 mmol, 1 eq),
1-chloromethy1-2-toluene (1.83 g, 12.98 mmol, 1.72 mL, 1.1 eq) and K2CO3 (2.45
g, 17.70
mmol, 1.5 eq), and the mixture was continuously stirred at 50 C for 12 hours.
Water (50 mL)
was added to the reaction solution and the mixture was extracted with ethyl
acetate (50 mL x2).
The organic phases were combined, washed with saturated brine (20 mLx2), and
concentrated
under reduced pressure to give a crude product. The crude product was purified
by silica gel
column chromatography (petroleum ether:ethyl acetate=100:1-1:100) to give
compound
VVX035-2. 11-1 NMR (400MHz, CDC13) 6= 7.89 (s, 1H), 7.36 - 7.29 (m, 1H), 7.26 -
7.16 (m,
89
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
3H), 5.42 (s, 2H), 4.00 (s, 3H), 2.27 (s, 3H).
[00489] Step 2: synthesis of compound WX035-3
[00490] To a round bottom flask were added THF (8 mL) and H20 (2 mL). VVX035-2
(1.6 g,
6.92 mmol, 1 eq) and Li011.1-120 (870.95 mg, 20.76 mmol, 3 eq) were then
added, and the
mixture was continuously stirred at 25 C for 2 hours. The reaction solution
was concentrated
under reduced pressure to remove THF. 1 M diluted hydrochloric acid solution
was added
dropwise to the remaining solution to adjust pH to less than 3, and the
mixture was filtered to
give WX035-3. 1H NMR (400MHz, DMSO-d6) 6= 13.28 (br s, 1H), 8.79 (s, 1H), 7.30
- 7.23
(m, 1H), 7.17 - 7.07 (m, 3H), 5.43 (s, 2H), 2.29 (s, 3H).
[00491] Step 3: synthesis of compound VVX035
[00492] To a round bottom flask was added N,N-dimethylformamide (1 mL). VVX035-
3
(17.71 mg, 81.53 pmol, 1.2 eq), BB-4 (30 mg, 67.94 pmol, 1 eq), DIPEA (26.34
mg, 203.82
mol, 35.50 L, 3 eq) and T3P (64.85 mg, 101.91 mot, 60.61 L, 50% purity, 1.5
eq) were
then slowly added, and the mixture was continuously stirred at 25 C for 2
hours. The reaction
solution was directly seperated by HPLC (Column: Xtimate C18 100*30mm*3 m;
Mobile
phase: [water (0.225%FA)-ACN]; acetonitrile%: 37%-67%, 8min) to give compound
WX035.
1H NMR (400MHz, CDC13) 6 = 8.81 (br d, J=7.0 Hz, 1H), 8.37 (d, J=4.5 Hz, 1H),
7.86 (s, 1H),
7.57 (d, j=7.8 Hz, 1H), 7.34 - 7.27 (m, 2H), 7.26 - 7.15 (m, 3H), 5.40 (s,
2H), 5.22 (td, J=6.7,
11.2 Hz, 1H), 4.79 (dd, J=6.4, 9.4 Hz, 1H), 4.38 - 4.26 (m, 1H), 3.93 (s, 3H),
2.29 (s, 3H);
LCMS m/z = 409.1 [M+1]+.
[00493] Example 36: VVX036
CI
0 N_N
, INN N
/
[00494] Route for synthesis:
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
:-< 0 ,
CI is CI
HO N"----j
WX036-1 VVX036-2 WX036-3
.,NH, CI
_N
s BB-4 0\\
I ,NIFI
S
WX-036
[00495] Step 1: synthesis of compound WX036-2
[00496] To a round bottom flask was added MeCN (20 mL) at 25 C. VVX036-1 (2.02
g, 15.89
mmol, leq), K2CO3 (4.39 g, 31.79 mmol, 2 eq) and 1-chloro-3-
chloromethylbenzene (3.07 g,
19.07 mmol, 2.42 mL, 1.2 eq) were then slowly added. The reaction solution was
continuously
stirred at 60 C under nitrogen for 12 hours. The reaction solution was slowly
poured into water
(100 ml), and the mixture was extracted with ethyl acetate (100 mL x 2). The
organic phases
were combined, washed successively with water (100 mL) and saturated brine
(100 mL), and
concentrated under reduced pressure to give a crude product. The crude product
was purified
by silica gel column chromatography (petroleum ether:ethyl acetate=100:20-
100:75) to give
compound WX036-2. 1H NMR (400MHz, CDC13) 8 = 8.15 (s, 1H), 7.35- 7.26(m, 3H),
7.17(d,
J=6.8 Hz, 1H), 5.40 (s, 2H), 4.04 - 3.93 (m, 3H).
[00497] Step 2: synthesis of compound VVX036-3
[00498] To a round bottom flask were added THF (14 mL) and H20 (2 mL) at 25 C.
VVX036-2
(1.80 g, 7.15 mmol, 1 eq) and Li011-1120 (900.33 mg, 21.46 mmol, 3 eq) were
then slowly
added. The reaction solution was continuously stirred at 25 C under nitrogen
for 1 hour. The
reaction solution was adjusted to a pH of 6-7 with diluted hydrochloric acid
(1 M), and the
precipitate was filtered to give compound WX036-3.
[00499] Step 3: synthesis of compound WX036.
[00500] To a round bottom flask was added N,N-dimethylacetamide (5 mL) at 25
C. BB-4 (20
mg, 45.29 mol, 1 eq), T3P (43.23 mg, 67.94 mot, 40.41 L, 50% purity, 1.5
eq), VVX036-3
(16.14 mg, 67.94 mol, 1.5 eq) and DIPEA (17.56 mg, 135.87 mot, 23.67 L, 3
eq) were then
slowly added, and the reaction solution was continuously stirred at 25 C
under nitrogen for 2
91
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
hours. The reaction solution was slowly poured into water (100 mL), and the
mixture was
extracted with ethyl acetate (100 mLx 2). The organic phases were combined,
washed
successively with water (100 mL) and saturated brine (100 mL), and
concentrated under
reduced pressure to give a crude product. The crude product was seperated by
preparative
HPLC (Column: Xtimate C18 100*30mm*31.1m; Mobile phase: [water (0.225%FA)-
ACN];
acetonitrile%: 35%-65%, 8min) to give compound WX036. 1H NMR (400MHz, CDC13) 5
=
8.95 - 8.69 (m, 1H), 8.37 (br d, J=3.1 Hz, 1H), 8.10 (s, 1H), 7.68 - 7.47 (m,
1H), 7.38 - 7.27 (m,
3H), 7.26 - 7.20 (m, 1H), 7.16 (br d, J=7.0 Hz, 1H), 5.38 (s, 2H), 5.26 - 5.10
(m, 1H), 4.79 (dd,
J=6.5, 9.4 Hz, 1H), 4.41 - 4.20 (m, 1H), 3.93 (s, 3H); LCMS miz =429.0 [M+1] .
[00501] Example 37: VVX037
Br
0 N_,N
C) .,NH
S
[00502] Route for synthesis:
0 m Br 0 N Br
-0 -0 HO N
VVX037-1 VVX037-2 WX037-3
,,NH2 Br
N N 0 N.. N
, s BB-4
N N
/ S
INX037
[00503] Step 1: synthesis of compound VVX037-2
[00504] To a round bottom flask was added MeCN (20 mL) at 25 C. WX037-1 (2.03
g, 15.97
mmol, leq), K2CO3 (4.41 g, 31.94 mmol, 2 eq) and 1-bromo-3-chloromethylbenzene
(3.94 g,
19.17 mmol, 241.82 1.11õ 1.2 eq) were then slowly added. The reaction solution
was
continuously stirred at 60 C under nitrogen for 12 hours. The reaction
solution was slowly
poured into water (100 mL), and the mixture was extracted with ethyl acetate
(100 mL x 2). The
organic phases were combined, washed successively with water (100 mL) and
saturated brine
(100 mL), and concentrated under reduced pressure to give a crude product. The
crude product
was purified by silica gel column chromatography (petroleum ether: ethyl
92
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
acetate=100:20-100:75) to give compound VVX037-2. 1H NMR (400MHz, CDC13) 8 =
8.14 (s,
1H), 7.59 - 7.38 (m, 2H), 7.30 - 7.26 (m, 1H), 7.25 - 7.20 (m, 1H), 5.39 (s,
2H), 4.01 (s, 3H).
[00505] Step 2: synthesis of compound VVX037-3
[00506] To a round bottom flask were added THF (14 mL) and H20 (2 mL) at 25 C.
VVX037-2
(2.0 g, 6.75 mmol, 1 eq) and Li0H-1120 (850.20 mg, 20.26 mmol, 3 eq) were then
slowly
added. The reaction solution was continuously stirred at 25 C under nitrogen
for 1 hour. The
reaction solution was adjusted to a pH of 6-7 with diluted hydrochloric acid
(1 M), and the
precipitate was filtered to give compound WX037-3.
[00507] Step 3: synthesis of compound WX037
[00508] To a round bottom flask was added N,N-dimethylacetamide (5 mL) at 25
C. BB-4 (20
mg, 45.29 mol, 1 eq), T3P (43.23 mg, 67.94 mot, 40.41 piL, 50% purity, 1.5
eq), VVX037-3
(19.16 mg, 67.94 pmol, 1.5 eq) and DIPEA (17.56 mg, 135.87 mot, 23.67 L, 3
eq) were then
slowly added, and the reaction solution was continuously stirred at 25 C
under nitrogen for 2
hours. The reaction solution was slowly poured into water (100 mL), and the
mixture was
extracted with ethyl acetate (100 mL x 2). The organic phases were combined,
washed
successively with water (100 mL) and saturated brine (100 mL), and
concentrated under
reduced pressure to give a crude product. The crude product was seperated by
preparative
HPLC (Column: Xtimate C18 100*30mm*31.1m; Mobile phase: [water (0.225%FA)-
ACN];
acetonitrile%: 35%-65%, 8min) to give compound VVX037. 1H NMR (400MHz, CDC13)
6 =
8.83 (br d, J=6.4 Hz, 1H), 8.37 (br d, J=4.5 Hz, 1H), 8.10 (s, 1H), 7.66 -
7.27 (m, 4H), 7.25 -
7.15 (m, 2H), 5.37 (s, 2H), 5.26 - 5.06 (m, 1H), 4.79 (br dd, J=6.5, 9.1 Hz,
1H), 4.33 (br t,
J=10.3 Hz, 1H), 3.93 (s, 3H); LCMS m/z =474.8 NATE.
[00509] Example 38: WX038
0 N-
a ) ,N1FN3 ocF3
N N-
I S
[00510] Route for synthesis:
93
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
0 m 0
<õN . " N
JHO N---=-1
OCF3 OCF3
WX038-1 WX038-2 WX038-3
.,NH2
0 N _N
N N
13B-4 ;<N 0CF3
S
WX038
[00511] Step 1: synthesis of compound VVX038-2
[00512] To a round bottom flask was added MeCN
(20 mL).
1-Chloromethy1-4-trifluoromethoxybenzene (2.73 g, 12.98 mmol, 517.03 p.L, 1.1
eq),
VVX038-1 (1.5 g, 11.80 mmol, 1 eq) and K2CO3 (2.45 g, 17.70 mmol, 1.5 eq) were
then added,
and the mixture was continuously stirred at 50 C for 12 hours. Water (50 mL)
was added to the
reaction solution and the mixture was extracted with ethyl acetate (50 mL x2).
The organic
phases were combined, washed with saturated brine (20 mLx2), and concentrated
under
reduced pressure to give a crude product. The crude product was purified by
silica gel column
chromatography (petroleum ether: ethyl acetate=100:1-1:100) to give compound
VVX038-2.
1H NMR (400MHz, CDC13) S= 8.17 (s, 1H), 7.36 (d, J=8.5 Hz, 2H), 7.27 - 7.23
(m, 2H), 5.50 -
5.40 (m, 2H), 4.08 - 3.96 (m, 3H).
[00513] Step 2: synthesis of compound WX038-3
[00514] To a round bottom flask were added THF (16 mL) and H20 (4 mL). VVX038-
2 (1.9 g,
6.31 mmol, 1 eq) and Li011-1-120 (794.01 mg, 18.92 mmol, 3 eq) were then
added, and the
mixture was continuously stirred at 25 C for 2 hours. The reaction solution
was concentrated
under reduced pressure to remove THF. 1 M diluted hydrochloric acid solution
was added
dropwise to the remaining solution to adjust pH to less than 3, and the
precipitate was filtered to
give compound VVX038-3. 111 NMR (400MHz, DMSO-d6) ö= 8.81 (s, 1H), 7.51 - 7.33
(m, 4H),
5.53 (s, 2H).
[00515] Step 3: synthesis of compound VVX038
[00516] To a round bottom flask was added N,N-dimethylformamide (1 mL). VVX038-
3
(23.41 mg, 81.53 pmol, 1.2 eq), BB-4 (30 mg, 67.94 pmol, 1 eq), DIPEA (26.34
mg, 203.82
35.50 pL, 3 eq) and T3P (64.85 mg, 101.91 innol, 60.61 pt, 50% purity, 1.5 eq)
were
94
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
then slowly added, and the mixture was continuously stirred at 25 C for 2
hours. The reaction
solution was directly seperated by HPLC (Column: Xtimate C18 100*30mm*31.1m;
Mobile
phase: [water (0.225%FA)-ACN]; acetonitrile%: 40%-70%, 8min) to give compound
WX038.
11-1NMR (400MHz, CDC13) 5- 8.84 (br d, J=7.3 Hz, 1H), 8.38 (dd, J=1.5, 4.5 Hz,
1H), 8.11 (s,
1H), 7.58 (dd, J=1.5, 8.0 Hz, 1H), 7.34 (d, J=8.8 Hz, 2H), 7.32 - 7.29 (m,
1H), 7.27 (s, 5H), 7.26
- 7.22 (m, 2H), 5.42 (s, 2H), 5.28 - 5.15 (m, 1H), 4.80 (dd, J=6.5, 9.5 Hz,
1H), 4.37 - 4.29 (m,
1H), 3.94 (s, 3H); LCMS m/z = 479.1 [M+11+.
[00517] Example 39: VVX039
0 0110
..NH N
/
[00518] Route for synthesis:
544_ H /rN,N
-0 le-j
H 0 /NN-----:11
WX039-1 WX039-2 WX039-3
0
..NH,
N N 0 0,, zN_N 410
/ s BB-4 0:
NH N"-
N N
/ S
WX039
[00519] Step 1: synthesis of compound VVX039-2
[00520] To a round bottom flask was added MeCN (20 mL) at 25 C. WX039-1 (2.0
g, 15.74
mmol, leq), K2CO3 (4.35 g, 31.48 mmol, 2 eq) and 1-chloromethy1-4-
methylbenzene (2.66 g,
18.89 mmol, 2.48 mL, 1.2 eq) were then slowly added. The reaction solution was
continuously
stirred at 60 C under nitrogen for 12 hours. The reaction solution was slowly
poured into water
(100 mL), and the mixture was extracted with ethyl acetate (100 mLx 2). The
organic phases
were combined, washed successively with water (100 mL) and saturated brine
(100 mL), and
concentrated under reduced pressure to give a crude product. The crude product
was purified
by silica gel column chromatography (petroleum ether:ethyl acetate=100:20-
100:75) to give
compound VVX039-2. NMR (400MHz, CDC13) 5 = 8.04 (s, 1H), 7.23 - 7.17 (m, 4H),
5.37 (s,
2H), 4.00 (s, 3H), 2.47 - 2.25 (m, 3H).
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00521] Step 2: synthesis of compound VVX039-3
[00522] To a round bottom flask were added THF (14 mL) and H20 (2 mL) at 25 C.
WX039-2
(1.5 g, 6.49 mmol, 1 eq) and Li011-1-120 (816.52 mg, 19.46 mmol, 3 eq) were
then slowly
added. The reaction solution was continuously stirred at 25 C under nitrogen
for 1 hour. The
reaction solution was adjusted to a pH of 6-7 with diluted hydrochloric acid
(1 M), and the
precipitate was collected by filtration to give compound WX039-3.
[00523] Step 3: synthesis of compound VVX039
[00524] To N,N-dimethylacetamide (5 mL) were added BB-4 (20 mg, 45.29 gmol, 1
eq), T3P
(43.23 mg, 67.94 timol, 40.41 jiL, 50% purity, 1.5 eq), WX039-3 (14.76 mg,
67.94 gmol, 1.5
eq) and DIPEA (17.56 mg, 135.87 mol, 23.67 j.tL, 3 eq) at 25 C, and the
reaction solution was
continuously stirred at 25 C under nitrogen for 2 hours. The reaction
solution was slowly
poured into water (100 mL), and the mixture was extracted with ethyl acetate
(100 mL x 2). The
organic phases were combined, washed successively with water (100 mL) and
saturated brine
(100 mL), and concentrated under reduced pressure to give a crude product. The
crude product
was seperated by preparative HPLC (Column: Xtimate C18 100*30mm*3 m; Mobile
phase:
[water (0.225%FA)-ACN]; acetonitrile%: 40%-70%, 8min) to give a product WX039.
1H
NMR (400MHz, CDC13) 6 = 8.80 (br d, J=7.3 Hz, 1H), 8.37 (dd, J=1.5, 4.5 Hz,
1H), 8.00 (s,
1H), 7.56 (dd, J=1.5, 7.8 Hz, 1H), 7.28 (dd, J=4.8, 8.0 Hz, 1H), 7.19 (s, 4H),
5.35 (s, 2H), 5.21
(td, J=6.8, 11.0 Hz, 1H), 4.78 (dd, J=6.4, 9.4 Hz, 1H), 4.32 (dd, J=9.7, 11.2
Hz, 1H), 3.93 (s,
3H), 2.63 - 2.13 (m, 3H); LCMS m/z =409.1 [M+11 .
[00525] Example 40: WX040
0N
H2N ..,NH N
0 s
[00526] Route for synthesis:
96
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
NHEloc
NHBoc NHBoc
F 02 HOhs.OHBB-3.2
OH
411 lir
0 N 0 0 ,0 8 -k" No2 111" NH2
0 0 0
WX040-1 WX040-2 WX040-3
0
N4, NHBoc 0 40 ,,NHBoc so õNH... Ho so ,NHBoc
0 H 0 0
WX040-4 WX040-5 WX040-6 WX040-7
rielti 0 H0NN-ji is
0
H2N :ii...NHBoc H2 N )...H2 BB-8
)..,NH
H2N 1iI
0 S 0 S 0 S
WX040-6 INX040-9 WX040
[00527] Step 1: synthesis of compound VVX040-2
[00528] To a round bottom flask was added THF (100 mL). VVX040-1 (10 g, 50.22
mmol, 1
eq), BB-3-2 (11.34 g, 55.24 mmol, 1.1 eq) and cesium carbonate (29.45 g, 90.39
mmol, 1.8 eq)
were then slowly added, and the mixture was continuously stirred at 65 C for
16 hours. TLC
(petroleum ether:ethyl acetate:acetic acid=1:1:0.1) showed that the raw
materials were
completely consumed. The reaction solution was poured into water (300 mL), and
2 M diluted
hydrochloric acid was then added dropwise to adjust pH to 3. The mixture was
extracted with
ethyl acetate (500 mL x2). The organic phases were combined and washed with
saturated brine
(50 mLx2). The organic phase was then concentrated under reduced pressure to
give VVX040-2.
1H NMR (400MHz, CDC13) 6= 8.46 (d, J=1.8 Hz, 1H), 8.20 (dd, J=2.0, 8.8 Hz,
1H), 7.12 (d,
J=8.8 Hz, 1H), 5.62 (br d, J=8.0 Hz, 1H), 4.83 -4.61 (m, 2H), 4.45 (dd, J=3.0,
9.3 Hz, 1H), 3.93
(s, 3H), 1.45 (s, 10H).
[00529] Step 2: synthesis of compound VVX040-3
[00530] To a hydrogenation bottle was added Me0H (300 mL). VVX040-2 (25.8 g,
67.13
mmol, 1 eq) and Pd/C (2.6 g, 26.02 mmol, 10% purity) were then slowly added.
The
atmosphere was replaced three times with argon gas, and the mixture was
continuously stirred
at 30 C under H2 (40Psi) atmosphere for 24 hours. A new spot appeared by TLC
(petroleum
ether:ethyl acetate:acetic acid=1:1:0.1) monitoring. The reaction solution was
filtered through
Celite, and the filtrate was concentrated under reduced pressure to give
compound WX040-3.
1H NMR (400MHz, CDC13) 6 = 7.50 - 7.44 (m, 1H), 7.39 (br s, 1H), 6.70 (d,
J=8.5 Hz, 1H),
97
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
6.53 (br s, 2H), 6.00 (br d, J=7.5 Hz, 1H), 4.73 (br d, J=7.0 Hz, 1H), 4.43
(br d, J=8.5 Hz, 1H),
4.31 -4.24 (m, 1H), 3.85 (s, 3H), 1.41 (s, 9H).
[00531] Step 3: synthesis of compound VVX040-4
[00532] To a round bottom flask was added ethyl acetate (200 mL). WX040-3
(12.5 g, 35.28
mmol, 1 eq), T3P (33.67 g, 52.91 mmol, 31.47 mL, 50% purity, 1.5 eq) and DIPEA
(13.68 g,
105.83 mmol, 18.43 mL, 3 eq) were then slowly added, and the mixture was
continuously
stirred at 25 C for 2 hours. Water (200 mL) was added to the reaction
solution and the layers
were seperated. The aqueous phase was extracted with ethyl acetate (200 mLx2).
The organic
phases were combined, and washed with saturated brine (100 mLx2), and then the
organic
phase was concentrated under reduced pressure to give a crude product. The
crude product was
purified by silica gel column chromatography (petroleum ether:ethyl acetate =
100:1-1:1) to
give compound VVX040-4. 1H NMR (400MHz, CDC13) 5= 8.15 (br s, 1H), 7.80 (dd,
J=2.0, 8.5
Hz, 1H), 7.73 (d, J=2.0 Hz, 1H), 7.13 (d, J=8.3 Hz, 1H), 5.62 (br d, J=5.3 Hz,
1H), 4.71 - 4.59
(m, 2H), 4.33 - 4.23 (m, 1H), 3.95 - 3.89 (m, 3H), 1.43 (s, 9H).
[00533] Step 4: synthesis of compound VVX040-5
[00534] To a round bottom flask was added N,N-dimethylformamide (200 mL).
VVX040-4 (17
g, 50.54 mmol, 1 eq), cesium carbonate (49.40 g, 151.63 mmol, 3 eq) and
iodomethane (21.52
g, 151.63 mmol, 9.44 mL, 3 eq) were then slowly added, and the mixture was
continuously
stirred at 25 C for 2 hours. Water (300 mL) was added to the reaction
solution, and the mixture
was extracted with ethyl acetate (300mLx2). The organic phases were combined,
and washed
with saturated brine (100 mLx2), and the organic phase was then concentrated
under reduced
pressure to give a crude product. The crude product was purified by silica gel
column
chromatography (petroleum ether:ethyl acetate-100:1-1:1) to give compound
VVX040-5. 1H
NMR (400MHz, CDC13) 5= 7.92 - 7.83 (m, 2H), 7.18 (d, J=8.4 Hz, 1H), 5.50 (br
d, J=6.1 Hz,
1H), 4.72 - 4.52 (m, 2H), 4.28 - 4.17 (m, 1H), 3.92 (s, 3H), 3.42 (s, 3H),
1.38 (s, 9H).
[00535] Step 5: synthesis of compound WX040-6
[00536] To toluene (40 mL) were slowly added VVX040-5 (4.01 g, 11.45 mmol, 1
eq),
Lawsson's reagent (5.09 g, 12.59 mmol, 1.1 eq) and Boc20 (10.60 g, 48.55 mmol,
11.15 mL,
4.24 eq), and the mixture was heated to 110 C and continuously stirred for 12
hours. The
reaction solution was slowly poured into saturated brine (30 mL), and the
mixture was
98
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
extracted with ethyl acetate (100 mLx 2). The organic phases were combined,
and washed with
saturated brine (30 mLx2), and the organic phase was then concentrated under
reduced
pressure to give a crude product. The crude product was purified by silica gel
column
chromatography (petroleum ether:ethyl acetate=100:1-1:1) to give compound
WX040-6. 1H
NMR (400MHz, CDC13) 6= 7.99 - 7.92 (m, 2H), 7.21 (d, J=8.3 Hz, 1H), 6.02 (br
d, J=7.8 Hz,
1H), 4.80 - 4.69 (m, 1H), 4.53 (dd, J=6.3, 9.5 Hz, 1H), 4.22 (dd, J=9.5, 11.3
Hz, 1H), 3.94 (s,
3H), 3.86 (s, 3H), 1.46 - 1.33 (m, 9H).
[00537] Step 6: synthesis of compound WX040-7
[00538] To a round bottom flask were added THF (8 mL) and H20 (2 mL). VVX040-6
(800 mg,
2.18 mmol, 1 eq) and Li011-1120 (183.23 mg, 4.37 mmol, 2 eq) were then slowly
added, and
the mixture was continuously stirred at 25 C for 2 hours. Diluted
hydrochloric acid solution
was added dropwise to the reaction solution to adjust pH to <3, and the
precipitate was filtered
and collected to give compound WX040-7. 1H NMR (400MHz, CDC13) 6 = 7.89 - 7.79
(m, 1H),
7.25 - 7.20 (m, 1H), 7.02 - 6.95 (m, 1H), 6.17 - 6.02 (m, 1H), 4.88 - 4.74 (m,
1H), 4.56 (dd,
J=6.4, 9.7 Hz, 1H), 4.31 - 4.17 (m, 1H), 3.85 (s, 3H), 1.41 (s, 9H).
[00539] Step 7: synthesis of compound WX040-8
[00540] To a round bottom flask was added N,N-dimethylformamide (5 mL). VX040-
7 (200
mg, 567.53 mot, 1 eq), NR4C1 (91.07 mg, 1.70 mmol, 3 eq), HATU (647.37 mg,
1.70 mmol,
253.15 1.1L, 3.00 eq) and DIPEA (366.75 mg, 2.84 mmol, 494.27 pL, 5 eq) were
then slowly
added, and the mixture was continuously stirred at 25 C for 2 hours. The
reaction solution was
directly seperated by HPLC (Column: Xtimate C18 100*30mm*3 m; Mobile phase:
[water
(0.225%FA)-ACN]; acetonitrile%: 30%-60%, 8min) to give compound WX040-8. 1H
NMR
(400MHz, CDC13) 6= 7.82 (s, 1H), 7.64 (br d, J=8.3 Hz, 1H), 7.22 (d, J=8.3 Hz,
1H), 6.98 (s,
2H), 5.01 (br s, 1H), 4.86 -4.66 (m, 1H), 4.52 (dd, J=6.3, 9.5 Hz, 1H), 4.30 -
4.11 (m, 1H), 3.86
(s, 3H), 1.40 (s, 9H).
[00541] Step 8: synthesis of compound WX040-9
[00542] To a round bottom flask was added ethyl acetate (10 mL). VVX040-8 (40
mg, 113.82
jimol, 1 eq) and HCl/ethyl acetate (4 M, 10.00 mL, 351.42 eq) were then slowly
added, and the
mixture was continuously stirred at 25 C for 1 hour. The reaction solution
was concentrated
under reduced pressure to give compound WX040-9. 1H NMR (400MHz, DMSO-d6) 6=
8.16 -
99
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
8.04 (m, 2H), 7.91 (d, J=8.5 Hz, 1H), 7.57 (s, 1H), 7.37 (d, J=8.3 Hz, 1H),
4.62 - 4.41 (m, 3H),
3.82 (s, 3H).
[00543] Step 9: synthesis of compound VVX040
[00544] To DMSO (1 mL) were slowly added VVX040-9 (30 mg, 119.38 mot, 1 eq,
HC1),
BB-8 (24.26 mg, 119.38 Innol, 1 eq), HATU (68.09 mg, 179.07 mol, 1.5 eq) and
DIEA (46.28
mg, 358.13 mot, 62.38 Iõ 3 eq), and the mixture was continuously stirred at
25 C for 2
hours. The reaction solution was directly seperated by HPLC (Column:
Phenomenex
Gemini-NX 80*30mm*3 m; Mobile phase: [water (10mM NH411CO3)-ACN];
acetonitrile%:
28%-58%, 9min) to give compound VVX040. 1H NMR (400MHz, CDC13) 6=8.70 (br d,
J=7.3
Hz, 1H), 8.04 (s, 1H), 7.69 (s, 1H), 7.39 - 7.36 (m, 1H), 7.31 - 7.28 (m, 7H),
5.39 (s, 2H), 5.20
(td, J=6.8, 11.0 Hz, 1H), 4.72 (dd, J=6.5, 9.4 Hz, 1H), 4.31 (t, J=10.3 Hz,
1H), 3.89 (s, 3H);
LCMS m/z = 437.1 [M+11+.
[00545] Example 41: WX041
0 (:), 011
,NH
N Cr,
/ s
[00546] Route for synthesis:
H A 11,N
-0 tel --0)V _N
HO
CF, CF3
WX041 -1 WX041 -2 WX041-3
Ns BB-4
NH N CF3
N N
/
WX041
[00547] Step 1: synthesis of compound WX041-2
[00548] To a round bottom flask was added MeCN (20 mi.) at 25 C. WX041-1 (2.68
g, 21.09
mmol, leq), K2CO3 (5.83 g, 42.17 mmol, 2 eq) and 4-(chloromethyp-
trifluoromethylbenzene
(4.92 g, 25.30 mmol, 3.73 mL, 1.2 eq) were then slowly added. The reaction
solution was
continuously stirred at 60 C under nitrogen for 12 hours. The reaction
solution was slowly
poured into water (100 mL), and the mixture was extracted with ethyl acetate
(100 mL x 2). The
100
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
organic phases were combined, and washed successively with water (100 mL) and
saturated
brine (100 mL), and the organic phase was then concentrated under reduced
pressure to give a
crude product. The crude product was purified by silica gel column
chromatography
(petroleum ether:ethyl acetate=100:20-100:75) to give compound WX041-2. 1H NMR
(400MHz, CDC13) 6 = 8.17 (s, 1H), 7.65 (d, J=8.0 Hz, 2H), 7.40 (d, J=8.0 Hz,
2H), 5.49 (s, 2H),
4.08 - 3.91 (m, 3H).
[00549] Step 2: synthesis of compound VVX041-3
[00550] To a round bottom flask were added THF (20 mL) and H20 (4 mL) at 25 C.
VVX041-2
(2.40 g, 8.41 mmol, 1 eq) and Li0H.H20 (1.06 g, 25.24 mmol, 3 eq) were slowly
added. The
reaction solution was continuously stirred at 25 C under nitrogen for 1 hour.
The reaction
solution was adjusted to a pH of 6-7 with diluted hydrochloric acid (1 M), and
the precipitate
was filtered and collected to give compound WX041-3.
[00551] Step 3: synthesis of compound VVX041
[00552] To a round bottom flask was added N,N-dimethylacetamide (5 mL) at 25
C. BB-4 (20
mg, 45.29 mol, 1 eq), T3P (43.23 mg, 67.94 mol, 40.41 L, 50% purity, 1.5
eq), VVX041-3
(18.42 mg, 67.94 mol, 1.5 eq) and DIPEA (17.56 mg, 135.87 mot, 23.67 L, 3
eq) were
slowly added, and the reaction solution was continuously stirred at 25 C
under nitrogen for 2
hours. The reaction solution was slowly poured into water (100 mL), and the
mixture was
extracted with ethyl acetate (100 mLx 2). The organic phases were combined,
and washed
successively with water (100 mL) and saturated brine (100 mL), and then the
organic phase
was concentrated under reduced pressure to give a crude product. The crude
product was
seperated by preparative HPLC (Column: Phenomenex Gemini-NX 80*30mm*31lm;
Mobile
phase: [water (10mM NH4HCO3)-ACN] to give compound VVX041. 1H NMR (400MHz,
CDC13) 6 = 8.77 (br d, J=7.5 Hz, 1H), 8.31 (br d, J=3.6 Hz, 1H), 8.07 (s, 1H),
7.65 - 7.45 (m,
3H), 7.33 (br d, J=8.0 Hz, 2H), 7.22 (dd, J=4.8, 7.9 Hz, 1H), 5.40 (s, 2H),
5.23 - 4.97 (m, 1H),
4.72 (dd, J=6.5, 9.4 Hz, 1H), 4.25 (t, J=10.3 Hz, 1H), 3.87 (s, 3H); 19F NMR
(377MHz, CDC13)
6 = -43.60 (s, 1F); LCMS m/z =463.1 [M+1]+.
[00553] Example 42: VVX042
101
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
o
0 N-N
,,NH N
MeNN
/ S
[00554] Route for synthesis:
WX042-1 1NX042-2 1NX042-3
C)C .NH2
N 0 N_
N N 40,
s BB-4
I N .,NH N¨
N
S
WX042
[00555] Step 1: synthesis of compound VVX042-2
[00556] To MeCN (20 mL) were added WX042-1 (2 g, 15.74 mmol, 1 eq), 3-
chloromethyl
anisole (2.46 g, 1534 mmol, 2.14 mL, 1 eq), and K2CO3 (2.61 g, 18.88 mmol, 1.2
eq), and the
mixture was reacted at 50 C for 12 hours. The reaction solution was filtered
to remove K2CO3.
The filter cake was washed with ethyl acetate (15 mLx3), and the filtrate was
washed with
saturated brine (50 mL). The organic phase was concentrated under reduced
pressure to give a
crude product. The crude product was purified by silica gel column
chromatography
(petroleum ether:ethyl acetate=100:1-100:100) to give compound VVX042-2. 1H
NMR
(400MHz, CDC13) 6= 8.10 - 8.01 (m, 1H), 7.30 - 7.21 (m, 1H), 6.91 - 6.80 (m,
2H), 6.77 (s, 1H),
5.34 (s, 2H), 3.96 (s, 3H), 3.75 (s, 3H).
[00557] Step 2: synthesis of compound VVX042-3
[00558] To THF (30 mL) was added VVX042-2 (2.5 g, 10.11 mmol, 1 eq). A
solution of
Li0H-1-120 (509.17 mg, 12.13 mmol, 1.2 eq) in H20 (3 mL) was then added. The
reaction was
stirred at 25 C for 3 hours. TLC (petroleum ether:ethyl acetate=1:1) showed
that the raw
materials were completely consumed. The reaction solution was adjusted to a pH
of 6 with 1M
dilute hydrochloric acid, and the mixture was concentrated under reduced
pressure to remove
the solvent. Toluene (10 mL) was added to the remaining solution and the
mixture was
concentrated under reduced pressure again to remove toluene to give compound
WX042-3. 1H
NMR (400MHz, CDC13) 8= 7.19 (s, 4H), 7.21 - 7.17 (m, 1H), 4.65 (s, 2H),
3.79(s, 3H); LCMS
102
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
= 233.9 [M+ 1]t
[00559] Step 3: synthesis of compound WX042
[00560] To N,N-dimethylformamide (5 mL) were added BB-4 (94.67 mg, 214.39
Imo', 1 eq),
VVX042-3 (50 mg, 214.39 mot, 1 eq), T3P (163.71 mg, 257.26 mot, 153.00 L,
50% purity,
1.2 eq), and DIPEA (41.56 mg, 321.58 pmol, 56.01 L, 1.5 eq), and the mixture
was reacted at
25 C for 2 hours. LCMS showed that the raw materials were completely consumed.
The
reaction solution was concentrated under reduced pressure to about 5 mL. The
residue was
purified by HPLC (formic acid system) to give compound VVX042.11-INMR (400MHz,
CDC13)
5= 8.81 (br cl, J=7.0 Hz, 1H), 8.37(dd, J=1.6, 4.6 Hz, 1H), 8.04 (s, 1H), 7.57
(dd, J=1.6, 7.9 Hz,
1H), 7.33 - 7.27 (m, 2H), 7.00 - 6.69 (m, 3H), 5.36 (s, 2H), 5.22(td, J=6.7,
11.1 Hz, 1H), 4.79
(dd, J=6.3, 9.5 Hz, 1H), 4.32 (dd, J=9.5, 11.0 Hz, 1H), 3.93 (s, 3H), 3.79 (s,
3H).
[00561] Assay example 1: In vitro assaying part
[00562] Assay steps:
[00563] 1.1 Reagents
Reagent Brand Batch No.
RPMI-1640 GIBCO 11875-119
10X DPBS GIBCO 14200-075
Fetal Bovine Serum (FBS) Bi owest S1810-500
Pen/Strep (100X) Biowest L0022-100
CellTiter Glo Promega G7571
Q-VD-OPh Hydrate Sigma SML0063-5MG
Recombinant human TNF-a Pepotech 300-01A-50
[00564] 1.2 Instruments and materials
CULTURPLATE-384 +LID /50W Brand PerkinElmer cat#6007680
Envision plate reader (Perkin Elmer, Cat#2104-0010)
[00565] 1.3 Formulation of reagents
(1) 1 x DPSB: To 100 mL of 10xDPBS was added 900 mL of deionized water.
(2) 1640 complete medium: To 89 mL of RPMI-1640 medium were added 10 mL of FBS
and
1 mL of penicillin/streptomycin
[00566] 2. Assay steps
1. U937 cells were centrifuged, and then the medium was discarded. The cells
were
103
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
resuspended in 1640 complete medium and counted. The cell concentration was
adjusted
to 5 x105 cells/mL for use, and the cells were arranged according to compounds
to be
assayed.
2. To the prepared resuspension of U937 cells were added QVD-OPh at a final
concentration
of 25 pM and TNF-a at a final concentration of 100 ng/mL, and then the mixture
was
mixed gently.
3. To a 384-well plate was added 30 pL/well of U937 cells containing 25 pM
of QVD-OPh
and TNF-a at a final concentration of 100 ng/mL, and blank control wells
without
QVD-OPh and TNF-a were set up.
4. To the dosing group was added 10 !IL of the assay compound at 4 times the
preset
concentration, and to the blank control well was added DMSO at the
corresponding
concentration.
5. The 384-well plate was placed in a 37 C and 5% CO2 cell incubator for
24 hours.
6. After 24 hours, the 384-well plate was taken out and equilibrated at
room temperature for
20 minutes.
7. 40 pL of CTG was added to each well, and then the plate was shaken on a
shaker in the
dark for 2 minutes.
8. The plate was incubated at room temperature in the dark for 10 minutes, and
then read
using an Envision plate reader.
[00567] Results of assay:
The results of assay of compounds of the present disclosure were shown in
Table 1.
[00568] Table 1. U937 cell activity assay results of the compounds of the
present disclosure
IC50 of cell assay IC50 of cell assay
Compound No. Compound No.
(nM) (nM)
VVX001 0.5 VVX023 29
VVX002 1.8 WX024 43
WX003 0.5 WX025 12
VVX004 0.3 WX026 5
WX005 2 VVX027 20
104
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
W'X006 9 WX028 4.7
WX007 70 WX029 2.2
VVX008 8.1 WX030 15.6
VVX009 1.4 VVX031 2A
WX010 47 WX032 5.7
VVX011 1.7 WX033 7.6
VVX012 12.1 WX034 3.7
WX013 1.8 WX035 4.9
VVX014 3.7 ,WX036 6.4
WX015 5.1 WX037 24
WX016 9.8 ,WX038 238
VVX017 59 WX039 3.4
WX018 1.3 WX040 4.8
VVX019 0.6 WX041 86.5
VVX020 0.6 WX042 24.8
WX021 13
VVX022 20
[00569] Conculusion of assay:
It can be seen from the above table that the compounds of the present
disclosure show a good
inhibitory activity in the cell activity assay of inhibiting TNFVQVD-OPh-
induced
programmed cell necrosis (Necroptosis).
[00570] Assay example 2: In vitro activity assay of mouse RIP1
[00571] Cell line
L929 (purchased from ATCC, Item No.: CCL-1)
[00572] Reagent
Reagent name Brand Item No.
EMEM medium ATCC 30-2003
105
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
Horse serum Gibco 16050130
Double antibiotics (penicillin, TMS-AB2-C
Millipore
streptomycin)
Recombinant murine tumor 410-MT-010
R&D
necrosis factor alpha (TNF-a)
Caspase inhibitor (QVD-OPh) R&D OPH001-01M
CellTiter Glo fluorescent cells Promega G7573
[00573] Instrument
Microplate reader (Perkin Elmer, Envision)
[00574] Formulation of reagents
L929 cell complete medium: EMEM+10% horse serum (volume ratio) + 1% double
antibiotics
(volume ratio)
[00575] Assay steps
1. The cultured L929 cells were digested with trypsin, centrifuged,
resuspended in complete
culture medium, and then counted. The cell concentration was then diluted to
lx105/mL
with complete culture medium.
2. The cell suspension was added to a 96-well plate at 100 uL per well and
incubated at 37 C
and 5% CO2 for 24 h.
3. Different concentrations of assay compounds were added to each well, and
dimethyl
sulfoxide was added to the control group. The plate was incubated at 37 C and
5% CO2 for
1 h.
4. To each well were added TNF-a at a final concentration of 50 ng/mL and Q-
VD at a final
concentration of 50 uM, and the plate was incubated at 37 C and 5% CO2 for 24
h.
5. To each well was added 50 !IL of CellTiter Glo fluorescent cells, and
the plate was shaken
in the dark for 10 min.
6. The plate was read on the microplate reader.
[00576] Results of assay
The results of assay of compounds of the present disclosure were shown in
Table 2.
[00577] Table 2. L929 cell activity assay results of the compounds of the
present disclosure
106
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
Compound No. IC50 of cell assay (nM)
VVX001 1161
VVX003 1213
WX005 1311
VVX008 47
VVX009 103
WX011 11
VVX013 14
VVX019 51
VVX020 29
VVX021 445
VVX028 65
VVX029 184
VVX031 174
VVX032 255
VVX039 64
[00578] Conculusion of assay:
It can be seen from the above table that the compounds of the present
disclosure show a good
inhibitory activity in the mouse L929 cell activity assay of inhibiting
TNFa/QVD-OPh-induced programmed cell necrosis (Necroptosis).
[00579] Assay example 3: Pharmacokinetic evaluation of the compound
[00580] Assay steps
[00581] Eight healthy adult C57BL/6 mice (6-9 weeks old, purchased from
Shanghai
Lingchang Biotechnology Co., Ltd.) were selected, and randomly divided into
two groups, 4
mice in each group (n=2, cross blood sampling). One group was given 0.5 mg/kg
of the assay
compound by intravenous injection, and the other group was given 1 mg/kg of
the assay
compound by gavage. Plasma samples were collected respectively from animals in
the
intravenous group and gavage group at 0.083, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0,
8.0, 24 hours after
107
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
administration. The blood concentration was determined by LC-MS/MS method.
Relevant
pharmacokinetic parameters were calculated by WinNonlinTM Version 6.3
(Pharsight,
Mountain View, CA) pharmacokinetic software using non-compaitmental model and
linear
logarithmic trapezoidal method. AUCo-iast represents the area under the plasma
concentration-time curve from zero time point to the last detectable
concentration time point;
C.ax represents the peak concentration; T. represents the time to reach the
peak; T1/2
represents the half-life; CL represents the clearance rate; Tist represents
the last quantifiable
time point; p.o. represents per os; i.v. represents intravenous injection; and
F% represents oral
bioavailability.
[00582] Results of assay
The results of assay of compounds of the present disclosure were shown in
Table 3.
[00583] Table 3 Pharmacokinetic properties of the compound
Compound WX009
T112 (h) 1.4
Vdss (L/kg) 1.1
i.v.
CL(mL/min/kg) 9.4
AUC0-1.t (nM.h) 2210
Tmax(h) 0.5
C. (nM) 1495
P.O.
AUCo-last (ilM.h) 3854
F% 89.1
[00584] Conculusion of assay
The compound of the present disclosure has good pharmacokinetic properties, in
vivo exposure,
and bioavailability.
[00585] Assay example 4: In vivo efficacy study in mouse model of tumor
necrosis factor
(TNF-u) induced systemic inflammatory response syndrome (SIRS)
[00586] Reagent
Reagent Brand Cat # or Lot
108
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
Tumor Necrosis Factor (TNF-a) Pepro Tech 315-01A-1MG
Caspase inhibitor zVAD GL Biochem (Shanghai) Ltd. GLS180522-01001
[00587] Instruments and materials
1) Electronic balance: Brand Changzhou Tianzhiping Instrument Equipment Co.,
Ltd.,
Model JY20002
2) Anal theimometer: Brand PHYSITEMP, model BAT-12
[00588] Formulation of reagents
1) TNF-a: TNF-a was centrifuged quickly (10000 rmp, 30s) before opening the
lid. One
bottle of TNF-a (1 mg) was dissolved in 1 mL of sterile water to prepare a
mother liquor
with a concentration of 1 mg/mL. The mother liquor was stored at 4 C and can
be stored
for one week. 1000 IA of the mother liquor was weighed and added to 5667 111,
of sterile
water, and then 333 mg of trehalose was added and dissolved to prepare a
working
solution.
2) zVAD: 20 mg of zVAD was weighed and added to 480 L of DMSO, and the
mixture was
vortexed, sonicated, and heated at 37 C, and then 15.52 mL of physiological
saline was
added. A working solution with a concentration of 1.25 mg/mL was prepared.
[00589] Assay steps
1) The mice were reared adaptively for 3 days, and then randomly grouped
into cages, 5 mice
in each cage. Ear tags were cut.
2) Firstly, the mice were given the corresponding compound by gavage according
to their
body weight, and then injected intraperitoneally with zVAD at a dose of 250
lig per mouse.
After the intraperitoneal injection of zVAD, the anal temperature was measured
immediately (0 h), and the time was recorded. The time when mice were given
zVAD was
defined as the 0th hour (Oh).
3) After 15 minutes, TNF-a was injected through the tail vein at a dose of
200 1.tL per mouse,
and then the anal temperature was measured 15 minutes later (0.5h).
4) After 1 h, zVAD was injected intraperitoneally at a dose of 125 i.tg per
mouse, and then the
anal temperature was measured immediately (1 h). The anal temperature was
measured
again at 2 h, 3 h, and 4 h.
109
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
[00590] Results of assay
The results of assay of the compound of the present disclosure were shown in
Table 4.
[00591] Table 4 Body temperature and survival rate of mice
Decrease in mouse body
Number of
temperature ( C) 4-hour survival
Groups animals iii
1 2 3 4 rate of animals
each group
hour hours hours hours
TNF-a + zVAD+ vehicle 5 2.94 9.02 - 0% after 2 hours
TNF-a + zVAD + WX009(105 100 %
0.94 1.2 1.42 1.52
mpk)
[00592] Conculusion of assay
The compound of the present disclosure shows a very good protective effect in
the mouse
model of inhibiting systemic inflammatory response syndrome (SIRS) induced by
TNF-a/zVAD, wherein the decrease in body temperature of mice was significantly
reduced,
and the survival rate of animals was increased from 0% to 100%.
[00593] Assay example 5: In vitro Caco-2 cell permeability assay
[00594] Cell culture
MEM (minimum essential medium) supplemented with 2 mM L-glutamine, 10% Fetal
Bovine
Serum (FBS), 100 U/mL penicillin-G and 100 1.tg/mL streptomycin was used for
cell culture.
The conditions for cell culture were 37 1 C, 5% CO2 and saturated humidity.
When cells were
grown to 80-90% confluency, trypsin (0.05%, w/v)/EDTA (0.02%, w/v) digestion
solution was
added to digest the cells for seeding. The cells were seeded in BD Falcon's
Transwell-96-well
plate at a seeding density of 1 x105 cells/cm2. The cells were cultured in a
carbon dioxide
incubator for 22 days and then used for transport assay.
[00595] Transport assay
Hank's balanced salt buffer containing 10 mM HEPES (pH 7.40 0.05) was used in
this assay as
transport buffer. Two-way transport of the assay compound and the positive
drug digoxin at a
concentration of 2 j.tM was assayed, each in duplicate. Transport of fenoterol
and propranolol
110
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
from the apical end to the basal end (A-B) was assayed. The concentration of
DMSO in the
incubation system was controlled below 1%. After the sample was added, the
cell plate was
incubated at 37+1 C, 5% CO2 and saturated humidity for 120 minutes. All
samples were
vortexed and then centrifuged at 3220 rpm and 20 C for 20 minutes. The control
and assay
samples were diluted 1:1 (v:v) with ultrapure water, and then stored at 4 C.
Liquid
chromatography tandem mass spectrometry (LC/MS/MS) was used for analysis and
testing.
[00596] Analysis of samples
In this assay, liquid chromatography tandem mass spectrometry (LC/MS/MS) was
used to
semi-quantitatively analyze the peak area ratio of the assay compound and the
control
substances fenoterol, propranolol and digoxin to the internal standard in the
starting solution,
the receiving solution, and the supernatant of the dosing well.
[00597] Data calculation
[00598] Apparent permeability coefficient (Papp, cm/s), efflux rate and
recovery rate were
calculated using the following folinulae.
[00599] The apparent permeability coefficient (Papp, cm/s) was calculated
using the following
formula:
[00600] Papp = (dCr/dt) X Vr / (A X Co)
[00601] wherein dCr/dt is the cumulative concentration of the compound at the
receiving end
per unit time ( M/s); Vr is the volume of solution at the receiving end (the
volumes of solutions
at the apical end and the basal end were 0.075 mL and 0.250 mL, respectively);
A is the relative
surface area of the cell monolayer (0.0804 crn2); Co is the peak area ratio of
the initial
concentration (nM) of the assay substance or the control substances at the
dosing end.
[00602] The efflux rate was calculated using the following formula:
[00603] Efflux rate = Papp (BA) / Papp (AB)
[00604] The recovery rate was calculated using the following formula:
[00605] % recovery rate = 100 x x Cr) + (Va x Ca)] / (Va x Co)
[00606] wherein Co is the initial concentration (nM) of the assay substance at
the dosing end or
the peak area ratio of the control substances; Va is the volume at the dosing
end (the apical end
was 0.075 mL, and the basal end was 0.250 mL); Ca and Cr are peak area ratios
of the final
concentrations (nM) of the assay substance or the control substances at the
dosing end and the
111
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
receiving end, respectively.
[00607] Results of assay
The results of assay of the compound of the present disclosure were shown in
Table 5.
[00608] Table 5. Results of Caco-2 cell permeability assay
Compound Apparent permeability Efflux rate
coefficient (10-6 cm/s)
WX009 18.35 0.75
[00609] Conculusion of assay
The compound of the present disclosure is a compound with high permeability
and has low
efflux rate.
[00610] Assay example 6: Assay of plasma protein binding rate (PPB)
[00611] 796 pi, of blank plasma from humans, SD rats and CD-1 mice (plasma
purchased from
BioreclamationIVT) were weighed, and the assay compound working solution or
warfarin
working solution was added so that the final concentration of the assay
compound and warfarin
in the plasma sample was 2 1.tM. The samples were mixed thoroughly. The final
concentration
of DMSO in the organic phase was 0.5%. 50 j.tL of plasma samples of the assay
compound and
warfarin were pipetted to a sample receiving plate, and the corresponding
volume of the
corresponding blank plasma or buffer was added immediately, so that the final
volume in each
sample well was 100 [tL, wherein the volume ratio of plasma:dialysis buffer
was 1:1. Stop
solution was then added to these samples. These samples were used as To
samples for
determination of recovery and stability. The plasma samples of the assay
compound and
warfarin were added to the dosing end of each dialysis well, and blank
dialysis buffer was
added to the corresponding receiving end of the dialysis well. The dialysis
plate was then
sealed with a breathable membrane, placed in a wet 5% CO2 incubator, and
incubated with
shaking at 100 rpm at 37 C for 4 hours. After the dialysis was over, 50 [ff_.
of dialyzed buffer
sample and dialyzed plasma sample were pipetted to a new sample receiving
plate. The
corresponding volume of the corresponding blank plasma or buffer solution was
added to the
samples, so that the final volume in each sample well was 1001.1L, wherein the
volume ratio of
112
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
plasma:dialysis buffer was 1:1. All samples were subjected to protein
precipitation, and then
analyzed by LC/MS/MS. Unbound rate (% Unbound), bound rate (% Bound), and
recovery
rate (% Recovery) of the compound were calculated using the following
formulae:
[00612] % Unbound = 100 * Fc / Tc,
[00613] % Bound = 100 - % Unbound, and
[00614] % Recovery = 100 * (Fc + Tc) / To,
[00615] wherein Fc is the concentration of the compound at the buffer end of
the dialysis plate;
Tc is the concentration of the compound at the plasma end of the dialysis
plate; and To is the
concentration of the compound in the plasma sample at time zero.
[00616] Results of assay
The results of assay of the compound of the present disclosure were shown in
Table 6.
[00617] Table 6. Results of assay of plasma protein binding rate
Compound PPB_Unbound (%)
WX009 5.7 (human) / 29.7 (rat) / 7.0 (mouse)
[00618] Conculusion of assay
The compound of the present disclosure has a reasonable plasma protein binding
rate in human,
rat, and mouse, and the drug in unbound state in human plasma is 5.7%.
[00619] Assay example 7: Assay of pharmacokinetic parameters in dogs
[00620] Assay steps
[00621] Four healthy adult beagle dogs were selected and randomly divided into
two groups.
One group was given the assay compound by intravenous injection, and the other
group was
given the assay compound by gavage. Plasma samples were collected respectively
from
animals in the intravenous group and gavage group at 0.083, 0.25, 0.5, 1.0,
2.0, 4.0, 6.0, 8.0, 24
hours after administration. The blood concentration was determined by LC-MS/MS
method.
Relevant pharmacokinetic parameters were calculated by WinNonhinTM Version 6.3
(Pharsight,
Mountain View, CA) pharmacokinetic software using non-compartmental model and
linear
logarithmic trapezoidal method. AUCo-Last represents the area under the plasma
concentration-time curve from zero time point to the last detectable
concentration time point;
113
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
G.ax represents the peak concentration; Tmax represents the time to reach the
peak; Ti/2
represents the half-life; CL represents the clearance rate; Vdss represents
apparent volume of
distribution; p.o. represents per os; i.v. represents intravenous injection;
and F% represents oral
bioavailability.
[00622] Results of assay
The results of assay of the compounds of the present disclosure were shown in
Table 7.
[00623] Table 7. Pharmacokinetic properties of the compounds of the present
disclosure
Compounds VVX009 VVX013
Dosing regimen iv=3mpk; po¨lOmpk iv¨lmpk; po=5mpk
T172 (h) 5.5 4.89
Vdss (L/kg) 2.4 2.02
iv
CL(mL/min/kg) 6.2 5.18
AUCot (nM.h) 20762 7417
Tmax (h) 2.0 2935
C. (nM) 284 1.50
po
AUCO-tast (nM.h) 23640 27744
F% 34.2% 80.1 %
[00624] Conculusion of assay
The compounds of the present disclosure have better pharmacokinetic properties
and higher in
vivo exposure in dogs. Especially, the half-life of the compounds of the
present disclosure
reaches about 5 hours which is relatively ideal.
[00625] Assay example 8: Kinase selectivity assay of the compound of the
present
disclosure
[00626] The purpose of this assay was to detect the in vitro inhibitory
activity of VVX009 on a
variety of kinases. The kinases used in this assay included 413 kinases, and
the activity
detection method was provided by Eurofins Pharma Discovery Service. A method
of detecting
radiolabeled kinase activity was used for the assay. The concentration of
VVX009 was 1 p,M,
and the concentration of ATP was 1 01.1.M. The assay results were shown in
Table 8.
114
Date recue / Date received 2021-11-30
CA 03142360 2021-11-30
1006271 Table 8 Results of kinase profile assay of VVX009
Inhibition rate Number of kinases Name of kinases
>80% 1 RIP1
50-79% 1 LIMIC2
<50% 411 All other kinases
1006281 Conculusion of assay: The compound of the present disclosure has
highly specific
kinase selectivity, and almost only has highly active inhibitory effect on
RIP1. Therefore, the
compound of the present disclosure has a lower risk of off-targeting to other
kinase targets.
115
Date recue / Date received 2021-11-30
